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Abstract. 
 
In adult life mesenchymal stem cells (MSCs) reside primarily in the bone 
marrow and are defined according to their ability to self-renew and differentiate 
into tissues of mesodermal origin. Due to their immuno-modulatory properties and 
ability to form cartilage and bone, MSCs have clinical potential, for the treatment of 
autoimmune diseases and tissue repair.  
This project determines the chemokine receptor profile on murine bone 
marrow MSCs at early and late passage and on human MSCs derived from a range of 
fetal tissues including fetal blood, bone marrow, amniotic fluid and placenta. The 
overwhelming result from this analysis is the consistency across species and tissue 
source with respect to chemokine receptor profiles. In addition it is clear that 
expression of specific chemokine receptors defines sub-populations of MSCs. 
Currently, clinical trials using MSCs have relied on continued in vitro culture in order 
to obtain sufficient numbers for treatment. Here, MSCs have been shown to lose 
external chemokine receptor expression and associated chemotactic ability, whilst 
growing in size upon continued culture. All cultured MSCs investigated in this thesis 
were shown to be a heterogeneous population of stem cells and progenitors that 
contained ‘true’ MSCs within its number. 
This thesis investigates a pharmacological approach to mobilise endogenous 
MSCs from the bone marrow, increasing their numbers in the blood. It has 
previously been reported that administration of VEGF-A over 4 days followed by a 
single dose with a CXCR4 antagonist (AMD3100) causes selective mobilisation of 
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MSCs into blood. The VEGF biology of this response has been interrogated. MSCs 
were shown to express high levels of VEGFR-1 and lower levels of VEGFR-2 on the 
cell surface but do not express VEGFR-3. By blocking VEGFR-1 with mAbs during 
VEGF-A165 treatment, a ten-fold increase in MSC mobilisation in response to 
AMD3100 was recorded, while treating with VEGFR-2 blocking mAbs had no effect. 
Using VEGF isoforms specific for VEGFR-1 and VEGFR-2 (PlGF and VEGF-E 
respectively), it was determined that MSC mobilisation was dependant on activation 
of VEGFR-2 and not VEGFR-1.  
PαS cells are a subset of MSCs found in the murine bone marrow that are 
PDGFRα+, Sca-1+, CD45-, Ter119-. Further characterisation of mobilised mMSCs by 
flow cytometric analysis of PαS cells, now provides a way to investigate the biology 
of MSCs, both in their steady state in vivo and in models of injury and inflammation. 
Molecular mechanisms lying downstream of VEGFR-2 have been explored and it has 
been shown that MMPs play a critical role in mobilisation. The use of drugs to 
mobilise MSCs into the blood may provide a cost effective, non-invasive treatment 
to promote tissue repair.  
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1.1. Stem Cells. 
 
 
The human body is constantly regenerating cells to replace those lost as a 
result of tissue damage or aging. Cells including erythrocytes, leukocytes, epithelial 
cells lining the gut and keritinocytes have a high rate of turnover as cells are 
constantly dying and tissue is being regenerated [1]. Organs rely on tissue specific 
adult stem and progenitor cells for tissue regeneration [2]. The most heavily 
researched of these stem cell populations are the haematopoietic stem cells (HSCs) 
which are multipotent cells capable of generating all blood cell types from the 
myeloid and lymphoid lineages, erythrocytes and platelets [3]. Autologous and 
allogeneic transplants of HSCs that are isolated from mobilised peripheral blood or 
from bone marrow have been used for >30 years clinically for bone marrow 
transplants [4,5,6,7]. Mesenchymal stem cells (MSCs) are a population of stem cells 
found predominantly in bone marrow and adipose tissue with the capacity to 
differentiate into adipose, bone and cartilage. MSCs are required for the 
maintenance of cartilage and bone and have been reported to promote regeneration 
of other tissues such as muscle [8,9,10], skin [11], lungs [12], heart [13], and more 
controversially, the nervous system [14,15] under homeostatic conditions when 
given i.v.  
Embryonic Stem Cells (ES cells) are a pluripotent population of stem cells 
found in the inner cell mass of the early embryo [16,17,18]. ES cells possess the 
capacity to differentiate into all cell types of the adult body [19]. After long term 
culture in vitro, ES cells have been shown to maintain the developmental potential 
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to form derivatives of all three embryonic germ layers, including gut epithelium 
(endoderm); cartilage, bone, smooth muscle, and striated muscle (mesoderm); and 
neural epithelium, embryonic ganglia, and stratified squamous epithelium 
(ectoderm) [16,20,21]. ES cells are capable of unlimited proliferation in vitro in their 
undifferentiated state [20]. Human ES cells express low levels of major 
histocompatability complex (MHC)-I antigens, lack expression of MHC-II antigens 
and co-stimulatory molecules, are not recognized by natural killer cells and inhibit T-
cell induced-stimulation by third-party antigen-presenting cells [22,23,24].  
Generation of Induced pluripotent stem cells (iPS cells) was first reported by 
Takahashi and Yamanaka in 2006 [25]. iPS cells are created in vitro via the de-
differentiation of adult cells into an undifferentiated state by upregulation of key 
genes, most commonly Oct4, Sox2, Klf4, and c-Myc [25]. This has been reported 
using several different methods of delivering these transgenes, including retroviral 
[26], lentiviral [27], transposon [28], Sendai virus [29], plasmid based [30], episomal 
plasmids [31], protein [32], minicircle vector [33], and mRNA [34,35]. iPS cells share 
many of the molecular, phenotypic and functional characteristics of embryonic stem 
cells (ES cells). Thus, they actively self-renew, proliferate, and divide at a rate equal 
to ES cells [36]. iPS cells express markers specific to ES cells, including SSEA-3, SSEA-
4, TRA-1-60, TRA-1-81, TRA-2-49/6E, and Nanog [37]. Like ES cells, iPS cells express 
high telomerase activity to sustain self-renewal and proliferation [38]. In terms of 
pluripotency, iPS cells appear to be able to differentiate into all lineages including 
neural and cardiac differentiation [39].  
MSCs, HSCs, ES cells and iPS cells are all potential candidates for use as stem 
cell therapies [40]. Whilst ES cells have the greatest potential in terms of 
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differentiation capacity and proliferation rate [41], there are ethical concerns about 
the cell source and evidence that ES cells in their undifferentiated state induce 
teratomas if injected i.v., as such they are used in their partially differentiated state. 
e.g. oligodendrocyte progenitors [10,42,43]. While in principle iPS cells could 
represent an alternative source of stem cells, at present technical issues are still 
being refined, for example, their efficiency of generation. Further, these cells are still 
undergoing rigorous characterisation at a molecular level. It has also been reported 
that abnormal gene expression in some cells differentiated from iPS cells can induce 
T-cell-dependent immune response in syngeneic recipients [44]. The immunogenicity 
of cells derived from patient-specific iPS cells should be further evaluated before 
they are used clinically. HSCs are currently used clinically to treat genetic blood 
disorders and leukaemia, and are currently being used in clinical trials with the aim 
of treating HIV [45,46].  
 
 
1.2 Mesenchymal Stem Cells 
 
While bone marrow and adipose contain large numbers of MSCs, they have 
also been isolated from nearly all human tissues [47]. These stem cells are 
multipotent and are therefore more restricted than ES cells with respect to the 
number of tissues they can differentiate into. However, the accessibility of MSCs 
combined with their rapid proliferation rate in vitro make them ideal candidates for 
cellular therapies on a clinical scale [48,49]. MSCs are a good alternative to ES cells 
for use clinically to treat specific diseases, as they lack the ethical problems 
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associated with ES cells. MSCs are currently being used for both autologous and 
allogeneic transplants due to their immuno-modulatory capacity [13,50].  
The term mesenchymal stem cell was first termed by Caplan in 1991 to 
describe cells responsible for bone and cartilage formation in the embryo, and repair 
these tissues in the adult [51]. There had been previous studies investigating the 
transplantation of bone marrow to heterotopic anatomical sites, which resulted in de 
novo generation of ectopic bone and marrow [52]. Friedenstein et al went on to 
show that the osteogenic potential was associated with a minor sub-population of 
bone marrow cells [53]. These cells demonstrated rapid adherence to plastic tissue 
culture flasks and the formation of colonies generated from a single cell (colony-
forming units, CFU-Fs). The original naming of MSCs was based on the hypothesis 
that they could differentiate into multiple cell types, beyond skeletal lineages [54]. 
However, this non-skeletal potential is yet to be consistently demonstrated either in 
vitro or in vivo [55,56]. The initial definition of MSCs referred to bone marrow 
derived stromal cells [53]. Further research has now led to the term being used to 
describe cell populations derived from other adult tissues [57]. The International 
Society for Cellular Therapy (ICST) established three minimal criteria for defining 
multipotent stromal stem populations as true MSCs. Human MSCs (hMSCs) must: 
 
(i) Be plastic-adherent when maintained in standard culture conditions,  
(ii) Express CD105, CD73, CD90 and lack CD45, CD34, CD14, or CD11b, 
CD79α, or Cd19 and HLA-DR,  
(iii) Differentiate into osteoblasts, adipocytes and chondrocytes [58,59]. 
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1.2.1. Sources of MSCs. 
 
hMSCs were originally identified in postnatal bone marrow [53]. MSCs have 
since been isolated from many adult tissues. Commonly researched populations 
include adipose [60], dental pulp [61], umbilical cord blood [62], liver [63], lung [64], 
spleen [65], placenta [66], and amniotic fluid [67]. In order to isolate MSCs from solid 
tissues, enzymatic treatment with collagenase is required [68]. Bone marrow MSCs 
can also be harvested in this way [68]. Identification of MSCs in umbilical cord blood 
prompted research into the presence of MSCs in early fetal life [62]. MSCs are closely 
associated with haematopoietic stem cells (HSCs) in adult bone marrow. High levels 
of HPCs in first trimester fetal blood [69] suggested that due to their role in 
development, the frequency of stem cells in fetal tissue may be greater than that of 
adult human tissue [70]. As it is known that the number of MSCs in adult tissues 
decreases with advanced age, it is hypothesised that fetal tissue may be a better 
source for isolating large numbers of MSCs [71]. 
MSCs have not been consistently isolated from circulating adult blood [72], 
and yet they are found in highly vascularised organs. It has been proposed that there 
is a relationship between MSCs and pericytes, which support small vessels and 
hence are present in all vascularised organs [73]. It is also possible that pericytes are 
derived from MSCs, although this is yet to be proven. Importantly, not all MSCs can 
be defined as pericytes as it has been reported that within the bone marrow exists a 
population of MSCs which stain negative for pericyte markers such as NG2 [74].  
Whilst cell populations derived from mouse brain, spleen, kidney glomeruli, 
liver, muscle, lung, bone marrow, pancreas and thymus all fit the required criteria to 
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be defined as MSCs, da Silva-Meirelles et al demonstrated that there was some 
variation in the tri-lineage differentiation capacity between each population. These 
differences involved the frequency of cells which actually differentiated in to the 
osteogenic or adipogenic phenotype, as well as on the degree of differentiation [72]. 
Furthermore, there have been reports of differences in marker expression of MSCs 
derived from different sources. For example, adipose tissue MSCs have been shown 
to express the required markers to define MSCs in addition to further markers which 
are not expressed on bone marrow derived hMSCs including CD49d [75], CD62e and 
CD31 [60]. It has been hypothesised that these differences are due to the influence 
of the local environment [76]. These findings are clinically relevant, in that MSC 
populations derived from different sources may be more suited to treating damage 
to the tissue from which they originate than cells isolated from other sources. Whilst 
the differentiation capacity of MSC populations from different sources has been 
investigated, to date very little research has been dedicated to comparing the 
functional differences of MSCs in terms of migratory ability, proliferative ability, and 
engraftment rate in vivo. One critical feature of an MSC population to be used in 
clinical trials is the ease by which MSCs can be harvested. Ideally, MSCs should be 
sourced from an ethically non-controversial and easily accessible tissue. The source 
must be rich in MSCs, which can be harvested with as little impact on patients as 
possible. For most fetal and adult tissues, including adult bone marrow, MSC 
collection represents an invasive procedure with a potential risk of infection. This 
has led to extensive research into umbilical cord blood [77,78,79]. Whilst banking of 
bone marrow and umbilical cord blood derived MSCs is becoming more common, 
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there are few facilities for storing MSCs from sources which would otherwise go 
unused, such as liposuction adipose and amniotic fluid from amniocentesis. 
Stem cell therapies would ideally utilise stem cell populations with 
pluripotent differentiation and self renewal capacities, whilst not being 
tumourogenic. Fetal MSCs from 1st trimester blood and bone marrow fit these 
criteria, and have been reported to display several advantageous properties over 
their adult counterparts. Fetal blood and bone marrow derived MSCs express 
pluripotent markers such as Oct-4, SSEA-3, SSEA-4 and Nanog, which are not 
expressed on adult blood or bone marrow derived MSCs [80]. They also elicit a 
greater proliferative capacity and maintain longer telomeres during repeated 
passage than their adult counterparts [80]. Availability of MSCs from human fetal 
blood and bone marrow may be limited due to ethical objections. The human term 
placenta, a temporary organ with fetal contributions that is discarded post-partum 
has been shown to host a set of MSCs which exhibit many markers that are common 
to adult bone marrow derived MSCs [66,81]. These are an ethically uncontroversial 
and easily accessible source of MSCs for research and clinical purposes. Amniotic 
fluid has also been shown to be an abundant source of fetal MSCs. Amniotic fluid-
derived MSCs are readily available from samples taken for amniocentesis and were 
first isolated from 2nd trimester amniotic fluid [82]. Further research into 1st 
trimester amniotic fluid-derived MSCs showed that they have a greater proven 
differentiation capacity than adult bone marrow derived MSCs, with the ability to 
differentiate into adipogenic, osteogenic, myogenic, endothelial, neuronal and 
hepatic lineages. These cells were also shown to express ES cell markers, such as Oct-
4 and SSEA-4 [83].  
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1.2.1.1. MSC Niche. 
 
It was originally reported that 
MSCs reside around the 
microvasculature of their tissue of 
origin. This was determined via 
identification of MSCs using the human 
antibody STRO-1 [84]. However, STRO-1 
is not exclusive to MSCs and its 
expression in hMSCs is gradually lost 
during culture expansion [85,86]. Within murine bone marrow, a sub-population of 
nestin+ MSCs has been identified which also occupy a perivascular localisation 
(Fig1.1). Nestin+ MSCs have also been shown to act as the functional components of 
the HSC niche [87,88], suggesting that the function and phenotype of MSCs may 
depend on their microenvironment/tissue of origin. MSCs support HSC homeostasis 
and have anti-proliferative features that are in common with physiological stromal 
niches [89].  
 
 
1.2.2. Isolation of MSCs. 
 
To date, there have been no minimal criteria for defining mMSCs [90]. For 
this reason, researchers investigating mMSCs tend to define mMSCs as murine cells 
which fit the criteria for hMSCs [91,92]. However, certain markers such as Sca-1, 
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have been identified as a positive marker for mMSCs but are not expressed on 
hMSCs as there is no human homologue. Conversely, Stro-1, a hMSC marker has no 
mouse counterpart. There is variation between mouse strains in the cell surface 
epitopes and in vitro differentiation capacities. mMSCs do not differentiate down 
the chondrogenic lineage as readily as hMSCs [93,94]. It has also been reported that 
mMSCs are karyotypically very unstable in culture, whereas human MSC are not 
[95,96,97]. By their nature, cell populations which can be classified as mMSCs in this 
way are heterogeneic when cultured in vitro [10]. Whilst human bone marrow 
stromal populations lose all CD45+ haematopoietic cell contamination after one 
passage in vitro, mMSCs require multiple passages (≥5) in order to generate a 
population of cells which can be defined as MSCs when isolated by plastic adherence 
alone [98]. Different laboratories have developed unique methods to isolate and 
expand the MSCs in culture. These varying isolation and culture techniques lead to 
differences in the phenotypic and functional characteristics of mMSCs [99]. 
MSCs make up a minor fraction of the cells in the bone marrow and other 
tissues [91]. Their rarity makes them difficult to isolate or identify in vivo. Studies in 
man have shown that the frequency of MSCs in bone marrow declines with age (1 x 
10-4 of nucleated marrow cells in newborns compared to 1 x 10-6 in an 80 year old) 
[100]. Due to their rarity it is proposed that in order to use the cells as an efficient 
cellular therapy, MSCs must be isolated and expanded in vitro. hMSCs can be 
expanded in vitro to 1 x107 cells from a 20ml bone marrow aspirate in a matter of 
weeks [101,102]. To date, there are few published results that assess how MSC 
numbers are related to their functional effects in vivo. However, if the beneficial 
effects of MSCs in damaged tissue are a result of factors produced by the MSCs, it 
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can be assumed that MSCs used as a cellular therapy will act in a dose dependent 
manner.  
As MSCs are generally isolated from the bone marrow by plastic adherence, 
they are contaminated by haematopoietic cells, particularly macrophages. In order 
to purify populations of mMSCs which are uncontaminated with cells of the 
haematopoietic lineage at early passage, several research groups have outlined 
methodology for selectively sorting CD45-, CD34- and CD11b- populations using 
fluorescence-activated cell sorting (FACS) [103] or magnetic beads [104] to enrich 
the MSC levels in the populations. The density at which the cells are seeded on 
tissue culture flasks has also been identified as a variable which affects the 
heterogeneity of the cell population when isolating MSCs via plastic adherence 
alone. High density seeded bone marrow populations remain contaminated with 
CD45+ cells for longer periods of culture than low density seeded populations [105]. 
Different research groups also use different culture media in an attempt to enhance 
the proliferative rate of the MSCs and consequently get larger numbers in a shorter 
time, a critical consideration when wanting to perform autologous transplantations. 
Standard culture media for both human and murine MSCs such as DMEM, is 
supplemented with 10% fetal calf serum (FCS) which has some variation between 
batches. It has also been shown that increasing the percentage of FCS in culture 
media can increase the proliferative capacity of the cells [106]. Other specific media 
is available commercially where added factors are not defined. Efforts are currently 
being directed toward developing animal serum free media for cell culture purposes 
in order to remove any threat of disease. [107,108]. This variation in methodology 
for generating pure populations of MSCs and culture conditions between 
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laboratories creates a potential problem when comparing results between labs 
where MSCs are clearly distinct populations. The result of this can be seen in Table 
1.1, which lists the discrepancies in surface marker profiles from different 
publications. 
 
 Human MSCs Murine MSCs  
Surface 
Antigen 
+ +/- - + +/- - References 
Stro-1 8 1 0 0 0 0 [84,86,109,110,111,112,113,114] 
CD13 5 0 0 1 0 1 [60,113,115,116,117,118,119] 
CD29 5 0 1 12 0 0 [60,72,113,115,116,117,119,120] 
CD44 11 0 0 10 1 0 [60,72,84,113,115,116,117,119,121] 
CD73 5 0 0 0 0 0 [112,113,115,116,122] 
CD105 7 0 2 2 0 0 [60,112,113,114,115,116,117,120,122] 
CD106 5 0 3 4 1 0 [60,86,112,113,114,115,117,118,123] 
CD11b 0 0 10 0 1 5 [60,84,115,117,119,123] 
CD31 0 3 10 0 0 6 [60,84,113,115,116,117,118,119,121,123] 
CD34 1 1 11 5 6 4 [60,72,84,113,115,116,117,118,120,121,123] 
CD45 0 0 3 0 0 7 [60,84,113,115,116,117,118,120,121,123] 
CD117 0 2 0 1 1 13 [60,72,84,115,117,118,119,123] 
Sca-1 0 0 5 6 5 4 [72,117,119,123] 
CD10 6 0 1 0 1 0 [60,113,116,117,118] 
CD90 11 1 1 2 4 10 [72,84,115,116,117,118,119,121,123] 
VEGFR-2 2 1 1 1 0 5 [84,118,123,124] 
 
Table 1.1. Expression of MSC surface markers in different studies. (Adapted from [85]) 
 
Differences in human and murine bone marrow MSC populations may also be 
due to collection methods. Human bone marrow aspirate is most often harvested 
from the superior ileac crest and only a small volume is taken [125]. Murine bone 
marrow is most commonly harvested by flushing the complete bone marrow from 
femurs and tibias [53]. Due to difference in isolation methods between research 
groups, various publications have reported discrepancies in the expression of each of 
these non specific markers [126]. The heterogeneity of cultured MSCs is further 
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demonstrated by the set of markers which can be used to define them. Thus, very 
often positively expressed markers are not expressed constitutively on all cells within 
a population. Rather a sub-population of cells stain positively for said markers [127].  
 
1.2.2.1. Phenotypic changes in MSCs upon culture. 
 
It is apparent that culture-expanded MSCs differ from their in vivo progeny, 
as proliferation on plastic surfaces induces both phenotypic and functional changes 
[78,128,129]. This may be due to changes in cell function lending towards 
proliferation, at the same time reducing the capacity of MSCs to migrate. Due to a 
lack of specific MSC markers, MSCs are generally isolated via their ability to adhere 
to plastic, which involves repeated passage [130,131]. Upon long term culture, MSCs 
may be phenotypically and functionally altered, and not necessarily a true 
representation of MSCs in their natural state in vivo [41,132] For example, MSCs 
have been reported to grow in size upon culture on plastic tissue culture flasks 
[133]. It has been reported that hMSCs at passage 2 express CXCR4, CXCR5, CXCR6, 
CCR1, CCR7 and CCR9 on the cell surface. However, when analysed at passage 12 – 
16, hMSCs express very low levels or none of these chemokine receptors on the 
surface. These late passage hMSCs also lack the functional capacity to migrate 
towards the ligands of these receptors in vitro [134,135]. Moreover, down 
regulation of chemokine receptor expression is accompanied by a decrease in the 
expression of adhesion molecules such as ICAM-1, ICAM-2, VCAM-1 and CD157. 
These phenotypic changes have been shown to be associated with increasing cell 
cycle arrest and induction of the apoptotic pathway [76]. 
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Currently, identification of MSCs is dependent on a combination of markers 
as there is no single marker that identifies this subset, as is the case for HSCs [136]. 
Identification of a specific marker for MSCs would enable pure populations of MSCs 
to be isolated without the need for expansion on plastic. Research in this area has 
proposed single markers such as SSEA-1 [137], SSEA-4 [138], Stro-1 [109] and the low 
affinity nerve factor receptor (CD271) [139] as specific markers for MSC populations 
within the human bone marrow. However, they have not been taken up by the 
scientific community at large. Research investigating the properties of these MSC 
populations has suggested that the bone marrow contains many sub-populations of 
stem or progenitor cells, each of which can be defined as MSCs [140,141]. 
 
 
1.2.3. Sub-populations. 
 
Sub-populations of bone marrow derived MSCs are often identified by 
surface markers, clonality or homogeneous differentiation potential. Characterised 
populations include human multipotent adult progenitor cells (MAPCs), human 
marrow isolated adult multi-lineage inducible (MIAMI) cells, and very small 
embryonic like stem (VSEL) cells, which have been identified in mice and man. 
Murine nestin+ bone marrow cells have also been shown to be MSCs, which form a 
unique bone marrow niche with HSCs made of heterotypic stem-cell pairs [87]. 
MAPCs are identified via CD45 and Ter119 depletion along with selection via analysis 
in culture, including morphology and high Oct-4 mRNA levels. Whilst this set of cells 
has been highly researched and shown to have many favourable characteristics for 
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clinical therapy, they cannot be easily identified in vivo. This is also the case for 
MIAMIs, which are isolated due to their ability to form CFU-Fs in vitro [142]. VSELs 
are CD45-, Lin-, Sca-1+ cells in murine bone marrow and thus, can be sorted via 
fluorescence activated cell sorting (FACS). VSELs are very small in relation to other 
cells in the bone marrow population, significantly smaller than HSCs (3.63 + 0.69 
versus 6.54 + 0.17µm in diameter) and express Oct-4, a marker of embryonic stem 
cells [143]. Differences in the phenotype of these sub-populations is characterised in 
table 1.2. 
 
Cell Type Species Marker expression 
MAPCs  Human SSEA-1+, CD13+, VEGFR-2low, Thy-1low, CD34−, CD44−, CD45−, 
CD117(c-kit)−, MHC I−, MHC II− 
MIAMIs  Human CD29+, CD63+, CD81+, CD122+, CD164+, c-met+, BMPR1B+, NTRK3+, 
CD34−, CD36−, CD45−, CD117 (c-kit)−, HLA-DR− 
VSELs Mouse/ 
Human 
CXCR4+, AC133+, CD34+, SSEA-1+ (mouse), SSEA-4+ (human), AP+, c-
Met+, LIF-R+, CD45−, Lin−, HLA-DR−, MHC I−, CD90−, CD29−, CD105 
 
Table 1.2. Phenotype of MSC sub-populations. (adapted from [142]) 
 
Morikawa et al reported a further methodology for prospectively identifying 
and isolating MSCs from adult murine bone marrow based on marker expression 
alone, using flow cytometry [144]. This MSC population, termed PαS cells, are 
isolated as PDGFR-α+, Sca-1+, CD45-, Ter119- bone marrow cells. As is true for 
hMSCs, mMSCs do not express many common surface antigens that are found on 
haematopoietic and endothelial cells. These include Ter119, an erythroid lineage 
marker [145], and CD45, a haematopoietic marker [123]. Both PDGFR-α and PDGFR-
β are expressed by mesenchymal cells and the PDGF signalling pathway has been 
shown to be important in promoting survival and proliferation in mesenchymal cells 
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[146,147]. Several reports have shown that the tri-lineage potential of cells isolated 
based on Sca-1 expression alone [148,149,150]. Unfortunately, Sca-1 expression 
varies between mouse strains [98]. However, Morikawa et al demonstrated that PαS 
cells can be found in different mouse strains including DBA-1, C57BL/6 and BALB/c 
mice and that the level of Sca-1 expression was similar between all strains tested 
[124]. This sorted population gives rise to MSCs that are capable of in vivo 
engraftment into both the bone marrow and adipose tissue of mice, when 
transplanted systemically. PαS cells can also generate mesenchymal and neural crest 
lineage cells with or without in vitro expansion [144]. The identification of this 
marker combination enables in vivo examination of MSCs by flow cytometry. MSCs 
were found to be predominantly located in the arterial perivascular space near the 
bone adjacent to the vascular smooth muscle cells (vSMCs) [124]. A fundamental 
problem with in vitro culture of MSCs is their increase in size, causing them to 
become entrapped in the lungs when administered i.v. [130]. PαS cells expanded in 
vitro were also found to become entrapped in the lungs when injected i.v. [124]. 
This may be due to an increase in the size of the PαS cells upon 2D culture on plastic. 
PαS cells in vivo are very small relative to the rest of the cells in the bone marrow 
[124]. 
 
 
1.2.4. Differentiation Potential. 
 
By definition MSCs must possess tri-lineage differentiation capacity, in that 
they must be able to differentiate into osteoblasts, adipocytes and chondrocytes 
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when cultured under set conditions in vitro [59]. There are reports that MSCs can 
differentiate into additional cell types of mesodermal origin such as skeletal muscle 
[139], smooth muscle [151] and endothelial cells [152]. More controversial is the 
differentiation into endodermal and neuroectodermal cell types such as 
cardiomyocytes [153], neurons and hepatocytes [154,155]. 
 
 
Fig. 1.2. Differentiation capacity of MSCs isolated by plastic adherence. 
Fig 1.2 shows the published differentiation potential of bone marrow derived MSCs. Points i, 
ii, and iii show the classic defining differentiation potential of bone marrow derived MSCs 
down the chondrogenic, adipogenic and osteogenic lineages, respectively. Points iv, v and vi, 
show cell types which MSCs have been reported to differentiate into under set conditions in 
vitro, including neurons [156], cardiomyocytes [157] and hepatocytes [158]. 
 
Transdifferentiation describes the ability of MSCs to differentiate into other 
cell lineages as well as cells originating from other germ layers [125]. Under various 
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defined culture conditions, MSCs have been reported to exhibit transdifferentiation 
plasticity (Fig. 1.2). Transdifferentiation of MSCs into neurons has generated much 
interest due to the range of potential applications for currently untreatable 
neurological disorders and degenerative disorders [125]. In vitro differentiation of 
MSC into cells displaying neuronal characteristics has also been reported [155,159]. 
MSCs when injected directly into neonatal mouse brain, have been reported to 
differentiate into a neuronal phenotype [160]. This transdifferentiation is a topic of 
debate as it has been reported that the MSCs are transforming due to cell fusion 
[161] or contamination by other cell types and MSC sub-populations such as 
multipotent adult progenitor cells (MAPCs) [118], or due to cytoxic changes induced 
by the media and staining procedures [162]. Much research is currently focussed on 
driving the MSCs down defined differentiation pathways in vitro, so that progenitor 
cells for the tissue of interest can be administered for specific diseases [163,164].  
 
 
1.2.5. Immunosuppression. 
 
In addition to their ability to differentiate, there are now a large number of 
studies reporting the immuno-modulatory effects of MSCs [165,166,167]. Following 
i.v. administration, MSCs can induce T-cell peripheral tolerance, home to inflamed 
tissues and exert a potent tissue-protective effect through the release of anti-
inflammatory and anti-apoptotic molecules [49,89]. The wide range of factors and 
the roles that they play is summarised in Fig 1.3. This demonstrates why MSCs are 
currently being researched as candidates to treat a broad range of autoimmune and 
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inflammatory diseases. The known immuno-modulatory properties of MSCs 
increases the scope of diseases which can be potentially resolved using MSC therapy.  
 
Fig 1.3. Factors secreted by MSCs in culture. 
 
Cultured MSCs express low levels of MHC Class I and are MHC Class II−, CD40−, and 
CD86−, suggesting these cells would not elicit an immune response [168,169]. The 
immuno-modulatory capacities of MSCs have been demonstrated by several 
independent research groups, both in vitro and in vivo, in animal models and in 
humans [89,166,170]. The immuno-modulatory functions of MSCs were first 
demonstrated in their ability to suppress in vitro proliferation of T lymphocytes 
[171]. Since then, several studies have shown that MSCs can modulate many cell 
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types involved in the immune response in vitro. These include natural killer (NK) 
cells, B lymphocytes and dendritic cells [89,166,170]. The inhibition of T cell 
proliferation has been shown to be transient, whereby the removal of MSCs 
reinstates the T cell proliferative state [170]. T cell proliferation inhibition by MSCs is 
also known to act independently of cell-cell contact with the suppressive effect 
attributed to the secretion of either Transforming growth factor-β (TGF-β), 
Hepatocyte growth factor (HGF), Prostaglandin E2 (PGE2), Indoleamine 2,3-
dioxygenase (IDO), Nitrous Oxide (NO) or Interluekin-10 (IL-10) [172,173]. This 
inhibition of proliferation is observed in both autologous and allogeneic responder 
cells [174]. By demonstrating that this action is not HLA restricted, MSCs are shown 
to be a good candidate therapy for use allogeneically [175]. MSCs interfere with 
functioning, differentiation and maturation of dendritic cells. Again, this is not 
dependent on cell-cell contact with the MSCs, but on soluble factors secreted by the 
MSCs including IL-6, IL-10, macrophage colony-stimulating factor (M-CSF) and PGE2 
[176]. The inhibition of B cells by MSCs is dependent on inflammatory conditions 
[177]. MSCs in the presence of IFNγ reduce B cell proliferation via the induction of 
IDO [178]. To inhibit NK cell proliferation, MSCs have been shown to require 
activation with either IL-2 or IL-15 [179,180]. 
As with much of the MSC functional analysis to date, the immunosuppressive 
mechanisms by which MSCs exert their effect have been established in vitro. 
However, it is not yet confirmed that these pathways of immunosuppression are 
conserved in vivo [181]. 
 
1.3. Stem Cell Therapies. 
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To date, iPS cells are yet to be used in clinical trials, ES cells have begun phase 
1 clinical trials, and there are multiple reports of completed trials using MSCs [182]. 
 
Fig. 1.4. Clinical trials using MSCs as a cell therapy. 
The number of clinical trials currently listed on clinicaltrials.gov using MSCs is shown in Fig. 
1.4, sorted depending on what disease or injury the MSCs are being used to treat (Fig. 1.4.a. 
adapted from [58]), or the source of the MSCs used in the clinical trials (Fig. 1.4.b). 
Generated by analysis of data on clinicaltrials.gov. 
 
Currently 46% of MSC based cellular therapies utilise patients own bone 
marrow cells and 54% use allogeneic transplants (Fig. 1.5). Techniques currently 
employed to raise MSC numbers rely on ex vivo expansion, which is associated with 
practical, technical and regulatory hurdles. While none of these issues are 
insurmountable, the final cost of such a therapy will be reflective of this [72,183]. 
Such therapies have shown some success in phase II trials for the treatment of acute 
graft versus host disease (GvHD) and there are currently >170 clinical trials 
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registered on clinicaltrials.gov using MSCs to treat conditions including ischemic 
tissue (e.g. ischemic heart disease and critical limb ischemia in diabetic patients), 
autoimmune diseases (e.g. aGvHD, multiple sclerosis and ulcerative colitis) and to 
promote bone or cartilage regeneration (e.g. in the context of osteogenesis 
imperfect and arthritis). Results for trials attempting to repair the damage caused by 
heart disease using MSCs have been inconsistent, though recent trials have shown a 
small but significant improvement in heart function [184].  
In other areas of medicine, early clinical 
trials attempted to repair damage to bone 
caused by diseases such as osteogenesis 
imperfecta, or to speed up recovery from bone 
fractures. These trials relied on the ability of 
MSCs to differentiate into osteoblasts under set 
conditions [185]. Despite initially encouraging 
results, subsequent in vivo studies in both mouse 
and man have shown that MSCs typically exhibit low levels of engraftment and 
transdifferentiation within injured or diseased tissue and therefore do not 
contribute physically to tissue regeneration to a significant extent [186,187,188]. 
These findings initially cast doubt on the prospect of harnessing MSC plasticity to 
treat disease [54]. However, observations that the therapeutic application of MSCs 
resulted in reduced inflammation, apoptosis and fibrosis, led to trials designed to 
capitalise on the ability of the cells to suppress immune reactions and prevent tissue 
remodelling [189]. As MSCs appear to be immunologically inert [190], the numbers 
of allogeneic MSC transplants currently outweighs that of autologous transplants in 
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MSC clinical trials (Fig. 1.5). However there are some concerns about the 
administration of allogeneic MSCs, as reports have suggested that delivery to an 
inflamed site can result in gain of immune potency with accelerated damage due to 
a heightened immune mediated inflammatory response [191]. 
MSCs tend to be administered systemically. This is both less invasive and 
more convenient for multiple dosing regimens. One problem associated with 
systemic administration is reports of extremely low engraftment (<1%) at sites of 
injury or inflammation, and corresponding high levels of cell entrapment in the liver, 
spleen and lungs [186,192]. MSCs become entrapped in the lungs due to their large 
size and expression of cell surface adhesion receptors [193]. Despite the low 
engraftment rate and the complications caused by entrapment of cells in the lungs, 
numerous animal studies have reported a positive outcome following MSC 
administration i.v. [194,195]. As a result of this, in an attempt to improve endpoints 
further, MSCs administered during clinical trials are usually applied in doses of 
hundreds of millions for each infusion [189,192], or directly at sites of injury (e.g. 
Injected directly into myocardium following myocardial infarction (MI)). However, 
little research has been carried out investigating whether the beneficial effects of 
MSCs are dose dependent. 
Clinical trials looking to exploit the immuno-modulatory qualities of MSCs 
include the treatment of amyotrophic lateral sclerosis (ALS), in which the MSCs are 
thought to improve the microenvironment for motor neurons, reducing cell 
degeneration rate [196]. In type 1 diabetes clinical trials, MSCs act by modulating the 
auto immune action and subsequent destruction or dysfunction of insulin producing 
beta cells in the pancreas [197].  
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Alternative approaches include the culture of MSCs in vitro under set 
conditions to generate replacement tissue ex vivo, or the genetic modification of 
MSCs to act as vehicles for treatments which will be recruited to sites of injury and 
inflammation. Recently, there have been reports of replacement tracheas built on 
decellularised or artificial scaffolds using chondrogenic progenitors derived from 
autologous bone marrow derived MSCs [198]. Researchers are now investigating the 
potential for culturing other tubular organs in this manner, as well as optimising 
current techniques to make the process more efficient [199]. Progress into artificial 
regeneration of other organs remains highly experimental as researchers still look to 
create decellularised tissue or suitable artificial scaffolds on which to seed the MSCs 
[200,201]. MSCs have been shown to home to tumour sites and could potentially act 
as a shield and vehicle for a tumouricidal gene therapy vector. To date, a number of 
anti-cancer genes have been inserted into MSCs which resulted in anti-cancer effects 
on various carcinoma models when transplanted in vivo, including TRAIL on breast 
cancer [202], glioma [203,204] and lung cancer [205], IFN-α on melanoma [206], IFN-
β on pancreatic cancer [207], IFN-γ on leukaemia [208], IL-2 on glioma [209], IL-12 on 
melanoma and hepatoma [210], and NK4 on lung cancer [211]. 
Until recently, pharmacological methods to harness the regenerative capacity 
of MSCs have concentrated on mobilisation or directing cell fate in vivo [120,212]. 
Osteoporosis occurs due to a lack of bone mineral density. There are attempts to 
manipulate the fate of MSCs in the bone marrow (using statins) in order to drive the 
MSCs along an osteoblast differentiation pathway, thus increasing the numbers of 
bone forming cells in the affected area [213]. 
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1.4. Chemokines and their receptors. 
 
Chemokines (chemotactic cytokines) are small proteins which direct the 
movement of circulating leukocytes to sites of inflammation or injury. In addition to 
effects on cell locomotion, certain chemokines are capable of eliciting a variety of 
other responses affecting leukocyte adhesion, activation, degranulation, 
mitogenesis, and apoptosis [214]. There is evidence that MSCs respond to 
chemotactic signalling in order to home to sites of injury and inflammation 
[215,216]. Chemokine receptors and their ligands play an important role in tissue-
specific homing of leukocytes and have also been implicated in trafficking of HPCs 
into tissues [217,218]. HPCs migrate to sites of injury and inflammation [219]. Under 
steady state, HPC populations are confined within the bone marrow, with basal 
release into the circulating blood. This retention is a result of constitutively 
produced CXCL12 binding to CXCR4 [220,221]. The CXCR4 antagonist AMD3100 
inhibits CXCL12/CXCR4 binding, thus allowing the mobilisation of HPCs 
[218,220,221].  
Systematically transplanted MSCs have been shown to preferentially home 
to sites of injury, where they support functional recovery [134,222,223]. This infers 
that MSCs also possess a migratory capacity. In terms of chemokine receptor 
expression, studies examining MSCs harvested from human bone marrow have 
reported conflicting data with respect to the profile of chemokine receptors 
expressed [134,224]. Due to variation in culture conditions and the known 
heterogeneity of MSC cultures, it is likely that differences in chemokine receptor 
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expression profiles are a reflection of these variables. There is also a suggestion that 
chemokine receptor profiles differ between human and murine MSC populations in 
vitro. To date hMSCs have been reported to express CXCR1, CXCR3, CXCR4, CXCR5, 
CXCR6, CX3CR1, CCR1, CCR3, CCR5, CCR7, CCR9, CCR10, when analysed at passage 2-
9 [225]. mMSCs at passage 7-9 were shown to not express CCR3, CCR5, CCR7, CXCR4 
or CXCR5 on the cell surface [134]. There is a growing body of evidence reporting on 
chemokine and chemokine receptor dependent modulation of MSC migration and 
proliferation [226,227,228,229,230]. In a murine model of MI, MSCs injected i.v, 
were shown to traffic to the heart in a CXCR4-dependent manner, with enhanced 
recruitment reported in mice where expression of CXCL12 was induced via the 
instillation of an adenoviral vector expressing CXCL12 into the myocardium [231]. 
Further, it has been shown that recruitment of MSCs to primary breast tumours was 
stimulated by CCL2 and it was subsequently shown that at a molecular level MSC 
migration via CCR2 was dependent on FROUNT [232,233]. Interestingly, MSCs also 
constitutively produce chemokines [229] (Fig. 1.3). There is also evidence that the 
proliferative capacity of MSCs is inversely linked to their ability to migrate [234]. It is 
important to investigate the mechanisms by which MSCs efficiently home to sites of 
injury and inflammation. 
 
1.4.1. CXCL12. 
The chemokine CXCL12 was first identified as Stromal Derived Factor (SDF)-
1 in the supernatant of bone marrow stromal cells [235,236]. It has since been 
shown to be expressed constitutively at high levels in the bone marrow. These high 
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levels are produced by osteoblasts, endothelial cells and reticular cells within the 
bone marrow stroma [237]. More recent studies have reported that CXCL12 levels in 
the bone marrow are regulated centrally by the sympathetic nervous system, 
noradrenalin acting via 2 adrenoreceptors on osteoblasts and 3 adrenoreceptors 
on nestin+ MSCs to reduce their production of CXCL12 [87,238]. There are two 
known chemokine receptors for CXCL12, CXCR4 and CXCR7 [239,240,241]. CXCR4 
interacts with a range of signalling molecules and pathways and stimulates 
chemotaxis of leukocytes and stem cells. In contrast CXCR7 has a very high affinity 
for CXCL12, but does not couple to the signalling pathways that drive migration 
[242]. On binding to CXCR7, CXCL12 is internalised and subsequently degraded, thus 
CXCR7 appears to act as a sink for CXCL12 [243].  
 
 
1.5. Stem Cell Mobilisation. 
 
The bone marrow is a reservoir of progenitor cells including MSCs, HPCs, 
fibrocytes, and endothelial progenitor cells (EPCs). In response to disease or tissue 
injury, these cells are mobilised from the bone marrow and recruited into tissues 
where they contribute either to disease progression or tissue repair [244,245]. 
Infusion of HSCs and cultured EPCs has been shown to augment neovascularisation 
of tissue following ischemia and contribute to re-endothelialisation after injury 
[246]. HPC mobilising agents have had a profound impact in the field of 
haematological transplantation [217]. For over 30 years granulocyte colony-
stimulating factor (G-CSF) and more recently CXCR4 antagonists, specifically 
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AMD3100, have been used to mobilise HPCs from the bone marrow into the blood 
so that they can be collected in a non-invasive manner in order to repopulate the 
bone marrow following radiotherapy [247] A combination of G-CSF and CXCR4 
antagonist treatment results in a synergistic mobilisation of HPCs [248]. 
It has been proposed that MSCs present in the bone marrow may act 
remotely to promote tissue repair. Hypoxia has been reported to be sufficient to 
increase circulating MSC levels in rats [249]. The effect of hypoxia is dependent on 
activation of HIF-1α and thought to be due to increased levels of vascular endothelial 
growth factor (VEGF)-A165 in the bone marrow and CXCL12 in the blood [249]. One 
study has reported an increase in circulating numbers of MSCs in the blood of 
patients with severe burns [250]. The detection of circulating MSCs in response to 
tissue injury suggest they can be mobilised from their niches upon appropriate 
signals and that they therefore target damaged tissue [250]. G-CSF has been 
classically applied to mobilise HSCs from the bone marrow which can then be easily 
isolated from peripheral blood. Although the protective effect of G-CSF in diseases 
such as stroke and ischemia has been proven [251,252], its capacity to mobilise 
MSCs into the peripheral blood is controversial [253,254]. Recent studies in mice 
have shown that G-CSF stimulated the proliferation of MSCs in the bone marrow as a 
result of an indirect effect of G-CSF, causing osteoclast resorption [120,255]. Direct 
mobilisation of MSCs from bone marrow after the unique combination of VEGF-A165 
and CXCR4 antagonist therapy has been reported, which suggests that particular 
molecular mechanisms do exist and can be exploited to boost MSC egress from the 
bone marrow [120].  
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The CXCR4 antagonist used in this set of experiments was AMD3100. The 
CXCL12/CXCR4 axis has been shown to be critical in the retention of HPCs, EPCs and 
MSCs following 4 day VEGF-A165 treatment. Disrupting this axis using AMD3100 
following VEGF-A165 treatment, results in the mobilisation of EPCs and MSCs into the 
blood. VEGF-A165 treatment alone results in no mobilisation [120]. Administration of 
VEGF-A165 stimulates the entry of HPCs into the S/G2/M phase of the cell cycle in 
vivo, severely impairing their migratory capacity. Indeed, AMD3100 does not 
mobilise HPCS in mice pretreated with VEGF-A165 [120]. VEGF-A165 treatment does 
not stimulate the proliferation of EPCs. Therefore, EPCs are still mobilised in 
response to CXCR4 antagonism. In terms of G-CSF this pre-conditioning disrupts the 
CXCL12/CXCR4 retention pathway, while it is currently not known how VEGF-A165 
pre-treatment augments the mobilisation of EPCs and MSCs in response to 
AMD3100. A greater understanding of the molecular mechanisms that induce or 
control their mobilisation will help develop more efficacious therapies for MSC 
mobilisation.  
The introduction of new mobilisation regimes such as this may also have 
detrimental effects under certain conditions such as cancer. Indeed, recruitment of 
vascular progenitors by tumours is observed in patients and drives the progression of 
cancer through increased tumour blood vessel formation in animal models [255]. 
 
   
1.6. VEGF. 
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VEGF exists in several isoforms, the most commonly researched of which is 
VEGF-A165. VEGF-A165 plays a critical role in blood vessel formation and the migration 
of endothelial cells [256]. VEGF-A165 was used in Pitchford et al’s experiments which 
first demonstrated MSC mobilisation, in order to assess its ability to mobilise EPCs 
[257]. Previously, it had been reported that it was necessary to treat mice with VEGF-
A165 for 4 days before EPCs were seen in the blood [257]. Treatment of 
immunosuppressed mice with a blocking mAb VEGFR-1 blocking mAb reduces cell 
cycling of HPCs and the survival of HSCs following engraftment [258,259]. This 
suggests that endogenous VEGF-A165 acting via VEGFR-1 regulates the proliferation 
and survival of HPCs and HSCs in the bone marrow [258]. Pitchford et al showed that 
selective blockade of VEGFR-1 abolishes the ability of exogenous VEGF-A165 to 
stimulate HPC entry into the cell cycle in vivo and restores the ability of CXCR4 
antagonists to mobilise HPCs from the bone marrow. VEGF-A165 promotes survival 
and stimulates the migration of endothelial cells through VEGFR-2 signalling [260]. 
The differential effects of VEGF-A165 in regulating HPC and EPC mobilisation are 
mediated via VEGFR-1 for HPCs and VEGFR-2 for EPCs. The ability of VEGF-A165 to 
differentially promote the cell cycling of HPCs as compared to EPCs explains why 
EPCs can be selectively mobilised by the CXCR4 antagonist in mice treated over 4 
days with VEGF-A165 [120]. 
The mobilisation of stem and progenitor cells out of the bone marrow is 
thought to be a multi-step process. The cells are released from their respective 
niches within the bone marrow, followed by migration through the bone marrow 
stroma to the sinusoidal endothelium [261]. In addition to its potent angiogenic 
functions VEGF-A165 can stimulate proliferation, delay senescence, suppress 
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apoptosis and promote survival of various cells [262]. VEGF-A165 has also been 
shown to decrease MSC expression of cell cycle inhibitors such as p16INK and p21, 
and increase MSC proliferation rates, and hence VEGF-A165 can mitigate culture-
induced stress of MSCs [263]. 
There are 3 known subtypes 
of VEGFRs, VEGFR-1 (Flt-1), VEGFR-
2 (KDR, Flk-1) and VEGFR-3 (Flt-4) 
[264]. VEGFR-1 promotes the 
survival and proliferation of 
haematopoietic cells whilst VEGFR-
2 promotes the proliferation of 
endothelial cells [265] and VEGFR-3 
is involved in lymphangiogenesis 
[266]. With regards to mMSC mobilisation via VEGF-A165 and AMD3100 treatment, 
Kolonin and Simmons state that it is likely VEGF-A165 is exerting an indirect effect as 
MSCs do not express VEGFRs [255], however contradicting studies have shown MSCs 
to express both VEGFR-1 [267,268] and VEGFR-2 [124,268]. Various VEGF isoforms 
exist including VEGF-A165, placental growth factor (PlGF), VEGF-B, VEGF-C and VEGF-
D [269]. VEGF related proteins have also been discovered including VEGF-E from the 
parapoxvirus Orf Virus [270] and VEGF-F in snake venom [262,271]. In particular, 
PlGF has been shown to act specifically on VEGFR-1 [271] and VEGF-E is known to 
activate VEGFR-2 (Fig. 1.6.) [262]. 
In cancer stem cells, which share many of the defining characteristics of 
MSCs, an autocrine positive loop exists where VEGF-A165 binds to VEGFR-1 and 
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VEGFR-2 resulting in the release of matrix metalloprotease (MMP)-2 and MMP-9 
[272]. Migration of leukocytes through extra-cellular matrix is facilitated by ECM-
degrading enzymes such as MMPs, and thus they may be playing a critical role in the 
mobilisation of MSCs [214]. The role of MMPs in MSC mobilisation have yet to be 
investigated. 
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1.7. Hypothesis and Aims. 
 
Trafficking of endogenous MSCs involves their mobilisation from the bone marrow 
and chemokine-dependent recruitment into tissues. 
 
The main aims are: 
 
1. To define a reproducible methodology for isolating a pure population of 
mMSCs at low passage number in order to characterise them in terms of 
chemokine receptor expression and determine the effects of continued in 
vitro culture on chemokine receptor expression levels. 
 
2. To compare chemokine receptor expression on hMSCs derived from a range 
of fetal tissues. 
 
3. To further characterise CD45-, Ter119-, PDGFR-α+, Sca-1+ (PαS) cells as a sub-
population of homogeneous murine bone marrow derived MSCs. 
 
4. To optimise previously reported selective mobilisation regimes for MSCs in 
order to enhance mobilisation. 
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5. To explore alternative methods of mobilising endogenous MSCs and further 
interrogate existing regimes in order to elucidate the molecular mechanisms 
by which MSCs are released into the blood. 
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2. Materials and Methods.  
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2. Materials and Methods. 
 
2.1. Materials. 
General laboratory chemicals and cell-culture reagents were purchased from either 
Invitrogen (Paisley, United Kingdom) or Sigma-Aldrich (Poole, United Kingdom). 
Recombinant murine chemokines/cytokines IFN-γ, TNF-α, and CXCL12 were 
purchased from PeproTech EC (London, United Kingdom). The CXCR4 antagonist 
AMD3100 was obtained from Sigma-Aldrich (Poole, United Kingdom). FACS 
antibodies were purchased from the following companies; anti-mCXCR3 PE, anti-
mCCR10 PE, anti-mCXCR4 PE, anti-mCXCR2 PE, anti-mCCR10 PE, anti-mSca-1 PE, 
anti-mCCR9 FITC, anti-mCXCR2 APC, anti-mCXCR6 PE, anti-mCCR3 FITC, anti-mCCR6 
FITC, anti-mCD105 PE – R & D Systems (Abingdon, UK); anti-mCCR1 PE – Santa Cruz 
Biotechnologies (Santa Cruz, USA); anti-mCXCR4 PE, Fc-block, anti-mCD45 PE, anti-
mCD11b PE – BD Biosciences (Oxford, UK); anti-mCD45 FITC, anti-mCXCR4 FITC, anti-
mCD140a APC – BD Pharmingen (Becton, USA); anti-mCCR7 APC, anti-mVEGFR-1 
APC - ebioscience (San Diego, USA). 
 
2.2. Animals. 
Female BALB/c mice were purchased from Harlan. Mice were used at the age of 3-30 
weeks. UK Home Office guidelines for animal welfare, based on the Animals 
(Scientific Procedures) Act of 1986 were strictly observed. 
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2.3. Statistical Analysis. 
Data are expressed as mean ± SEM. Data were analysed using paired t-tests or one-
way analysis of variance (ANOVA), followed by Bonferroni multiple-comparisons 
test. All analyses were conducted using the GraphPad Prism statistical package 
(version 4.0; Graph Pad, San Diego, CA). P values less than 0.05 were considered 
significant. P < 0.05 denotes *, P < 0.01 denotes **, P < 0.001 denotes ***. 
 
2.4. Cell isolation and culture.  
2.4.1. Harvest of murine bone marrow MSCs. 
Femurs and tibias were isolated from mouse hind legs (m=10). The bone marrow 
was then flushed from the femurs and tibias with 2ml of DMEM +10% FCS per 
mouse, using a syringe. The cell suspension was then centrifuged at 1200rpm for 5 
minutes at room temperature (r.t.). The pellet was re-suspended in Mesencult (Stem 
Cell Technologies) and cells were incubated at 37oC, 5% CO2. Half of the media was 
replaced after 3 days. After 1 week of culture, the cells became confluent and were 
passaged and reseeded into new T75 flasks. These were designated passage 1 (P1) 
cells. 
 
2.4.2. Human fetal blood derived MSC isolation. 
Fetal blood collection was approved by the Research Ethics Committee of 
Hammersmith & Queen Charlotte's Hospital in accordance with the Declaration of 
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Helsinki. Blood (gestation 10 weeks and 4 days) was collected by cardiocentesis 
under ultrasound guidance. Cells were selected by adherence, cultured in DMEM–
high glucose (Invitrogen, Paisley, United Kingdom) supplemented with 10% fetal 
bovine serum (BioSera, Ringmer, United Kingdom), 100 IU/mL penicillin, and 100 
µg/mL streptomycin (Invitrogen), and expanded at 10 000 cells/cm2 at 37°C with 5% 
CO2. 
 
2.4.3. Human fetal bone marrow derived MSC isolation. 
Bone marrow samples were obtained from 4 fetuses (median gestational age, 13 
weeks). Single-cell suspensions of fetal bone marrow were prepared by flushing the 
bone marrow cells out of the humeri and femurs using a syringe and 22-gauge 
needle into DMEM (Sigma-Aldrich, United Kingdom) supplemented with 10% fetal 
bovine serum (FBS) (Stem Cells Technology, Vancouver BC, Canada), 2 mM L-
glutamine, 50 U/mL penicillin, and 50 mg/mL streptomycin (Gibco BRL, Life 
Technologies, Paisley, United Kingdom). Fetal liver samples were taken from 4 
fetuses (median gestational age, 11 weeks). Single-cell suspensions were prepared 
by mincing the organ through a 70-mm nylon filter (Becton Dickinson, United 
Kingdom), and cells were re-suspended as for the bone marrow samples. 
 
2.4.4. Human placenta derived MSC isolation. 
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Human second-trimester placenta tissue was obtained after informed consent from 
10 women undergoing socially indicated termination of pregnancy at a mean 
gestational age (GA) of 19 weeks.  
 
2.4.5. Human 1st and 2nd trimester amniotic fluid-derived MSC isolation. 
Amniotic fluid was derived from human first-trimester and second-trimester 
pregnancies after informed consent. Amniotic fluid was collected by ultrasound 
guided transabdominal puncture using a 22-gauge spinal needle (Vygon, Ecouen, 
France). 
 
2.4.6. Tracheal fibroblast culture. 
Murine tracheas were minced to pieces of around 1 to 2 mm3. The minced pieces 
were transferred to eppendorfs and washed in PBS by vigorous mixing with a vortex 
mixer. The excess supernatant was removed and the pieces were re-suspended in 
DMEM + 10% FCS and plated in T75 tissue culture flasks. The flasks were incubated 
at 37oC, 5% CO2. Half of the media was replaced after 3 days. Upon reaching 
confluence, the fibroblasts were passaged and reseeded into new T75 flasks. These 
were designated passage 1 (P1) cells. 
 
2.5. FACS analysis. 
57 
 
2.5.1. Flow cytometry analysis of MSC marker and chemokine receptor expression 
on mMSCs and hMSCs. 
To perform flow cytometric (FACS) analysis the cells were detached by 
trypsinisation, and were allowed to recover for 2hrs at 37oC in culture media before 
staining. Cells were then re-suspended in FACS buffer (PBS, 1% Bovine Serum 
Albumin (BSA), 0.1% sodium azide; 5 x 105 cells/100µl FACS-buffer), pre-incubated 
with murine Fc block (rat anti-mouse CD16/32 mAb) for 10min at 4oC and then 
stained with specific antibodies for 20 min at 4oC in the dark. For intracellular FACS 
staining cells were fixed in 2% formaldehyde for 20 min at rt, washed once in FACS 
buffer and then re-suspended in Saponin buffer at 4oC (PBS, 1% Bovine Serum 
Albumin (BSA), 0.1% sodium azide, 0.5% saponin). Fc block and specific antibody 
stains were performed in Saponin buffer. Afterwards cells were washed and re-
suspended in FACS-buffer. Relative chemokine receptor expression intensity levels 
were measured using MFI levels recorded on CellQuest software. 
 
2.5.2. PαS cell identification and mobilisation. 
For bone marrow PαS staining [124], femurs and tibias were isolated from mouse 
hind legs. The bone marrow was then flushed from the femurs and tibias of mice 
with 2ml of DMEM +10% FCS per mouse, using a syringe. The cell suspension was 
then centrifuged at 1200rpm for 5 minutes at room temperature (r.t.). The excess 
supernatant was removed and the pellet was re-suspended in FACS buffer (PBS, 1% 
Bovine Serum Albumin (BSA), 0.1% sodium azide; 5 x 105 cells/100µl FACS-
buffer)[145]. Cardiac bleeds were taken from treated and control mice, grouped in 2 
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for each experiment. RBCs were lysed using ACK buffer (0.15 M ammonium chloride, 
1 M potassium hydrogen carbonate and 0.01 mM EDTA, pH 7.2) for 4 minutes at 
room temperature. The cell suspension was then centrifuged at 1200rpm for 5 
minutes at room temperature (r.t.). The excess supernatant was removed and the 
pellet was re-suspended in FACS buffer. Cells were pre-incubated with murine Fc 
block (rat anti-mouse CD16/32 mAb) for 10 min and then stained with the following 
antibodies for 20 min in the dark: allophycocyanin (APC) anti-mouse CD140a 
(PDGFRα), fluorescein isothiocyanate (FITC) anti-mouse CD45, fluorescein 
isothiocyanate (FITC), anti-mouse TER-119 (ebioscience), phycoerythrin (PE)-
conjugated monoclonal anti-mouse Sca-1 (R&D Systems). Afterwards cells were 
washed and re-suspended in FACS-buffer. All samples were run on a BD FACSaria cell 
sorter (BD Biosciences). Gates were defined as positive for PDGFRα and Sca-1 and 
negative for CD45 and TER119, according to the isotype control fluorescence 
intensity. 
 
2.5.3. PαS cells from collagenase treated bone marrow. 
Femurs and tibias were dissected and crushed with a pestle. For collagenase treated 
experiments, bone and bone marrow fragments were incubated for 1h at 37oC in 
0.2% collagenase (Wako)/DMEM (Gibco) containing 1% Penicillin-Streptomycin 
(P/S). Cell suspensions were collected and bone and bone marrow fragments were 
crushed. The suspension was filtered with a cell strainer, and collected by 
centrifugation at 1200rpm for 7 min at 4oC. Both collagenase-treated or -untreated 
bone marrow cells were collected in the pellet and soaked in 1 ml water (Sigma) for 
59 
 
5–10 seconds to burst red blood cells, after which 10ml of DMEM + 10% FCS was 
added, and the suspension was filtered through a cell strainer [144]. The excess 
supernatant was removed and the pellet was re-suspended in FACS buffer. Cells 
were pre-incubated with murine Fc block (rat anti-mouse CD16/32 mAb) for 10 min 
and then stained with the following antibodies for 20 min in the dark: 
allophycocyanin (APC) anti-mouse CD140a (PDGFRα), fluorescein isothiocyanate 
(FITC) anti-mouse CD45, fluorescein isothiocyanate (FITC), anti-mouse TER-119 
(ebioscience), phycoerythrin (PE)-conjugated monoclonal anti-mouse Sca-1 (R&D 
Systems). Afterwards cells were washed and re-suspended in FACS-buffer. All 
samples were run on a BD FACSaria cell sorter (BD Biosciences). Gates were defined 
as positive for PDGFRα and Sca-1 and negative for CD45 and TER119, according to 
the isotype control fluorescence intensity. 
 
2.5.4. Expression of markers and chemokine receptors on PαS cells. 
Specific markers and chemokine receptors were examined on PαS cells by staining 
the cell populations with the following antibodies for 20 min in the dark: 
allophycocyanin (APC) anti-mouse Sca-1, fluorescein isothiocyanate (FITC) anti-
mouse CD45, fluorescein isothiocyanate (FITC), anti-mouse TER-119 (ebioscience), 
PE-Cy7 anti-mouse CD140a (PDGFRα), and all other markers of interest stained with 
phycoerythrin (PE)-conjugated mAbs. 
 
2.5.5. Size comparison of uncultured and cultured PαS cells. 
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PαS cells in uncultured bone marrow and P25 bone marrow derived mMSCs were 
compared by staining with the following antibodies for 20 min in the dark: 
allophycocyanin (APC) anti-mouse CD140a (PDGFRα), fluorescein isothiocyanate 
(FITC) anti-mouse CD45, fluorescein isothiocyanate (FITC), anti-mouse TER-119 
(ebioscience), phycoerythrin (PE)-conjugated monoclonal anti-mouse Sca-1 (R&D 
Systems). Cells gated as CD45-, Ter-119-, PDGFRα+, Sca-1+ were then compared 
using forward and side scatter. 
 
2.5.6. Cell cycle analysis of PαS cells using TO-PRO. 
Cells were stained for PαS cell markers as described above. The cells were then fixed 
using ice cold ethanol added drop-wise. Cells were incubated in 50μl of TO-PRO (100 
μg/ml), and 50 μl RNase (100 μg/ml) before running the cells on a BD FACSaria cell 
sorter (BD Biosciences). Histograms of the gated cells showed the first peak to 
represent cells in G0/G1 and subsequent peaks represent actively dividing cells. 
 
2.6. Differentiation of MSCs. 
2.6.1. In vitro differentiation of MSCs. 
To induce differentiation of MSCs into adipogenic and osteogenic lineages, 
differentiation media was added to confluent MSC cultures. A standard 
differentiation media containing 10% FBS, penicillin/streptomycin and fungizone was 
used, to which specific compounds were then added. For osteogenic differentiation, 
50μg/ml ascorbic acid-2-phosphate, 10nM dexamethasone and 10mM β-glycerol 
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were added to the standard media. Adipogenic differentiation was induced by 
adding 50μg/ml indomethacin, 100nM dexamethasone and 10ng/ml insulin to the 
standard. The micromass culture technique was used to induce chondrogenic 
differentiation. Confluent MSC cultures were trypsinised and 2 x 105 cells were 
pelleted in a 15ml falcon tube. To the basic media, 10ng/ml TGF-β, 50nM ascorbic 
acid-2-phosphate and 6.25μg/ml insulin were added. The chondrogenic 
differentiation media was changed every 3 days for 3 weeks. The media were 
replaced every 3 days for 3 weeks. 
 
2.6.2. Staining of differentiated MSCs. 
To confirm differentiation of MSCs into osteocytes, adipocytes and chondrocytes, 
the cell populations were stained with cell type specific dyes as reported in previous 
publications [115]. MSCs cultured in osteogenic media were stained with Alizarin red 
(Sigma-Aldrich). This dye is used to demonstrate the presence of calcium. Interaction 
of Alizarin dye with calcium ions results in a bright red stain. MSCs cultured in 
adipogenic media were stained with Oil red O (Sigma-Aldrich) which is a fat soluble 
dye that stains triglycerides and lipids of fixed cells with a deep red colour. Cells 
cultured in chondroinductive media were stained using Toluidine Blue, which stains 
the background blue (orthochromatic staining) and the areas of cartilage matrix red-
purple (metachromatic staining). Slides were mounted using Histomount mounting 
medium (VWR International Ltd.). Images were obtained using a Nikon DMX1200 
digital camera and processed using LUCIA software (Jasc® Software Inc.). 
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2.7. Mobilisation of endogenous MSCs into the blood. 
2.7.1. CFU-MSC assay. 
5 x 105 cells were added to Mesencult media including supplements (Stemcell 
Technologies) in 30mm petri dishes. Dishes were incubated for 7 days before media 
was changed, and then incubated for a further 14 days before the enumeration of 
MSC colonies. Colonies were defined as containing ≥ 30 cells and counted at X40 
magnification. 
 
2.7.2. Bone marrow colony assays. 
1 x 105 cells are added to Mesencult media including supplements (Stemcell 
Technologies). Dishes are incubated for 7 days before media is changed, and then 
incubated for a further 14 days before the enumeration of MSC colonies. 
 
2.7.3. Mobilisation of mMSCs via VEGF-A165 + AMD3100 treatment. 
Eight- to ten-week old female BALB/c mice (Harlan, Oxford, UK) were administered 
VEGF-A165 (2.5 μg/mouse, 1.25μg/mouse, or 0.625 g/mouse i.p.)(PeproTech) or 
vehicle on 4 consecutive days. Twenty-four hours after the last injection, mice were 
administered a CXCR4 antagonist (AMD3100, 5 mg/kg i.p) or vehicle and blood was 
collected via cardiac puncture 60 min later for enumeration of circulating MSC 
levels.  
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2.7.4. Repeated VEGF-A165 + AMD3100 administration. 
Mice in group A were pre-treated with vehicle (PBS) once daily for 9 days. Twenty-
four hours after the last injection, mice were administered a CXCR4 antagonist 
(AMD3100 5mg/kg i.p,). Mice in group B were pre-treated with VEGF-A165 once daily 
for 4 days (100μg/kg i.p.). On day 5 they received a CXCR4 antagonist (AMD3100 
5mg/kg i.p,). On days 6-9 they were treated with vehicle (PBS) once daily. Twenty-
four hours after the last injection, mice were administered a CXCR4 antagonist 
(AMD3100 5mg/kg i.p,). Mice in group C were pre-treated with VEGF-A165 once daily 
for 4 days (100μg/kg i.p.). On day 5 they received a CXCR4 antagonist (AMD3100 
5mg/kg i.p,). On days 6-9 they received further treatment with VEGF-A165 once daily 
(100μg/kg i.p.) Twenty-four hours after the last injection, mice were administered a 
CXCR4 antagonist (AMD3100 5mg/kg i.p,). Blood was taken for analysis of circulating 
MSCs 60 minutes post final AMD3100 administration. MSC numbers are shown as 
number of colonies per ml blood. 
 
2.7.5. MSC mobilisation following treatment with VEGF-A165 + CCL27, CXCL11 or 
PDGF. 
Eight to ten-week old female BALB/c mice (Harlan, Oxford, UK) were administered 
VEGF (2.5 μg/mouse i.p.) or vehicle on 4 consecutive days. Twenty-four hours after 
the last injection, mice were administered a vehicle (PBS), CCL27, CXCL11 or PDGF 
(250μl 50nM i.v.) or a CXCR4 antagonist (AMD3100 5mg/kg i.p.) and blood was 
collected via cardiac puncture either 1 hour, 6 hours, or 24 hours later for 
enumeration of circulating MSC levels. 
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2.7.6. VEGF-A165 + CXCL12 challenge. 
Mice were pre-treated with VEGF-A165 or vehicle (PBS) once daily for 4 days 
(100μg/kg i.p.). Twenty-four hours after the last injection, mice were administered a 
CXCR4 antagonist (AMD3100 5mg/kg i.p,), CXCL12 (50nM, 200µl, i.v.), or vehicle 
(PBS, 200µl, i.v.). Sixty minutes later, blood was taken for analysis of circulating 
MSCs. 
 
2.7.7. Administration of Anti-VEGFR1 + anti-VEGFR2 Antibodies. 
Mice were pre-treated with VEGF for 4 days, as previously described. On days 1 and 
3, mice were administered anti-VEGFR1, anti-VEGFR2, a combination of anti-VEGFR1 
+ anti-VEGFR2, or control IgG (2.5 mg/kg i.p.) [273] 30 min before VEGF 
administration. Twenty-four hours after the last injection, mice were administered a 
CXCR4 antagonist (AMD3100, 5 mg/kg i.p) or vehicle and blood was collected via 
cardiac puncture 60 min later for enumeration of circulating MSC levels. 
 
2.7.8. Treatment with different VEGF isoforms and PlGF. 
Mice were treated with 100µg/kg of VEGF-A165, PlGF or 1000µg/kg VEGF-E, or 
vehicle (i.p.) on 4 consecutive days. On day 5 mice were administered AMD3100 
(5mg/kg, i.p.) or vehicle. Cardiac bleeds were taken 60 minutes later for 
enumeration of mobilised MSCs. 
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2.7.9. Blocking protease activity during VEGF and AMD3100 treatment. 
Mice were administered marimastat (30mg/kg)(Tocris) in PBS.0.01% Tween 
(vehicle), vehicle or PBS 60 min before VEGF administration daily during the 4 day 
VEGF treatment protocol. Twenty-four hours after the last injection, mice were 
administered a CXCR4 antagonist (AMD3100, 5 mg/kg i.p) or vehicle and blood was 
collected via cardiac puncture 60 min later for enumeration of circulating MSC 
levels. 
 
2.8. Enzyme-linked immunosorbent assays (ELISA). 
2.8.1. Analysis of CXCL12 levels in cell supernatants. 
To determine the amount of CXCL12 in the cell-free culture supernatant, commercial 
murine ELISA kits (R & D systems) were used according to the manufacturer’s 
instructions and read at 450nm. 
 
2.8.2. Analysis of CXCL12 levels in blood plasma. 
Following different treatment regimens, blood was taken via cardiac bleed. The 
blood samples were then transferred to eppendorfs and centrifuged at 1000rpm for 
3 minutes. The top layer of blood plasma was subsequently removed and the 
amount of CXCL12 in each sample was compared using commercial murine ELISA 
kits (R & D systems). 
66 
 
 
2.9. P5 bone marrow derived mMSC population doubling times.  
Cells were seeded at densities of 5 x 104, 1 x 105 and 2.5 x 105 cells per well in a 6 
well plate. At 24, 48, 72 and 96 hours cell numbers were counted using a 
haemocytometer. Population doubling times (Td) were calculated using Td = 
log(2)/(log(1 + (r/100))).  
 
2.10. Propidium Iodide (PI) staining. 
Cell cycle analysis was performed on 2 x 105 cells suspended in 50μl RNase 
(100μg/ml), 50μl Propidium Iodide (PI:100μg/ml and azide), and 150μl 0.1% Triton X, 
and then analysed immediately in FACSCalibur (BD) flow cytometer. A dot-plot of PI 
width against PI area was recorded. Aggregates of cells were detected as events 
having a larger PI-W profile and were not included in the gate. A PI-A histogram of 
the gated cells showed the first peak to represent cells in G0/G1, the second peak in 
G2/M, and the in-between area S phase cells. 
 
2.11. Collagen 1 immunofluorescent staining. 
1 x 104 cells of each analysed cell type were plated in each well of an 8 well chamber 
slide. Cells were cultured as previously described until confluent. Cells were then 
stained with Collagen-1 FITC conjugated antibodies (Millipore) and visualised under 
a fluorescence microscope. 
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2.12. Boyden chamber chemotaxis assay. 
Harvested cells were incubated for 2-3hrs at 37oC in DMEM + 10% FCS. 
Simultaneously, the filter/membrane (8μm pore size, NeuroProbe) was placed in 
10μg/ml fibronectin for 1hr at 37oC, after which it was washed twice in PBS. The 
whole assembled Boyden chamber (except filter) was blocked by adding 90μl of 
buffer (HBSS – 30mM HEPES, 0.25% BSA) and incubating for 1 hr at 37oC, before 
rinsing once with buffer. 28μl of buffer ± chemoattractant was added to each of the 
lower wells. The polycarbonate filter/membrane was then positioned on top. 50μl of 
cells were added to each of the top wells (1-2 x 104 cells/well). The chamber was 
incubated for 15 hrs at 37oC in a humidified box. After incubation, the contents of 
the upper wells were carefully removed with a pipette. Filters were removed, wiped 
off on the upper side and air dryed. The filters were fixed for 15 minutes in 4% PFA, 
stained with Diffquick and the underside of the filters scanned for migrated cells 
under a light microscope. MSCs were counted in 5 fileds of view (100 x 
magnification). 
 
2.13. Indium111 labelling of P5 bone marrow derived mMSCs. 
0.1mCi (approx 4MBq) of Indium111 radionucleotide was chelated in 100µl 2-
mercaptopyridine-N-oxide. 1ml of a cell suspension containing 1 x 106 MSCs were 
added to the 111InCl3-chelate for 15 mins at r.t. The cells were washed with 10ml 
PBS/Tyrode’s and centrifuged (1200rpm, 5 mins, r.t.) 3 times. After the final wash, 
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the cells were re-suspended in 1ml PBS/Tyrode’s. 100µl of 111In-labelled MSCs were 
injected either via the i.v. or i.p. route. After incubating for 4 hours, the mice were 
culled under terminal anaesthesia and dissected into the following sections; blood, 
thymus, heart, lungs, liver, spleen, kidneys, femurs, intestinal tract, mesenteric 
lymph nodes and tail. Blood and tissue levels of Indium111 were determined using a 
gamma counter with a 100-500 KeV energy range. 
 
2.14. Murine model of LPS induced lung inflammation. 
Mice were challenged intratracheally with 40μl of 50µg/ml LPS, 30 mins later 2 x 105 
Indium111 MSCs were injected i.p. After 5.5 hrs mice were anaesthetised, blood 
collected by cardiac puncture, peritoneum lavaged with 1ml PBS, tissues collected, 
and radioactivity in each measured as previously described. 
 
2.15. Quantitative PCR of PαS cells, mES cells and mMSCs. 
RNA isolation and DNAse treatment was performed using a liquid handling system 
(BiomekFxp, Beckman Coulter) to automate and integrate protocols from Agencourt 
RNAdvance Cell v2 (Beckman Coulter) and TURBO DNA-free (Applied Biosystems). 
Reverse transcription was performed using the High-capacity cDNA Reverse 
Transcition kit (Applied Biosystems) and Veriti thermal cycler (Applied Biosystems). 
Quantitative PCR was performed on a 7900HT (Applied Biosystems) using TaqMan 
gene expressions assays including FAM™ dye-labelled TaqMan® MGB probe and 
primers set spanning 2 exons each specific for the target genes and the loading 
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controls (Hmbs and Gapdh). Data analysis was performed using DataAssist Software 
v1.0 (Applied Biosystems) using the geometric mean of two loading controls (Hmbs 
and Gapdh) for normalization. The acquisition of this data was carried out by Dr. 
Michela Noseda. 
 
2.16. Matrigel protocol. 
Matrigel is a gelatinous material that is a liquid at 0°C and a solid at body 
temperature. After anesthetization the skin was shaved on the back of the neck and 
Matrigel plugs (250µl) were injected subcutaneously. MSCs were mobilised from the 
bone marrow via chronic VEGF treatment and AMD3100 challenge, as previously 
described. Matrigel plugs were excised at days 5 and 10. Upon excision, Matrigel 
plugs were weighed and then digested by incubation with 2.5 ml of dispase for 90 
min at 37°C. Cell suspensions were then centrifuged at 1200rpm for 5 minutes at r.t. 
The excess supernatant was removed and the pellet was re-suspended in mesencult. 
MSC numbers were quantified by colony assays. 
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3. Isolating and characterising a population of murine bone marrow MSCs. 
 
3.1 Introduction. 
 
 Human MSCs are defined by the ICST [59] as: 
 Plastic adherent under standard culture conditions. 
 Positive and negative for a range of defined cell surface markers. 
 Capable of differentiation into osteoblasts, adipocytes and chondrocytes 
under specific conditions [59]. 
MSCs have been isolated from nearly all human and murine tissues. While all 
grow on plastic and possess tri-lineage differentiation capacity, considerable 
variation has been reported with respect to their phenotype (Table 1.1). It does not 
appear that this variation is due to tissue source of MSCs, more likely due to 
methods for isolation and expansion. Further, it is unclear whether these different 
phenotypes impact on the functionality of the MSCs. However, there have been 
some disappointing results in some high profile clinical trials using allogeneic MSC, 
where the nature of MSCs administered to patients have not been disclosed. This 
makes interpretation of these clinical trials difficult. Further understanding on how 
MSC isolation and culture conditions impact on phenotype and functions are 
absolutely necessary. With respect to murine MSCs, a similar situation exists where 
many labs have developed individual isolation and expansion protocols and MSCs 
that are studied are experimental populations and clearly different phenotypically. 
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This chapter focuses on exploring some of the basic mechanisms by which mMSCs 
act both in vitro and in vivo. The phenotype of mMSCs has been shown to be highly 
conserved when compared to that of hMSCs [134]. However, in comparison to 
hMSCs, purification and characterisation of mMSCs are still relatively poorly 
documented [274]. 
Whereas all mMSCs must possess tri-lineage differentiation capacity and the 
ability to adhere and proliferate on plastic surfaces, there is debate over the range 
of cell surface markers which mMSCs express. Table 1.1 lists published reports of 
mMSCs staining both positively and negatively for CD34, Sca-1, CD90, CD13 and 
CD117. This is most likely due to the difference in isolation techniques between 
laboratories. A clear difference between murine and human cultures of bone 
marrow stromal cells is the levels of contamination of CD45+ haematopoietic cells 
that represent a high percentage in mouse and persist over several passages of 
culture [93]. This may be in part due to the way in which the cells are isolated. The 
human bone marrow from which hMSCs are derived is specifically extracted from 
the iliac crest and only a small amount is taken, relative to the total femoral bone 
marrow. In contrast, in the mouse, the whole femoral bone marrow is flushed. This 
means that there are potential differences in the isolated stem cell populations due 
to differences in their anatomical localisation, from which MSCs are cultured. CD45+ 
murine bone marrow cells of the haematopoietic lineage appear to be more 
persistent than their human counterparts in their ability to adhere to plastic and the 
stromal cells cultured upon it. For this reason, various laboratories use different 
methods to deplete CD45+ cells as well as increasing the number of passage in order 
to isolate a pure population of mMSCs, which stains negative for CD45 
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[268,275,276]. These different methodologies have led to phenotypic differences in 
the MSC populations isolated by different laboratories. It is also clear from Table 1.1. 
that mMSCs cannot be identified by any one specific marker and they do not express 
a defined set of markers. Due to a lack of a specific marker to identify, mMSCs are a 
heterogeneous population containing within its’ number, cells at different stages of 
the cell cycle and with differing levels of plasticity [277]. The first aim of this project 
was to develop methodology to reproducibly isolate a population of MSCs from 
murine bone marrow. 
There are various factors that must be considered in order to create a 
reproducible methodology. An early report suggested that extensive passaging of 
mMSCs was required to obtain a pure population of stem cells. Thus in this chapter, 
the phenotypic and functional characteristics of low and high passage MSCs were 
assessed. Phinney et al compared bone marrow derived mMSCs from various strains 
of mice to assess differences between strains and to identify the most suitable strain 
for mMSC isolation and culture in vitro [278]. They found that of the strains 
investigated, BalbC were optimum for mMSC isolation and culture, in that they had 
the highest proliferative activity of the strains investigated and cells within the MSC 
population could readily differentiate down osteogenic, adipogenic and 
chondrogenic lineages. However, it has been reported that proliferating cells will not 
migrate as readily as those in a quiescent state [120].  
Chemokine receptors and their ligands play an important role in tissue 
specific homing of leukocytes [134]. An important feature of stem cells to be used 
for cellular therapies is that they must either: a) migrate to sites of injury and 
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inflammation, or b) if applied locally, must be retained at sites of injury and 
inflammation [279]. A common feature found when administering MSCs in vivo is 
the low engraftment rate at the target site [167]. We hypothesised that this may be 
due to a loss of chemokine receptors or adhesion molecules on the surface of the 
cells as a result of in vitro culture conditions. This chapter characterises the 
chemokine receptor profiles of mMSCs having undergone different levels of passage. 
Having assessed chemokine receptor levels, it is then critical to quantify the 
functionality of these receptors in terms of migratory potential. Due to the 
heterogeneous nature of MSC populations, it is likely that receptors will not be 
expressed on all of the cells in a given population [85]. Therefore, subtle changes in 
receptor levels may have functional relevance in terms of chemotactic ability. 
Recent studies have reported that chemokine receptor expression profiles are 
similar between mouse and human bone marrow MSCs [134]. Knowing this, it can 
be hypothesised that mMSCs can act as a good model for further study of 
chemokine receptors and the role they play in directing migration of MSCs in man. It 
is important to assess whether the reported conflicting characterisation of mMSC 
markers between laboratories extends to external chemokine receptor levels.  
It is currently thought that upon reaching a site of injury or inflammation, 
MSCs may differentiate into tissue specific cells to replace damaged or dead cells, or 
alternatively, resolve the damage in a paracrine manner [280,281]. A considerable 
amount of studies investigating the role of these cells in disease, suggest that a very 
low proportion of the MSCs actually differentiate at the site and repair the tissue via 
cell replacement [282]. Instead, the role of MSCs in modulating the immune 
response appears to be the main driving force in guiding the repair of tissues [283]. 
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MSCs have been shown to avoid allorecognition [284]. MSCs have also been shown 
to modulate the function of T cells and lack expression of MHC II [285]. This means 
that MSCs are ideal for transplantation into allogeneic hosts.  
Having established methodology to culture mMSCs and characterised their 
chemokine receptor expression, experiments were performed to assess tissue 
distribution of MSCs in vivo in naïve mice and in a model of acute lung inflammation. 
The impact of the route of administration and the cell numbers injected was 
investigated. 
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3.2 Aims. 
 
 To develop a reproducible method for isolating early passage bone marrow 
derived mMSCs. 
 Characterisation of early passage bone marrow derived mMSCs in terms of 
antigen phenotype, internal and external chemokine receptor profile and 
chemotactic ability. 
 Examination of migratory patterns of cultured early passage bone marrow 
mMSCs when administered in different ways, both in naïve mice and in a 
model of acute inflammation. 
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3.3 Results. 
 
In order to develop methodology and confirm reproducibility of an early 
passage bone marrow mMSC population, the easiest way to analyse the cell 
populations was to investigate their antigen phenotype. The antigen phenotype of 
MSCs is widely reported to be negative for the haematopoietic lineage markers 
CD45 and CD11b, but positive for CD29 and CD105 [59,286,287]. Fig. 3.1. shows the 
expression of these markers on cell populations cultured in different ways in order 
to ascertain whether these cell populations fit the antigen profile to be classed as 
MSCs. This also illustrates how different culture conditions can affect the phenotype 
of the cell populations. The cell populations analysed in Fig. 3.1.a. and 3.1.b. both 
show CD45 and CD11b expression. These figures show P2 bone marrow populations 
before and after CD45 depletion using magnetic beads, respectively. Before CD45 
depletion, CD29 expression is low at 12.67 ± 4.16% and the haematopoietic lineage 
markers are very highly expressed (75.53 ± 4.88% expression). As expected, the 
number of cells expressing CD45 or CD11b following CD45 depletion drops to 29.00 
± 25.24%. P5 and P25 bone marrow populations, can be seen in Fig. 3.1.c. and 3.1.d. 
respectively. These populations have not been CD45 depleted. The antigen 
phenotype for these cells is similar with <5% CD45/CD11b expression (P5 3.31 ± 
2.04%, 2.95 ± 2.21% P25 0.33 ± 0.33 %, 0.33 ± 0.33%), ~80% CD29 expression (P5 
85.20 ± 8.34%, P25 79.17 ± 3.02%) and ~40% CD105 expression (P5 49.50 ± 7.55%, 
P25 36.03 ± 10.06%). From this, it is clear that, in terms of marker expression, P2 
bone marrow populations with or without CD45 depletion cannot be classified as a  
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Fig. 3.1. Creating a population of CD45- MSCs. 
Bone marrow cell populations were cultured in Mesencult (StemCell technologies) at 37oC, 
5% CO2 and passaged 2 or 5 times. FACS analysis of P2 bone marrow populations for the 
haematopoietic markers CD45 and CD11b, and MSC positive markers CD29 and CD105 (Fig 
3.1.a). FACS analysis of a P2 bone marrow population after depletion using Miltenyi CD45-
binding magnetic beads (MACs:Miltenyi Biotech) (Fig 3.1.b ). FACS analysis of a P5 bone 
marrow population (Fig 3.1.c). FACS analysis of a P25 bone marrow population (Fig 3.1.d). 
Expression levels are illustrated as the mean FACS measurements ± SEM. n = 3-4. 
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population of MSCs. However, P5 and P25 bone marrow populations express marker 
profiles consistent with those of MSCs. In order to further assess their MSC-like 
phenotype, the presence or absence of further antigen markers on P5 bone marrow 
populations was analysed (Fig. 3.2). P5 bone marrow cells isolated via plastic 
adherence alone are CD45-, CD11b-, CD34-, CD29+, CD105+, Sca-1+. The histogram 
plots in Fig. 3.2.b. are representative of each bar in Fig. 3.1.a. This shows that, of the 
positively expressed markers, only CD29 appears to be constitutively expressed. It is 
apparent that CD105 and Sca-1 are only positively expressed on a subset of the total 
bone marrow derived population. 
In order to be classified as MSCs, this cell population must also show 
trilineage differentiation potential and proliferate on plastic surfaces in vitro. P5 
bone marrow cells cultured in vitro can differentiate into osteoblasts, chondrocytes 
and adipocytes. (Fig. 3.3.a). Population doubling times of P5 and P25 bone marrow 
populations in plastic culture flasks in vitro are compared in Fig. 3.3.b. Doubling 
times have been reported to decrease with increased passage number. Consistent 
with this doubling times of P25 bone marrow mMSCs were reduced from 49.71 ± 
10.87 hours to 35.50 ± 8.82 hours in the first 96 hours of culture, when compared to 
P5 bone marrow mMSCs.  
Late passage bone marrow mMSCs also fulfil MSC criteria in terms of the 
antigen profile. Fig. 3.4 shows the expression and the representative histogram plots 
of several markers on P25 bone marrow cells. These cells are CD45, CD11b, CD34-, 
CD29, CD105, Sca-1+. In comparison to the P5 bone marrow cells, the only  
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Fig. 3.2. Cell marker expression on P5 mMSCs. 
Bone marrow cell populations were cultured in Mesencult (StemCell technologies) 
at 37oC, 5% CO2 and passaged 5 times. (Fig 3.2.a) FACS analysis of P5 bone marrow 
populations for the haematopoietic markers CD45 and CD11b, EPC and haematopoietic 
marker CD34, MSC markers CD29, CD105 and Sca-1. Expression levels are illustrated as the 
mean FACS measurements ± SEM. n = 3-6. (Fig 3.2.b ). FACS histogram plots of selection of 
markers on bone marrow mMSCs at passage 5 isolated by plastic adherence (grey plots = 
isotype controls, red plots = marker of interest on cell population). Data shown is 
representative. 
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Fig 3.3. Differentiation and population doubling times of P5 and P25 mMSCs. 
Bone marrow cell populations were cultured in Mesencult (StemCell technologies) at 37oC, 
5% CO2 and cultured to passage 5. 3 x 10
5 P5 mMSCs were plated in each well of a 6-well 
plate. Different culture media was added to each depending upon published differentiation 
protocols as described in the methods [115]. Untreated control cultures (Fig 3.3.a.i). The 
presence of lipid-rich vacuoles stained with Oil Red O confirmed adipogenic induction (Fig 
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3.3.a.ii). Alizarin Red S staining shows mineralization of the extracellular matrix confirming 
osteogenic lineage (Fig 3.3.a.iii). Toluidine Blue (arrows) staining revealed the deposition of 
proteoglycans and lacunae confirming differentiation into the chondrogenic lineage (Fig 
3.3.a.iii). Fig 3.3.b. Cells were seeded at densities of 5 x 104, 1 x 105 and 2.5 x 105 cells per 
well in a 6 well plate. At 24, 48, 72 and 96 hours cell numbers were counted using 
haemocytometers. Population doubling times (Td) were calculated using Td = log(2)/(log(1 + 
(r/100))). n = 3. (Fig 3.3.c) 
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significant difference is the expression levels of Sca-1. 67.20 ± 21.72% of P25 bone 
marrow cells express Sca-1, as opposed to 26.37 ± 11.47% of P5 bone marrow cells.  
If there are functional differences between the early and late mMSC 
populations, it is likely to be related to migratory and chemotactic ability. 
Chemokine receptor profiles often correlate with the trafficking ability of the cell 
populations [288]. The external receptor levels of several chemokine receptors on 
the P5 bone marrow mMSC population can be seen in Fig 3.5.a. Fig. 3.5.b. shows 
representative histogram plots for each receptor. CXCR3 (41.48 ± 16.81%), CXCR4 
(46.33 ± 15.57%), CCR9 (40.91 ± 14.16%) and CCR10 (34.31 ± 11.85%) are the highest 
expressed surface chemokine receptors of those analysed, all of which are 
expressed on >30% of the P5 bone marrow mMSC population. CCR3 (3.25 ± 0.50%) 
and CCR6 (3.06 ± 1.92%) are both expressed by <5% of the cells. The histogram plots 
suggest that there are sub-populations of cells within the P5 bone marrow mMSC 
population, expressing either CXCR1, CXCR2, CXCR3 or CXCR4 on the cell surface.  
 Knowing that repeated passage can affect the properties of the MSC 
population, late passage (P25) bone marrow mMSCs were also characterised in 
terms of their chemokine receptor profile. The external receptor levels of several 
chemokine receptors on the P25 bone marrow mMSC population are shown in Fig. 
3.6. Fig. 3.6.b. shows representative histogram plots for each receptor. CXCR3, CCR7, 
and CCR10 are the highest expressed of all the receptors on the cell surface, each 
expressed by ~20% of the P25 bone marrow mMSCs (21.48 ± 13.54%, 22.32 ± 1.27%, 
19.60 ± 17.06%). CXCR2, CXCR4, CXCR6, CXCR7, CCR3 and CCR6 are all expressed by 
<10% of P25 bone marrow mMSCS (5.87 ± 3.50%, 6.54 ± 2.86%, 8.67 ± 5.28%, 1.83 ±  
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Fig. 3.4. Cell marker expression on P25 mMSCs. 
Bone marrow cell populations were cultured in Mesencult (StemCell technologies) at 37oC, 
5% CO2 and passaged 25 times. Fig 3.4.a FACS analysis of P25 bone marrow populations for 
the haematopoietic markers CD45 and CD11b, EPC and haematopoietic marker CD34, MSC 
markers CD29, CD105 and Sca-1. Expression levels are illustrated as the mean FACS 
measurements ± SEM. n = 3. Fig 3.4.b. FACS histogram plots of selection of markers on bone 
marrow mMSCs at passage 25 isolated by plastic adherence. Data shown is representative. 
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Fig. 3.5. External chemokine receptor expression on expression on P5 mMSCs. 
Fig 3.5.a. Bone marrow cell populations were cultured in Mesencult (StemCell technologies) 
at 37oC, 5% CO2 to passage 5. Cells were trypsinised, recovered and analysed for external 
chemokine receptor expression. 1 x 105 cells were used to stain for each receptor. 
Representative external chemokine receptor expression levels of P5 mMSCs were measured 
using a FACSCalibur flow cytometer (BD Biosciences) and analysed using CellQuest software. 
Expression levels are illustrated as the mean FACS measurements ± SEM. n = 3-13. Fig 3.5.b. 
FACS histogram plots of external chemokine receptor expression on bone marrow mMSCs at 
passage 5 isolated by plastic adherence. Data shown is representative. 
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Fig. 3.6. External chemokine receptor expression on expression on P25 mMSCs. 
Fig 3.6.a. Bone marrow cell populations were cultured in Mesencult (StemCell technologies) 
at 37oC, 5% CO2 to passage 25. Cells were trypsinised, recovered and analysed for external 
chemokine receptor expression. 1 x 105 cells were used to stain for each receptor. 
Representative external chemokine receptor expression levels of P25 mMSCs were 
measured using a FACSCalibur flow cytometer (BD Biosciences) and analysed using 
CellQuest software. Levels were recorded by subtracting the isotype control expression 
levels from the marker stained population expression levels. Expression levels are illustrated 
as the mean FACS measurements ± SEM. n = 3-8. Fig 3.6.b. FACS histogram plots of external 
chemokine receptor expression on bone marrow mMSCs at passage 25 isolated by plastic 
adherence (grey plots = isotype controls, red plots = marker of interest on cell population). 
Data shown is representative. 
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1.27%, 6.50 ± 2.31%). Interestingly, bone marrow mMSCs at late passage (P25) have 
significantly reduced surface receptor expression levels of CXCR2, CXCR3, CXCR4, 
CXCR6 and CCR9 when compared to early passage (P5) bone marrow mMSCs (Fig. 
3.7.). The most significant of these reductions in surface receptor expression is 
CXCR4, reduced from 46.33 ± 15.57% at P5 to 6.54 ± 2.86% at P25.  
If chemokine receptors are present intracellularly in the MSC population, 
there is the potential to upregulate cell surface expression levels which may in turn 
increase the migratory capacity of the MSCs. It has previously been reported that 
mature neutrophils expressing low levels of CXCR4 on their surface rapidly 
upregulate expression in culture over a matter of 8 hours [220]. These cells were 
shown to have large intracellular stores of CXCR4. By comparing the intracellular 
levels of chemokine receptors, it is possible to see whether any changes externally 
are due to increases in the intracellular expression levels. Fig. 3.8. shows the 
intracellular chemokine receptor levels of P5 and P25 bone marrow mMSCs. In 
general, intracellular levels of chemokine receptors are much higher than external 
levels for both P5 and P25 bone marrow mMSCs. Over 40% of P5 bone marrow 
mMSCs express CXCR3 (97.32 ± 1.17%), CXCR4 (78.12 ± 17.37%), CXCR6 (46.64 ± 
11.39%), CCR6 (53.47 ± 10.70%), CCR7 (74.33 ± 7.23%), CCR9 (91.49 ± 6.44%) or 
CCR10 (87.78 ± 9.09%) intracellularly (Fig. 3.8.a). Nearly 100% of cells in the 
population expressed CXCR3, CCR9, and CCR10 intracellularly. There was little or no 
expression of CXCR2 (3.60 ± 2.07%) or CCR1 (0.33 ± 0.58%) intracellularly in this 
population. Over 60% of P25 bone marrow mMSCs expressed CXCR2 (60.01 ± 
19.62%), CXCR3 (97.14 ± 3.62%), CXCR4 (79.68 ± 18.92%), CCR6 (82.14 ± 10.11%), 
CCR7 (89.63 ± 1.01%), CCR9  
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Fig. 3.7. Comparison of external expression of chemokine receptors on passage 5 and 
passage 25 murine bone marrow derived MSCs. 
Bone marrow cell populations were cultured in Mesencult (StemCell technologies) at 37oC, 
5% CO2 to passage 5 or passage 25. Cells were trypsinised, recovered and analysed for 
external chemokine receptor expression. 1 x 105 cells were used to stain for each receptor. 
Representative external chemokine receptor expression levels of P5 and P25 mMSCs were 
measured using a FACSCalibur flow cytometer (BD Biosciences) and analysed using 
CellQuest software. Expression levels are illustrated as the mean FACS measurements ± 
SEM. n = 3-13. *p < 0.05, **p < 0.01, and ***p < 0.001 between selected groups. 
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Fig. 3.8. Comparison of intracellular chemokine receptor expression on murine bone 
marrow MSCs at differing passage numbers. 
Fig 3.8.a. Bone marrow cell populations were cultured in Mesencult (StemCell technologies) 
at 37oC, 5% CO2 to passage 5. Cells were trypsinised, recovered and analysed for 
intracellular chemokine receptor expression. 1 x 105 cells were used to stain for each 
receptor. Representative intracellular chemokine receptor expression levels of P5 mMSCs 
were measured using a FACSCalibur flow cytometer (BD Biosciences) and analysed using 
CellQuest software. Expression levels are illustrated as the mean FACS measurements ± 
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SEM. n = 3-5. Fig 3.8.b. Bone marrow cell populations were cultured in Mesencult (StemCell 
technologies) at 37oC, 5% CO2 to passage 25. Cells were trypsinised, recovered and analysed 
for intracellular chemokine receptor expression. 1 x 105 cells were used to stain for each 
receptor. Representative intracellular chemokine receptor expression levels of P25 mMSCs 
were measured using a FACSCalibur flow cytometer (BD Biosciences) and analysed using 
CellQuest software. Expression levels are illustrated as the mean FACS measurements ± 
SEM. n = 1-3. Fig 3.8.c. Comparison of representative intracellular chemokine receptor 
expression levels of P5 and P25 mMSCs. Expression levels are illustrated as the mean FACS 
measurements ± SEM. n = 1-5. 
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(98.62 ± 1.15%) or CCR10 (96.85 ± 2.07%) intracellularly. CCR1 and CCR3 were not 
expressed (Fig. 3.8.b). When these two populations were compared (Fig. 3.8.c), 
there were similar intracellular expression levels of CXCR3, CXCR4, CXCR6, CCR1, 
CCR7, CCR7, CCR9 and CCR10. However, early passage (P5) bone marrow mMSCs 
expressed significantly more intracellular CCR3 (22 ± 3.46% vs. 0%), whereas late 
passage (P25) bone marrow mMSCs expressed significantly more intracellular CXCR2 
(60.01 ± 19.62% vs. 3.60 ± 2.07%). 
P5 bone marrow mMSCs have a different external chemokine receptor 
profile to that of P5 tracheal fibroblasts. The varying external chemokine receptor 
profiles of these 2 cell populations can be seen in Fig. 3.10.a. While both P5 bone 
marrow mMSCs and P5 tracheal fibroblasts had similar expression levels of CXCR2 
(21.20 ± 9.33%, 13.45 ± 2.79%), CXCR3 (41.48 ± 16.81%, 54.94 ± 13.46%) and CCR10 
(34.31 ± 11.85%, 45.86 ± 20.85%), there were significant differences in the levels of 
CXCR4 (46.33 ± 15.75%, 11.42 ± 9.56%), CXCR6 (40.91 ± 14.16%, 9.16 ± 5.44%) and 
CCR6 (3.06 ± 1.92%, 41.17 ± 11.73%). Other populations of murine fibroblasts were 
also found to have different chemokine receptor profiles (data not shown). 
Importantly, P5 murine tracheal fibroblasts expressed high levels of collagen-1 
intracellularly whereas P5 bone marrow mMSCs did not express collagen-1 (Fig. 
3.10.b). 
The functionality of these receptors, specifically the chemokine receptor 
levels on the surface of the cells was then tested. MSCs were cultured for 48h in the 
absence of serum to arrest the cells in G0 of the cell cycle prior to performing 
chemotaxis assays. As shown in Fig. 3.9.a. The number of actively dividing cells  
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Fig 3.9. Varying chemotaxis of P5 and P25 mMSCs towards CXCL10, CXCL12, CCL27 and 
CXCL16. 
P5 mMSCs were seeded at a density of 3 x 105 cells/well. After 24 hours recovery in 
Mesencult culture media was replaced with either DMEM + 0.1% FCS or DMEM + 10% FCS. 
Fig 3.9.a. PI staining to illustrate the percentage of cells in each stage of the cell cycle having 
been cultured for 48 hours in either; DMEM + 0.1% FCS (Fig. 3.9.a.i: M1=95.58%, M2=0.48%, 
M3=3.94%) or DMEM + 10% FCS (Fig 3.9.a.ii: M1=79.62%, M2=3.46%, M3=16.92%). PI 
staining analysis was carried out using a FACSCalibur flow cytometer (BD Biosciences) and 
CellQuest software. Fig 3.9.b. Cells were cultured to confluence at P5 or P25 in Mesencult. 
Cells then had the Mesencult replaced with DMEM + 0.1% FCS for 48 hours to enter the cells 
into a quiescent state. Cells were trypsinised, recovered and placed in the top wells of a 
Boyden chamber. CXCL10, CXCL12, CCL27 or CXCL16 (30nM) were added to the bottom 
chamber as indicated. Migration of mMSCs is expressed as the mean number of cells 
transmigrated to the lower side of the membrane ± SEM. n=3. Statistical comparisons were 
made between indicated columns using a paired student T –test (P < 0.05 denotes *) (P5 vs. 
P25 mMSCs towards CXCL10, P=0.0568) 
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(3.94%, Fig. 3.9.a.i) is significantly lower than that of bone marrow MSCs cultured in 
media containing 10% serum for 48 hours (16.92%, Fig. 3.9.a.ii). The relative 
chemotactic ability of P5 and P25 bone marrow mMSCs is shown in Fig. 3.9.b. P5 
mMSCs show a higher chemotactic response to the ligands of all 4 receptors 
investigated. P5 bone marrow mMSCs showed a significant increase above controls 
in the level of migration to the CXCR4 ligand CXCL12 (6.34 ± 0.511 vs. 2.26 ± 0.31) 
and the CXCR6 ligand CXCL16 (3.10 ± 0.38 vs. 1.08 ± 0.18). Overall, while P5 mMSCs 
exhibited robust chemotactic responses to all of these chemokines, P25 MSCs 
exhibited very low levels of migration, consistent with low levels of CXCR3, CXCR4, 
CXCR6 and CCR10 expressed by the cells. 
To enable accurate determination of the distribution of MSCs in vivo, MSCs 
were labelled with 111In and then injected either i.v. or i.p. These administration 
routes were chosen as they have been used by others to examine the therapeutic 
effects of MSCs in animal models [289,290]. When P5 bone marrow mMSCs were 
injected into mice i.p. and i.v., they showed different localisation patterns after 4 
hours. When 2.5 x 105 cells were injected i.v., the majority (76.75 ± 6.84%) of cells 
were located in the lungs after 4 hours, with a small population in the liver (12.34 ± 
1.41% Fig. 3.11.a). However, when 2.5 x 105 P5 bone marrow mMSCs are injected 
i.p., the majority (66.48 ± 13.11%) were associated with the intestine after 4 hours. 
There are also relatively small but significant numbers found in the liver, spleen and 
bone marrow (9.167 ± 4.53%, 8.08 ± 5.33%, 7.09 ± 3.01%, respectively (Fig. 3.11.b). 
A second experiment was performed injecting fewer cells to see whether that would 
reduce the acute entrapment and more tissues were assessed to determine tissue 
distribution more accurately. When lower numbers of P5 bone marrow mMSCs were 
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injected i.p. or i.v. (1 x 105 cells) there was a greater tissue distribution after 4 hours 
(Fig. 3.12.a & 3.12.b). When injected i.v. The majority of P5 bone marrow mMSCs 
were still found in the lungs (40.83 ± 14.13%), but markedly less when compared to 
the previous experiment. Significant percentages of the cells were found in the liver, 
bone marrow, intestine, skin and ribcage (14.51 ± 3.45%, 3.92 ± 2.35%, 6.76 ± 3.15%, 
5.56 ± 4.14%, 10.39 ± 8.76%). When injected i.p., the most notable difference was 
that 24.25 ± 9.25% of cells had homed to the skin. Significant numbers of the cells 
were also found in the peritoneal lavage, the liver, the bone marrow and the spine 
(8.66 ± 1.72%, 7.44 ± 1.56%, 4.34 ± 1.47%, 7.54 ± 4.07%). Next, the tissue 
distribution of injected P5 bone marrow mMSCs was examined under inflammatory 
conditions, in which chemokines would be released at relevant tissue sites. Mice 
therefore received a single dose of LPS i.t. (40 μl, 50 μg/ml) 1 hour prior to i.p. 
injection of 1 x 105 bone marrow mMSCs. There were no MSCs found in the lungs 
after 4 hours. The distribution was not significantly different at this time point to the 
distribution when injected i.p. into naïve mice. 
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Fig 3.10. Different characteristics of passage 5 bone marrow derived mMSCs and passage 5 
murine tracheal fibroblasts. 
Fig 3.10.a. The two different cell populations were cultured in DMEM + 10% FCS at 37oC, 5% 
CO2 to passage 5. Cells were trypsinised, recovered and analysed for external chemokine 
receptor expression. 1 x 105 cells were used to stain for each receptor. Representative 
external chemokine receptor expression levels of P5 mMSCs and P5 murine tracheal 
fibroblasts were measured using a FACSCalibur flow cytometer (BD Biosciences) and 
analysed using CellQuest software. Expression levels are illustrated as the mean FACS 
measurements ± SEM. n = 2-8. Fig 3.10.b. Varying expression of collagen-1 in passage 5 
bone marrow derived mMSCs (Fig 3.10.b.i) and P5 murine tracheal fibroblasts (Fig 3.10.b.ii). 
The two different cell populations were cultured in DMEM + 10% FCS at 37oC 5% CO2 to 
passage 5. Cells were then stained as described in the methods for Collagen 1 and assessed 
using an immunofluoresence microscope. 
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Fig 3.11. 2.5 x 105 Indium111 labelled MSCs injected i.v. or i.p. into naïve mice. 
Fig 3.11.a Indium111 labelled MSCs were injected i.v. 4 hours after administration, the 
relative levels of radioactive cells were measured throughout the mice. Integrated 
absorbance of segmented specimens was determined using a gamma counter over 100-500 
KeV energy range. Mice were divided into 12 sections. Distributed percentages of MSCs 
throughout the body are shown in each case. Results are expressed as the mean levels ± 
SEM. n=3. Fig 3.11.b. Indium111 labelled MSCs were injected i.p. 4 hours after administration, 
the relative levels of radioactive cells were measured throughout the mice. Integrated 
absorbance of segmented specimens was determined using a gamma counter over 100-500 
KeV energy range. Distributed percentages of MSCs throughout the body are shown in each 
case. Results are expressed as the mean levels ± SEM. n=3.  
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Fig 3.12. 1 x 105 Indium111 labelled MSCs injected i.v. or i.p. into naïve mice. 
Fig 3.12.a. Indium111 labelled MSCs were injected i.v. 4 hours after administration, the 
relative levels of radioactive cells were measured throughout the mice. Integrated 
absorbance of segmented specimens was determined using a gamma counter over 100-500 
KeV energy range. Mice were divided into 19 sections. Distributed percentages of MSCs 
throughout the body are shown in each case. Results are expressed as the mean levels ± 
SEM. n=4. Fig 3.12.b. Indium111 labelled MSCs were injected i.p. 4 hours after administration, 
the relative levels of radioactive cells were measured throughout the mice. Integrated 
absorbance of segmented specimens was determined using a gamma counter over 100-500 
KeV energy range. Distributed percentages of MSCs throughout the body are shown in each 
case. Results are expressed as the mean levels ± SEM. n=3.  
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Fig 3.13. Injection of Indium111 labelled MSCs into an LPS mouse model. 
LPS was administered i.t. 1 hour before i.p injection of 2 x 105 MSCs. 4 hours after 
administration, the relative levels of radioactive cells were measured throughout the mice. 
Integrated absorbance of segmented specimens was determined using a gamma counter 
over 100-500 KeV energy range. Distributed percentages of MSCs throughout the body are 
shown in each case. Results are expressed as the mean levels ± SEM. n=4. 
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3.4 Discussion. 
 
MSCs are generally isolated from tissues by adherence to plastic and 
expanded in a standard cell culture medium (e.g. DMEM) containing FCS. It is clear 
from the work presented here and what has been published previously that this 
generates a heterogeneous population of cells. The work presented here shows that 
for MSCs derived from bone marrow, by passage 5 the MSCs were devoid of 
contaminating haematopoietic cells. However, while these MSCs expressed markers 
of MSCs they were clearly not homogeneous. 
Generally mMSCs are known to be CD45-, CD11b-, CD34-, CD29+, CD105+, 
Sca-1+ [287,291]. These markers were therefore used in order to ensure that 
mMSCs isolated in this chapter could reproducibly fit these criteria. Figs. 3.1 and 3.2 
show representative marker expression on populations isolated using different 
methodology. These figures highlight the need for repeated passage in order to 
purify and deplete the population of CD45+ cells of the haematopoietic lineage. 
When culturing human bone marrow derived MSCs, the non-adherent CD45+ cells 
are lost following a single passage [115]. Fig 3.1.a illustrates how this is not the case 
with murine bone marrow, which at passage 2 has 75.33 ± 4.88% of its population 
staining positive for CD45. The CD45+ cells in murine bone marrow appear to be 
more persistent and it takes further passaging to deplete the population of these 
cells. This phenomenon may also be due to differences in methodology between 
human and murine bone marrow extraction. It was found that, at passage 5, the 
level of cells that stain positive for CD45 is at an acceptable level of <5% (3.314 ± 
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2.039%, 2.95 ± 2.21%, respectively). Attempts to deplete the population of CD45+ 
and CD11b+ cells using magnetic beads proved inefficient, with a high level of 
variability between depleted populations and passage 2 CD45 depleted bone 
marrow populations still containing within their number 29 ± 25.24% of cells that 
were either CD45+ or CD11b+. The P5 bone marrow mMSCs do not express CD45, 
CD11b or CD34, but do express CD29, CD105 and Sca-1. However, CD105 and Sca-1 
only appear to be expressed on a sub-population of these cells, demonstrating that 
the population remains heterogeneous. This is consistent with previous reports 
stating that mMSCs are a heterogeneous population [127,292].  
Continued culture of MSCs in vitro to increase population numbers may have 
detrimental consequences with regards to maintaining the beneficial properties of 
the MSCs for use in clinical therapies. These properties include the ability of MSCs to 
differentiate into specific lineages, migrate to sites of injury, and their immuno-
modulatory capacity [293]. In order to be classified as MSCs, as well as the correct 
marker profile, the cells must also proliferate on plastic surfaces and differentiate 
into chondrocytes, adipocytes and osteoblasts. Thus, the status of P5 bone marrow 
mMSCs was confirmed by their proliferative capacity and ability to differentiate 
down the 3 required lineages upon correct stimulus. However, of note it was clear 
that not all of the MSCs differentiated, again showing that not all of the cells in each 
population are true stem cells. Thus, it is most likely that MSCs isolated and 
expanded in this way are a mixture of stem and progenitor cells. 
The finding that all chemokine receptors expressed on these populations are 
only found on a percentage of the cells further suggests that this is a heterogeneous 
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population. Late passage bone marrow mMSCs express much lower levels of 
chemokine receptors on their surface when compared to their early passage 
counterparts. This can be seen in Fig. 3.7 in which a number of chemokine receptors 
show a significantly reduced level of expression on the surface of P25 bone marrow 
mMSCs in comparison to P5 bone marrow mMSCs (CXCR2, CXCR3, CXCR4, CXCR6, 
CCR9). The most notable of these reductions was CXCR4. As previously noted, the 
CXCL12/CXCR4 axis plays a critical role in the trafficking of several sets of stem cells 
around the body [294]. This reduced chemokine receptor expression may be a result 
of changes to their phenotype due to excessive passaging, resulting in an increased 
number of cells actively dividing which in turn inhibits their ability to migrate [168]. 
Prelimonary data looking at P5 bone marrow mMSC populations stained with mAbs 
for both CXCR3 and CXCR4 suggest that there is no double staining. This infers that 
the mMSCs that are CXCR4 positive are a distinct population to mMSCs which are 
CXCR3 positive. Further studies to investigate and compare the phenotypes of these 
sub-populations may help identify homogeneous populations of MSCs for use in 
treating disorders with different chemokine expression profiles. 
Interestingly, while there were dramatic differences with respect to external 
expression of chemokine receptors, internal expression levels were consistent. One 
hypothesis for future research is that these intracellular levels can be up-regulated 
to be expressed on the surface of the cells, thus, creating a population of MSCs that 
can proliferate rapidly to obtain sufficient numbers for clinical applications 
efficiently, whilst maintaining their ability to home to sites of injury or inflammation. 
Preliminary studies carried out, did not reveal rapid up-regulation of this pool of 
chemokine receptors when MSCs were stimulated with a range of inflammatory 
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cytokines (data not shown). Chamberlain et al reported high levels of CXCR3 and  
CXCR6 on the surface of bone marrow derived mMSCs, consistent with levels 
reported here [134]. However, they found no expression of CXCR4 on the cell 
surface. This discrepancy is likely to be due to different culture protocols, in 
particular the use of DMEM as a culture medium and not Mesencult. 
The functionality of the external receptors on P5 and P25 bone marrow 
mMSCs was compared in Fig. 3.9. Here, it was confirmed that the loss of chemokine 
receptor expression on the surface of P25 bone marrow mMSCs does result in a loss 
of chemokine dependent motility. From this it is apparent that cells which have 
undergone excessive passaging are not suitable for systemic administration in 
clinical therapies because they may lose their ability to migrate into specific areas of 
injury within tissue. They may function if administered locally, but it has not yet 
been assessed whether this in vitro culture methodology results in the loss of further 
surface molecules, including adhesion molecules, such as VCAM-1 [295]. These 
factors play a critical role for the engraftment of MSCs at target sites and are thus 
important to consider when choosing the population of stem cells to use for 
therapies [296]. In Fig. 3.9. it is clear that P5 bone marrow mMSCs have a greater 
capacity to migrate to the ligands for CXCR3 and CXCR4 (CXCL10 and CXCL12, 
respectively) than the ligands for CXCR6 and CCR10 (CXCL16 and CCL27, 
respectively). This finding may have implications in directing MSCs to sites of 
different injuries which propagate the release of different chemokines at the site. 
There has been much debate in the literature as to the exact nature of MSCs. 
In particular some reports suggest that both pericytes [74] and fibroblasts [297] 
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have MSC-like functionality when cultured under certain conditions. Whilst the 
nomenclature of the cells is not particularly important in comparison to their 
beneficial effects as cellular therapies, fibroblasts and in particular fibrosis can be 
detrimental in tissue repair [298]. Fig 3.10. confirms that the P5 bone marrow 
mMSCs that have been investigated in this chapter are phenotypically distinct from 
fibroblasts. There are obvious differences in expression levels of CXCR4, CXCR6 and 
CCR6, while levels of CXCR3, CCR9 and CCR10 are comparable. Most importantly, P5 
bone marrow mMSCs do not express collagen-1, whereas P5 tracheal fibroblasts do 
(Fig. 3.10.b), suggesting that the P5 bone marrow mMSC are not fibroblast like. Of 
note, while collagen-1 is synthesised by chondrocytes and osteoblasts, it is not 
expressed by their progenitors [299]. Whilst P5 bone marrow mMSCs can 
differentiate into chondrocytes and osteoblasts, a lack of collagen-1 suggests that a 
percentage of the cells within the P5 bone marrow mMSCs are undifferentiated. 
The in vitro data on P5 bone marrow mMSCs suggests that the cells should 
readily migrate to specific sites and organs in vivo. To investigate whether this in 
vitro data is applicable in in vivo models, P5 bone marrow mMSCs were radioactively 
labelled with Indium111 and injected i.v. or i.p. into naïve mice (Fig. 3.11 and 3.12) 
and a murine model of acute lung inflammation (Fig 3.13). Due to the large size of 
mMSCs cultured on plastic (>10µm), there have been reports of mMSCs getting 
caught in the lungs following i.v. administration [134]. Consistent with this, 4 hours 
post administration of 2.5 x 105 P5 bone marrow mMSCs i.v., the majority of cells 
were found in the lungs (76.75 ± 6.84%), with 12.34 ± 1.41% also found in the liver. 4 
hours post administration of 2.5 x 105 P5 bone marrow mMSCs i.p., the majority of 
cells (66.48 ± 13.11%) were associated with the intestines, with significant levels also 
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detected in the liver, spleen and bone marrow. It is known that the lungs, liver, 
lymph nodes, spleen and bone marrow all express high levels of CXCL12 [300]. 
Therefore, consistent with the original hypothesis, these data suggest that CXCL12 
generated at sites of inflammation and injury may aid MSC recruitment and suggest 
that one strategy to enhance recruitment could be to stimulate CXCL12 expression 
at these sites, or deliver exogenous chemokines to these sites. The high levels in the 
lungs may be due to cellular entrapment in the pulmonary capillary network, which 
may be problematic if repeated in man. The large numbers associated with the 
intestines of mice which received the cells i.p. may be a result of the cells not 
migrating but adhering locally. The variation in mMSC distribution patterns 
demonstrates that the way in which mMSCs are administered is critical were these 
cells to be used as clinical therapies and reach the desired target organ in man. In an 
attempt to overcome the potential problem of large cell numbers in the lungs after 4 
hours when administered i.v., lower mMSC numbers were given both i.v. and i.p. 
and the distribution patterns compared. In addition, more tissues were assessed to 
try and account for all the MSCs injected. The results of this can be seen in Fig. 3.12. 
Importantly, in Fig 3.12.a. it is notable that the number of mMSCs in the lungs 4 
hours after administration was 40.83 ± 14.13%, a significant reduction when 
compared to levels following i.v. administration of 2.5 x 105 mMSCs (76.75 ± 6.84%). 
The distribution among other tissues in both figures (Fig. 3.12.a. and 3.12.b.) is 
markedly increased. Therefore, administration of lower numbers of MSCs may be 
beneficial for clinical applications, as higher numbers of MSCs may reach the 
preferred target. Again, significant levels of mMSCs are found in the liver, bones and 
bone marrow in both experiments, suggesting that CXCL12 may be guiding mMSC 
107 
 
migration due to surface expression of CXCR4. As illustrated in Fig. 3.5., only 46.33 ± 
15.57% of the P5 bone marrow mMSCs express CXCR4 on the cell surface. This may 
explain why not all cells are migrating to these organs. Interestingly, similar levels of 
mMSCs were found in the blood of mice when administered i.p. or i.v. This shows 
that the cells are actively migrating even 4 hours post administration. This also infers 
that any effect of the mMSCs may not be apparent in the 4 hour timeframe which 
these experiments were limited to due to the terms of the licence. Also of note is 
the high levels of mMSCs found in the skin of mice that were given the cells i.p. It is 
known that the skin expresses high levels of CXCL10 [301], a ligand of CXCR3. Fig 3.9 
demonstrated that P5 bone marrow mMSCs could migrate in response to CXCL10 in 
an efficient manner. One explanation could be that mMSCs which express CXCR3 on 
the surface (41.48 ± 16.81%) preferentially migrate to tissue expressing ligands of 
CXCR3, such as the skin. However, this was only seen when cells were given i.p. 
Therefore, point of administration clearly impacts on distribution pattern. These 
findings have implications with regards to mMSC sub-population selection, with a 
view to treating different site-specific injuries and diseases. An example of this is 
psoriasis, a skin disease and potential target for MSC therapies. By sorting the P5 
bone marrow mMSCS which positively express CXCR3 on their surface, the number 
of mMSCs recruited to the skin may be increased. Likewise, for diseases of the liver, 
lungs, spleen and bones, P5 bone marrow MSCs which express CXCR4 on their 
surface could offer greater levels of engraftment at the site of injury. 
To investigate whether culture expanded MSCs could traffic to a site of 
inflammation, P5 bone marrow mMSCs were injected i.p. into an murine model of 
acute inflammation in the lung. LPS administered i.t. induces chemokine production 
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in the lungs [302]. In Fig. 3.11.b. and 3.12.b., it was demonstrated that when P5 
bone marrow mMSCs are administered i.p., no cells are found in the lungs 4 hours 
post administration. This may however be due to the short time period given to 
allow cells to migrate from the peritoneal cavity. Future research could focus on the 
distribution of P5 bone marrow mMSCs at later time points and in response to 
different models of injury or inflammation. 
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4. Characterisation and comparison of human MSCs from different tissues. 
 
4.1 Introduction. 
 
Having established the profile of chemokine receptors expressed by mMSC, 
comparisons were made with hMSCs isolated from different sources. MSCs have 
been isolated from various tissues, but questions remain as to whether these 
different subsets can actually be classified as the same cell type and whether their 
suitability for clinical therapies is consistent across populations from different 
sources. Identification of mesenchymal progenitors in adult human blood [303] and 
subsequent identification in term cord blood [62] prompted research into the 
presence of MSCs in early fetal life. MSCs are closely associated with haematopoietic 
stem cells (HSCs) in adult bone marrow. High levels of HPCs in first trimester fetal 
blood [69] suggested that due to their role in development, the frequency of stem 
cells in fetal tissue may be greater than that of adult human tissue [70]. Campagnoli 
et al originally isolated MSCs from human 1st trimester blood, liver and bone 
marrow [63]. Since then, 2nd trimester fetal liver, lungs, spleen, pancreas and kidney 
have also been found to be rich sources of MSCs [304]. In this chapter, MSC 
populations are assessed that were derived from human fetal bone marrow, fetal 
blood, placenta, 1st and 2nd trimester amniotic fluid.  
Stem cell therapies would ideally utilise stem cell populations with 
pluripotent differentiation and self renewal capacities, whilst not being 
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tumourogenic [305]. Fetal MSCs from 1st trimester blood and bone marrow have 
been reported to display several advantageous properties over their adult 
counterparts. Fetal blood and bone marrow MSCs have been shown to express 
pluripotency markers such as Oct-4, SSEA-3, SSEA-4 and Nanog, which are not 
expressed by adult blood or bone marrow derived MSCs [306]. They also elicit a 
greater proliferative capacity and maintain longer telomeres during repeated 
passage than their adult counterparts [80]. However, availability of MSCs from 
human fetal blood and bone marrow may be limited due to ethical objections. The 
human term placenta, a temporary organ with fetal contributions that is discarded 
post-partum has also been shown to host a set of MSCs which exhibit many markers 
that are common to adult bone marrow derived MSCs [66,81]. These are an ethically 
uncontroversial and easily accessible source of MSCs for research and clinical 
purposes.  
Amniotic fluid has also been shown to be an abundant source of fetal MSCs. 
Amniotic fluid MSCs were first isolated from 2nd trimester amniotic fluid [82]. 
Amniotic fluid-derived MSCs are readily available from samples taken for 
amniocentesis. Further research into 1st trimester amniotic fluid-derived MSCs 
showed that they have a greater proven differentiation capacity than adult bone 
marrow derived MSCs, with the ability to differentiate into adipogenic, osteogenic, 
myogenic, endothelial, neuronal and hepatic lineages [83]. These cells were also 
shown to express ES cell markers, such as Oct-4 and SSEA-4 [307], but importantly 
do not form teratomas in vivo [308]. These cells may be cultured under specific 
conditions to provide specific progenitor cells which may have higher success rates 
for resolving organ specific injuries and diseases. 
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There has been a large amount of research assessing the fate of MSCs 
administered in vivo and how they affect disease progression in both animal models 
and human clinical trials [309]. Typically, these MSCs exhibit low levels of 
engraftment within diseased or injured tissue [310]. However, the paracrine effect 
of these cells has been shown to alter the tissue micro-environment, which may be 
affecting tissue repair [311]. Therefore, the ability to enhance MSC numbers at the 
site of injury or inflammation is a highly advantageous property. In Chapter 3, it was 
established that chemokine receptor levels and the subsequent ability of MSCs to 
migrate towards chemokines vary according to how MSCs are passaged in vitro. This 
may impact on whether MSCs reach their desired target when used as cell therapies. 
Currently, the majority of clinical trials carried out using MSCs have used adult bone 
marrow derived MSCs (Fig. 1.4). However, there is increasing awareness of the stem 
cell populations in other tissues. This can be seen with an increased use of adipose 
derived MSCs in recent trials. Several government and commercial institutions are 
now banking human umbilical cord and tissue derived MSCs. There are currently no 
banking facilities for any of the MSC sources described in this chapter. 
Fetal MSCs have been shown to proliferate at a greater rate than their adult 
counterparts [312]. For this reason, they could represent a better source for any 
therapeutic application in which large cell numbers are needed. However, the ability 
of these cells to home to, and be retained at the appropriate target site has yet to be 
fully investigated. Different injuries and diseases result in the production of different 
inflammatory mediators and chemokines. The likelihood that MSCs will reach the 
site of injury in different disease states may depend on the chemokine receptor 
profile of the population. To date, the chemokine receptor profile of MSCs derived 
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from these sources has not been investigated. This data should inform future 
researchers on the suitability of these different hMSC populations for their use in 
clinical trials for the treatment of diseases with different inflammatory profiles. 
Studies were performed in collaboration with Dr. P. Guillot’s lab, who has 
ethical approval for collection and has established methodology for expansion of 
these hMSC populations. All MSCs have been characterised and were shown to be 
CD105+, CD73+, CD29+, CD44+ with the potential to engraft and differentiate in vivo 
[313]. MSCs from different sources were all isolated via plastic adherence analysed 
at passage 5 so as not to be affected by the changes to proliferation rate and 
external chemokine receptor expression associated with long term passaging as 
described in Chapter 3. 
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4.2 Aims. 
 
 To characterise populations of hMSCs derived from different tissues in terms 
of chemokine expression. 
 To compare chemokine receptor profiles of P5 hMSCs to P5 bone marrow 
mMSCs. 
 To investigate functionality of any differences in chemokine receptor 
expression between MSC populations. 
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4.3 Results. 
 
In order to investigate the migratory potential of the hMSCs of differing fetal 
origin, the chemokine receptor profiles for each set of MSCs was characterised using 
flow cytometry. In Fig. 4.1.a. it can be seen that over 45% of 1st trimester amniotic 
fluid-derived hMSCs express either CXCR1 (45.07 ± 22.18%), CXCR3 (64.02 ± 5.99%), 
CXCR4 (48.02 ± 13.43%), CXCR6 (49.39 ± 18.77%), CCR9 (60.16 ± 15.30%) or CCR10 
(54.60 ± 9.77%) on the cell surface. There was expression of CXCR2 (16.54 ± 8.87%) 
and CCR3 (10.07 ± 1.42%) on these cells, although at much lower levels. There was 
little/no expression of CCR2, CCR4, CCR6 and CCR7 on the surface of the cells. The 
receptors expressed on the highest proportion of cells was CXCR3 and CCR9, which 
were both expressed by >60% of the 1st trimester amniotic fluid-derived MSC 
population. Representative histogram plots for each chemokine receptor 
investigated can be seen in Fig. 4.1.b. For each of the highly expressed receptors 
(>45%) it is a sub-population of MSCs which are expressing the receptor on the cell 
surface.  
The chemokine receptor profile on P5 2nd trimester amniotic fluid-derived 
hMSCs can be seen in Fig. 4.2.a. This shows that CXCR3 (52.12 ± 13.37%), CXCR4 
(43.79 ± 1.33%), CXCR6 (41.80 ± 13.13%), CCR9 (61.95 ± 10.34%), and CCR10 (42.02 
± 10.32%) were all expressed by >40% of the hMSC population. There was 
expression at a lower level for CXCR1 (29.93 ± 7.93%), CXCR2 (18.15 ± 6.81%) and 
CCR7 (17.92 ± 9.60%). There was low expression of CCR3 (11.58 ± 3.81%) and CCR4 
(6.07 ± 3.44%) on this MSC population and there was no expression of CCR2 and  
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Fig. 4.1. Comparative external chemokine receptor expression and binding intensity of 1st 
trimester amniotic fluid-derived hMSCs. 
Fig. 4.1.a shows the external chemokine receptor profile for 1st trimester amniotic fluid-
derived hMSCs, determined by FACS analysis. Fig. 4.1.b shows representative FACS 
histograms for each of the external chemokine receptors. Expression levels are illustrated as 
the mean FACS measurements ± SEM. n = 3. 
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Fig. 4.2. Comparative external chemokine receptor expression and binding intensity of 2nd 
trimester amniotic fluid-derived hMSCs. 
Fig. 4.2.a shows the external chemokine receptor profile for 2nd trimester amniotic fluid-
derived hMSCs, determined by FACS analysis. Fig. 4.2.b shows representative FACS 
histograms for each of the external chemokine receptors. Expression levels are illustrated as 
the mean FACS measurements ± SEM. n = 3. 
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Fig. 4.3 Comparative external chemokine receptor expression and binding intensity of 
fetal bone marrow derived hMSCs. 
Fig. 4.3.a shows the external chemokine receptor profile for fetal bone marrow derived 
hMSCs, determined by FACS analysis. Fig. 4.3.b shows representative FACS histograms for 
each of the external chemokine receptors. Expression levels are illustrated as the mean 
FACS measurements ± SEM. n = 3. 
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Fig. 4.4. Comparative external chemokine receptor expression and binding intensity of 
fetal blood derived hMSCs. 
Fig. 4.4.a shows the external chemokine receptor profile for fetal blood derived hMSCs, 
determined by FACS analysis. Fig. 4.4.b shows representative FACS histograms for each of 
the external chemokine receptors. Expression levels are illustrated as the mean FACS 
measurements ± SEM. n = 3. 
  
124 
 
a 
 
b 
 
 
125 
 
Fig. 4.5. Comparative external chemokine receptor expression and binding intensity of 
placental derived hMSCs. 
Fig. 4.5.a shows the external chemokine receptor profile for placental derived hMSCs, 
determined by FACS analysis. Fig. 4.5.b shows representative FACS histograms for each of 
the external chemokine receptors. Expression levels are illustrated as the mean FACS 
measurements ± SEM. n = 3. 
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CCR6. The highest expressed receptors on this population were CXCR3 and CCR9, 
both being expressed by over 50% of the MSC population. Fig. 4.2.b. shows 
representative histogram plots for each of the receptors analysed. Each of the highly 
expressed receptors (CXCR3, CXCR4, CXCR6, CCR9, CCR10) appear to be expressed 
by a defined sub-population of the 2nd trimester amniotic fluid-derived hMSCs. The 
chemokine receptors expressed at lower levels (CXCR2, CCR3, CCR4, CCR7) did not 
appear to be expressed on a defined sub-population.  
The comparative external chemokine receptor expression on fetal bone 
marrow derived MSCs isolated by plastic adherence alone at P5 can be seen in Fig. 
4.3.a. This showed that CXCR3 (48.96 ± 3.27%), CXCR4 (43.62 ± 5.36%), CCR9 (46.97 
± 9.88%) and CCR10 (42.10 ± 1.14%) were expressed on the surface of these hMSCs. 
CXCR1 (32.44 ± 11.66%) and CXCR6 (34.91 ± 8.40%) were also expressed on a 
significant proportion of the cells. There was low levels of expression of CXCR2 
(17.97 ± 9.99%) and CCR7 (15.07 ± 3.41%), and very low or no expression of CCR2, 
CCR3, CCR4 and CCR6 on the surface of these cells. The most highly expressed 
receptors on this population are CXCR3 or CCR9 which were both expressed by 
nearly 50% of the population. Fig. 4.3.b. shows representative histogram FACS plots 
for each of the chemokine receptors analysed. Of the 12 plots, 6 show that the 
expression of the respective chemokine receptors is on a defined sub-population of 
the fetal bone marrow derived hMSCs, as illustrated by a double peak in their 
respective histograms. These 6 histogram plots represent the 6 most highly 
expressed receptors on this population, namely CXCR1, CXCR3, CXCR4, CXCR6, CCR9 
and CCR10. The comparative external chemokine receptor expression on P5 fetal 
blood derived hMSCs isolated by plastic adherence alone can be seen in Fig. 4.4. Fig. 
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4.4.a. shows that there is significant expression of CXCR1 (24.36 ± 13.48%), CXCR3 
(28.82 ± 9.60%), CXCR4 (25.41 ± 10.40%), CXCR6 (21.96 ± 5.52%), CCR9 (41.59 ± 
21.25%), CCR10 (22.25 ± 4.70%), each of which are expressed on the surface of more 
than 20% of the cell population. There is expression, at a lower level, of CXCR2 
(12.40 ± 13.75%) and CCR7 (13.57 ± 9.33%), each of which are present on the 
surface of more than 10% of the population. There is little or no expression of CCR2, 
CCR3, CCR4 and CCR6. CCR9 is expressed on a higher proportion of the population 
than any of the other chemokine receptors, with over 40% of the cells expressing 
the receptor on the cell surface. Fig. 4.4.b. shows representative histogram FACS 
plots for each of the chemokine receptors analysed. Of the 12 plots, 4 show clearly 
that the expression of the respective chemokine receptor is on a defined sub-
population of the fetal blood derived hMSCs, as illustrated by a double peak in the 
FACS histogram plots. These 4 histogram plots are that of CXCR1, CXCR4, CCR9 and 
CCR10. The respective histogram plots of CXCR3 and CXCR6 however show a definite 
shift but no clear double peak and thus, it cannot be suggested that these receptors 
are solely expressed on a sub-population of this set of hMSCs.  
The external chemokine receptor expression on P5 placental derived hMSCs 
isolated by plastic adherence alone can be seen in Fig. 4.5. Fig. 4.5.a shows that 
CXCR3 (44.13 ± 12.08%), CXCR6 (42.82 ± 6.95%), CCR9 (55.77 ± 7.10%) and CCR10 
(44.03 ± 1.99%) are expressed by over 40% of the hMSC population. CXCR1 (31.64 ± 
2.26%) and CXCR4 (30.4 ± 7.92%) are also significantly expressed with over 30% of 
the cells expressing each of the receptors. The remaining 6 chemokine receptors 
which were analysed; CXCR2, CCR2, CCR3, CCR4, CCR6 and CCR7, are not 
significantly expressed on the surface of these cells. All 6 are expressed by <10% of 
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the population. Of all the receptors analysed, CCR9 is expressed on the highest 
proportion of the placental derived hMSCs. Fig. 4.5.b. shows representative 
histogram plots for the external chemokine receptors analysed. Of the 6 receptors 
that stained positively, CXCR1, CXCR3, CXCR4, CCR9 and CCR10, all have double 
peaks showing that the positive cells represent a sub-population within the hMSC 
population. CXCR6 is the only positive receptor which doesn't appear to be solely 
expressed on a sub-population. 
Having obtained external chemokine receptor profile datasets for hMSCs 
isolated from 5 separate sources using the same culture conditions, the profiles can 
now be compared. In doing this, the classification of these cells as MSC populations 
with matching phenotypes could be assessed, and any differences would provide 
insight into the suitability of each source for clinical application. This can be seen in 
Fig. 4.6. Fig. 4.6.a. shows the external chemokine receptor profile of the 5 sets of 
hMSCs. The general pattern of receptor expression is maintained across all subsets. 
There are however, variations in the levels of expression between the hMSCs from 
different sources. Of note is the lack of CCR7 expression on hMSCs derived from 1st 
trimester amniotic fluid. Of the 5 most abundantly expressed receptors across the 
hMSC sets, hMSCs derived from amniotic fluid show the highest percentage of 
positive cells, with 1st trimester amniotic fluid-derived hMSCs expressing the highest 
receptor levels for 4 out of 5 of them (CXCR3, CXCR4, CXCR6, CCR10). For all 5 of the 
highly expressed receptors, fetal blood derived hMSCs had the lowest percentage of 
cells positive for each receptor. The binding intensity of the chemokine receptor 
marker antibodies, as measured via the mean fluorescence intensity (MFI) has also 
been compared (Fig. 4.6.b). This gives an indication of the comparative levels of each  
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Fig. 4.6. Comparative external chemokine receptor expression and binding intensity of 
fetal hMSCs. 
Fig. 4.6.a. shows the external chemokine receptor profile for various sources of fetal derived 
hMSCs, determined by FACS analysis. Fig. 4.6.b shows the pattern of external chemokine 
receptor binding intensity for the various receptors on the different cell sources. Expression 
levels are illustrated as the mean FACS measurements ± SEM. n = 2-3. 
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Fig. 4.7. Comparative intracellular chemokine receptor expression of fetal hMSCs. 
Intracellular chemokine receptor profile for various sources of fetal derived hMSCs, 
determined by FACS analysis. Expression levels are illustrated as the mean FACS 
measurements ± SEM. n = 1-3. 
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chemokine receptor on individual cells. As with the percentages of cells expressing 
each receptor, the MFI levels are preserved across the hMSC sets for each receptor. 
There is no notable variation between the hMSCs derived from different cell 
sources. However, these MFI levels are a representation of the whole cell population 
and not necessarily representative of the chemokine expressing sub-population. 
In Chapter 3, intracellular levels were investigated and demonstrated that mMSCs 
express high levels of chemokine receptors intracellularly. If these sets of hMSCs 
also display high levels of chemokine receptors intracellularly, there is the potential 
for upregulation of chemokine receptors on the cell surface. It is hypothesised that 
increased levels of chemokine receptors on the cell surface could lead to increased 
migratory activity toward the ligand for each relevant receptor. This has implications 
for clinical therapies where greater levels of MSCs may be directed to target sites via 
chemokine administration at the site. Fig. 4.7. shows a comparison of intracellular 
chemokine receptor expression on the 5 sets of hMSCs isolated from different 
sources. Of the 7 chemokine receptors analysed, 3 of the receptors were expressed 
at high levels (>70%) of all 5 hMSC subsets (CXCR3, CXCR4, CCR9). Fetal blood, fetal 
bone marrow and 1st trimester derived hMSCs expressed high levels of CCR10 
(>70%), whereas a lower, but still significant percentage (40-50%) of 2nd trimester 
amniotic fluid and placental derived hMSCs expressed CCR10 intracellularly. CXCR2 
was expressed at low levels on cells (>20%) in all hMSC groups. CXCR6 and CCR6 
showed varying levels of intracellular expression across the 5 hMSC sets. CXCR6 was 
expressed on 80% of 1st trimester amniotic fluid-derived hMSCs, ~60% of fetal bone 
marrow and 2nd trimester amniotic fluid-derived hMSCs, and ~40% of fetal blood 
and placental derived hMSCs. CCR6 was expressed on 60-70% of fetal blood, fetal  
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Fig. 4.8. Boyden chamber chemotaxis of human fetal blood and bone marrow derived 
MSCs towards CXCL12, CXCL10, CXCL16 & CCL27. 
Fig. 4.8.a. Comparison of CXCR3, CXCR4, CXCR6 and CCR10 expression on the surface of fetal 
blood and fetal bone marrow derived hMSCs. Fig. 4.8.b. Boyden chamber chemotaxis of 
human fetal blood and human fetal bone marrow derived MSCs towards ligands of 4 highest 
expressed chemokine receptors (10ng/ml), as determined by external chemokine receptor 
FACS analysis. Expression levels are illustrated as the mean FACS measurements ± SEM. 
Statistical analysis using students t-test. *p < 0.05, and **p < 0.01 between selected groups. 
n = 3. 
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bone marrow and 1st trimester amniotic fluid-derived hMSCs, 40% of 2nd trimester 
derived hMSCs and <20% of placental derived hMSCs.  
The relevance of any subtle differences in external chemokine receptor levels 
in Fig. 4.6. must be assessed in order to demonstrate the clinical relevance of this 
novel data. To compare functionality of external chemokine receptor expression 
levels on hMSCs derived from different sources, chemotaxis assays were carried out. 
The chemotactic ability of hMSCs derived from fetal bone marrow and fetal blood at 
P5 can be seen in Fig. 4.8. Fig. 4.8.a. shows a comparison of 4 of the highest 
expressed receptors on the hMSCs between the fetal blood and fetal bone marrow 
derived hMSCs. Fetal bone marrow derived hMSCs express significantly higher levels 
of CXCR3 and CCR10 on their surface than fetal blood derived hMSCs. Fig. 4.8.b. 
illustrates the functionality of CXCR4, CXCR4, CXCR6 and CCR10 in chemotaxis assays 
to their respective ligands. Greater numbers of the fetal bone marrow cells migrate 
to each of the ligands (CXCL12, CXCL10, CXCL16 and CCL27). The difference is only 
significant for CCR10 migration to CCL27. However, for both sets of cells the number 
of cells that have chemotaxed to the 4 ligands is higher than basal levels. 
For both sets of cells, the highest level of chemotaxis is to CXCL12. For both 
sets of these cells the corresponding receptor for CXCL12, CXCR4 is the highest 
expressed receptor. The functional relevance of this remains unclear. However, in 
order to further confirm the validity of mMSCs as a research model, the ability of the 
5 sets of fetal hMSCs to produce CXCL12 was investigated. CXCL12 levels in the 
culture media of P5 cells cultured for 72 hours were measured (Fig. 4.9). All 5 sets of 
cells create large amounts of CXCL12. Of note, there are no significant differences in 
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the levels of CXCL12 produced by the 5 sets of hMSCs isolated from different 
sources, as compared by one-way ANOVA followed by Bonferroni multiple-
comparisons test. 
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Fig. 4.9. CXCL12 production by P5 hMSCs obtained from different sources. 
CXCL12 levels in hMSC supernatants were measured using ELISAs after 3 days culture in 
vitro in T75 flasks. Levels are quantified per ml of supernatant. Expression levels are 
illustrated as the mean ELISA measurements ± SEM. n = 4. 
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4.4 Discussion. 
 
Having determined that mMSCs express a distinct profile of chemokine 
receptors, comparisons were made with human adult bone marrow MSCs and then 
MSCs from a range of fetal tissue sources [134]. The external chemokine receptor 
profile has been characterised for all 5 sets of hMSCs investigated in this chapter. 
Strikingly, each set of P5 hMSCs displays a similar external chemokine receptor 
profile. This general trend can be seen in Table. 4.1. 
Table. 4.1. Expression of external chemokine receptors on hMSCs. 
Expression Level External Receptors 
High (>40%) CXCR3, CXCR4, CXCR6, CCR9, CCR10 
Mid (10-40%) CXCR1, CXCR2, CCR7 
Low/Negative (<10%) CCR2, CCR3, CCR4, CCR6 
 
Not only does this novel data suggest that hMSCs from different sources are 
highly conserved in their phenotype with respect to chemokine receptor expression, 
the subtle differences between populations may be important to consider when 
deciding which hMSC populations are to be used for different cell therapies. Of the 5 
highest expressed receptors across the hMSC populations, amniotic fluid-derived 
hMSCs show the highest expression levels, with 1st trimester amniotic fluid-derived 
hMSCs expressing the highest levels of CXCR3, CXCR4, CXCR6 and CCR10 of all 5 
populations. These 4 receptors were investigated in terms of chemotactic ability on 
P5 bone marrow mMSCs due to the high levels of expression on the surface of the 
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mMSCs. Of the 5 hMSC populations, fetal blood derived hMSCs have the lowest 
expression levels for each of the receptors.  
The variations in chemokine receptor levels across the hMSC populations 
investigated in this chapter were not shown to be functional when comparing the 
ability of human fetal blood and human fetal bone marrow derived hMSCS to 
chemotax to CXCL12, CXCL10, CXCL16 (ligands for CXCR4, CXCR3, and CXCR6 
respectively). Representative histogram plots of these populations show that the 
cells which stain positive for CXCR1, CXCR2, CXCR3, CXCR4, CCR9 and CCR10 
represent a sub-population of the total hMSC populations. It is unknown whether 
these sub-populations express multiple chemokine receptors or a single receptor. 
Future experiments could investigate whether greater numbers of hMSCs will 
migrate to media containing multiple chemokines of interest. This has clinical 
relevance when hoping to direct high numbers of hMSCs to a defined region [314]. 
Further investigation of these chemokine receptor positive subsets may also identify 
homogeneous sub-populations of hMSCs or mesenchymal progenitor cells (MPCs). 
In terms of hMSCs from different sources, the subtle differences in chemotactic 
ability between fetal blood and fetal bone marrow derived hMSCs suggests that 
stem cell populations which express higher levels of chemokine receptors will 
migrate more efficiently to sites of injury of inflammation. Considering this, it can be 
hypothesised that human amniotic fluid hMSCs, particularly 1st trimester amniotic 
fluid-derived hMSCs are the most suitable of the 5 populations analysed for use in 
clinical therapy. Although there were no notable differences in the MFI of whole 
populations, further analysis of the chemokine receptor positive sub-populations 
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and the changes in MFI between sources may show differences in levels of 
expression at a cellular level. 
Whilst the external chemokine receptor profile of hMSCs is consistent with 
that of mMSCs reported in Chapter 3, there are some differences to previously 
reported levels on adult bone marrow derived hMSCS.  Chamberlain et al reported 
high levels of CCR3 and CCR2 on the cells surface, which were not expressed on the 
fetal hMSCs described here. They did however see high levels of CXCR3, CXCR6 and 
CCR9, consistent with levels reported here [134]. Sordi et al also report expression 
of CXCR3, CXCR6 and CCR9 on the cell surface, although at much lower levels [315]. 
These differences can be attributed to differences in the duration of culture and the 
seeding density. 
Currently umbilical cord blood and adult bone marrow derived MSCs are the 
most commonly banked MSC populations [77]. Of the 5 sources of hMSCs described 
in this chapter, there are ethical concerns regarding the clinical use of fetal blood 
and fetal bone marrow derived hMSCs. However, amniotic fluid and placental 
derived hMSCs are generally discarded materials. Currently thousands of pregnant 
women undergo amniocentesis procedures annually [316]. Unused amniotic fluid 
could be used to culture cells for banking to provide an alternative source of 
potentially viable hMSCs for future cell therapies. 
The paracrine effects of MSCs are thought to be playing a role in resolving 
injury and inflammation. For this reason, CXCL12 levels produced by hMSCs from the 
5 different sources are compared. All 5 populations produce large amounts of 
CXCL12 when cultured in vitro. However, there are no significant differences in 
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levels between the populations. Future experiments will examine the secretome of 
MSCs derived from different sources. The expression of chemokine receptors on the 
surface of all MSC populations investigated, subsequent chemotactic ability and 
paracrine effects suggest that any one of these populations is a good candidate for 
clinical use. Further interrogation of the heterogeneous hMSC populations may 
provide homogeneous populations of MSCs which are better suited for the 
treatment of specific diseases, depending on the specific range of chemokines 
produced as a result of said diseases or injuries. All of the data from the hMSC 
populations in Chapter 4 is highly consistent with the data on P5 bone marrow 
mMSCs in Chapter 3, adding further confidence in the use of these cells as a model 
for hMSCs.  
Of note these studies indicate that the profile of chemokine receptors 
expressed by hMSCs is consistent across different tissue sources of these MSCs. 
Moreover this pattern is consistent across species. These studies indicate that MSCs 
isolated by this methodology are not a homogeneous population as there are clear 
sub-populations expressing specific chemokine receptors. Assuming that chemokine 
receptors orchestrate the recruitment of MSCs to sites of injury or inflammation, it 
can be deduced that specific sub-populations of MSCs may be recruited to sites 
expressing defined chemokines. It will be important therefore to further 
characterise these sub-populations with respect to their ability to differentiate into 
specific lineages and their secretome. 
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5. Characterisation of PαS cells. 
 
5.1 Introduction. 
 
There are no specific markers for murine MSCs. Thus different research 
groups often have conflicting data as they compare heterogeneous and therefore 
different populations. This is often as a result of variations in isolation techniques 
[275,276,317]. To date the most consistent way to isolate and characterise mMSCs 
has been isolation via depletion assays in addition to plastic adherence, for analysis 
at early passage. This is problematic, as it is also known that persistent passaging of 
MSCs may cause phenotypic and functional changes in MSCs [129]. Plastic is an 
unnatural material for cells to grow on, and culture conditions are generally 
optimised for proliferation rather than the maintenance of MSCs. As demonstrated 
in Chapters 3 and 4, these culture methods result in a heterogeneous population of 
adherent cells that contain a percentage of unidentified, putative stem cells. This 
makes it very difficult to predict how MSCs are acting in vivo [115]. This is not the 
case for other stem cells. HSCs can be identified via surface markers, sorted and 
transplanted without ever undergoing culture. This has resulted in a rapid growth of 
knowledge of HSC biology and how they function in vivo [318,319]. It can be 
hypothesised that identification of specific mMSC markers will result in a similar 
rapid expansion in the knowledge of MSC biology. mMSCs are far more difficult to 
isolate and more susceptible to haematopoietic cell contamination than hMSCs 
[320]. For this reason, there has been more research on hMSCs than mMSCs. This 
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lack of research into how MSCs act in mouse models has greatly hindered the 
exploitation of the therapeutic potential of MSCs. 
Recent research identifying MSC specific markers has reported specific 
marker combinations to identify homogeneous populations of murine bone marrow 
derived MSCs [321,322,323,324]. Of note, Morikawa et al reported methodology for 
prospectively identifying and isolating MSCs from murine bone marrow using flow 
cytometry [124]. This sorted population gives rise to MSCs that are capable of in vivo 
engraftment when transplanted systemically and can generate mesenchymal and 
neural crest lineage cells with or without in vivo expansion [144]. This MSC 
population, termed PαS cells, are isolated as PDGFR-α+, Sca-1+, CD45-, Ter119- 
murine bone marrow cells. mMSC cultures are often contaminated with 
haematopoietic cells [325]. CD45 is expressed at high levels on the cell surface of all 
nucleated haematopoietic cells and their precursors, and Ter119 is expressed on 
cells of erythroid lineage [326,327]. By selectively sorting for cells which are negative 
for these two markers, the mMSC population is haematopoietic cell free. Via a 
screening process, platelet derived growth factor receptor-α (PDGFR-a an early 
mesodermal marker [328]) and stem cell antigen-1 (Sca-1 [329]), a murine stem cell 
marker, were found to be good selective markers for a population of homogeneous 
MSCs. The identification of this marker combination enables in vivo examination of 
MSCs which were found to be predominantly located in the arterial perivascular 
space near the bone adjacent to the vascular smooth muscle cells (vSMCs) [124]. 
Interestingly, i.v. administration of uncultured PαS cells, were found to integrate 
into both the bone marrow and adipose tissue of mice [124]. Two fundamental 
problems with in vitro culture of MSCs is their loss of migratory capacity with 
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continued culture [129] and their increased size, causing them to become entrapped 
in the lungs when administered i.v. [330]. PαS cells expanded in vitro were also 
found to become entrapped in the lungs [124]. This may be due to changes in cell 
morphology and increase in the size of the PαS cells upon 2D culture on plastic. PαS 
cells isolated directly from murine bone marrow are very small relative to the rest of 
the cells in the cells in the bone marrow. These results add further weight to the 
argument that in order to recruit to target sites in vivo, MSCs should not be 
expanded ex vivo. 
Other homogeneous stem cell sub-populations have been identified in 
murine bone marrow. These include marrow isolated adult multilineage inducible 
cells (MIAMIs) [324], multipotent adult progenitor cells (MAPCs) [322], and very 
small embryonic like cells (VSELs) [321]. MAPCs are isolated via CD45 and Ter119 
depletion, along with selection via analysis in culture, including morphology and high 
Oct-4 mRNA levels. Whilst this set of cells has been highly researched and shown to 
have many favourable characteristics for clinical therapy, they cannot be identified 
in vivo [322]. This is also the case for MIAMIs, which are isolated due to their ability 
to form CFU-Fs in vitro [142]. VSELs are CD45-, Lin-, Sca-1+ cells and thus, can be 
sorted in a very similar manner to PαS cells. VSELs are also found to be very small 
indeed, significantly smaller than HSCs (3.63 ± 0.69 versus 6.54 ± 0.17µm in 
diameter) and express Oct-4, a marker of embryonic stem cells [143]. Interestingly, 
PαS cells have been shown to express surface markers common to P5 bone marrow 
mMSCs including CD105 and VEGFR-2, and differentiate robustly into adipocytes, 
chondrocytes and osteoblasts. As yet, PαS cells have only been identified in the 
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bone marrow, but clearly it is possible to investigate whether these cells are present 
in other tissues.  
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5.2 Aims. 
 
 To identify and further characterise the PαS cell population found in murine 
bone marrow. 
 To investigate the effects of in vitro culture on the PαS cell population. 
 To compare the external chemokine receptor expression profile of PαS cells 
with that of P5 bone marrow mMSCs. 
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5.3 Results. 
 
A lack of common markers for mMSCs has led to discrepancies in the 
standardisation of mMSC characterisation [85]. By sorting PαS cells, a clearly defined 
population of mMSCs defined by antigen expression alone can be used for in vivo 
detection. In order to further characterise PαS in terms of chemokine receptor 
profiling and the effects of in vitro culture on this population, the previously 
published isolation techniques were reproduced [124]. The results of PαS cell sorting 
can be seen in Fig. 5.1. Figs. 5.1.a.i, ii and iii are FACS dot plots of whole femoral 
bone marrow stained with fluorescent antibodies for CD45 (FITC), Ter119 (FITC), 
PDGFR-α (APC) and Sca-1 (PE). By gating the CD45- and Ter119- (FITC-) cells and 
subsequently gating the PDGFR-α+, Sca-1+ cells, a population of PαS cells was 
isolated. These PαS cells are a rare population, making up only 0.08 ± 0.04% of the 
total bone marrow (Fig. 5.1.b.ii). In Figs. 5.1.b.i and 5.1.b.ii, it can be seen that there 
were large numbers of cells in the bone marrow which were either CD45-, Ter119-, 
PDGFR-α+, Sca-1- or CD45-, Ter119-, PDGFR-α-, Sca-1+, consistent with previous 
findings [124]. It has been reported that a greater number of PαS cells can be sorted 
in a shorter time period by treating crushed bone with collagenase [124]. Having 
isolated PαS cells from murine bone marrow, murine femurs were crushed and 
treated with different isoforms of collagenase. The resulting relative percentages of 
PαS cells in the bone marrow or bone populations is illustrated in Fig. 5.2.a and 
representative dot plots can be seen in Fig. 5.2.b. Collagenase treatment of crushed 
bones resulted in 0.27 ± 0.06% PαS cells compared to 0.08 ± 0.04% of the murine  
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Fig. 5.1. Identification and isolation of PαS cells from murine bone marrow. 
Fig. 5.1.a. PαS cells are isolated from the bone marrow (Fig. 5.1.a.i) and defined as CD45- 
Ter119- (Fig. 5.1.a.ii) PDGFRα+ Sca-1+ (Fig. 5.1.a.iii). Quantification of levels of PαS cell 
numbers found in murine bone marrow per million cells (Fig. 5.1.b.i) and as a percentage of 
the total bone marrow (Fig. 5.1.b.ii). 
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Fig. 5.2. Isolation of PαS cells from murine bone marrow or bone via collagenase 
treatment. 
Fig. 5.2.a. Quantification of PαS as a percentage of the total number of cells sorted, when 
isolated using different protocols. Fig. 5.2.b. PαS cells isolated from the bone marrow via 
flushing with DMEM + 10% FCS. Fig. 5.2.c. PαS cells isolated from flushed murine femurs and 
tibias after crushing with a pestle and mortar and collagenase 1 treatment for 1 hour in a 
37oC shaking water bath. Fig. 5.2.d. PαS cells isolated from flushed murine femurs and tibias 
after crushing with a pestle and mortar and collagenase 2 & 4 treatment for 1 hour in a 37oC 
shaking water bath. 
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Fig. 5.3. Differential expression of CD34 on CD45- Ter119- bone marrow subgroups as 
defined by PDGFRα and Sca-1 expression. 
Fig. 5.3.a. Quantification of CD34 expression on CD45- Ter119- bone marrow subgroups as 
defined by PDGFRα and Sca-1 expression. n = 3. Fig. 5.3.b. Expression of CD34 on CD45-, 
Ter119-, PDGFRα-, Sca-1+. Fig. 5.3.c. Expression of CD34 on CD45-, Ter119-, PDGFRα+, Sca-
1-. Fig. 5.3.d. Expression of CD34 on CD45-, Ter119-, PDGFRα-, Sca-1-. Fig. 5.3.e. Expression 
of CD34 on CD45-, Ter119-, PDGFRα+, Sca-1-.  
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bone marrow and 4.6 x 10-4 ± 7.07 x 10-7% of flushed bones treated with 
collagenases 2 and 4. But importantly, absolute numbers of PαS cells that could be 
harvested by these procedures were e.g. 12720 per femur by flushing and 10530 per 
femur by crushing the bones, suggesting that while PαS cells represent a significantly 
higher percentage of cells in bone, similar numbers can be isolated from both 
sources. 
Having consistently identified and sorted PαS cells from murine bone marrow 
and crushed bone, further characterisation of uncultured PαS cells was carried out 
by investigating the expression of other cellular markers in a 4th FACS channel. This 
was the case for CD34 expression on PαS cells as illustrated in Fig. 5.3. which shows 
uncultured PαS cells stained with CD34 in the PE-Cy-7 channel. Of the 4 sub-
populations in Fig. 5.3, it can be seen that PαS cells (blue, upper right quadrant), 
CD45-, Ter119-, PDGFR-α-, Sca-1- cells (yellow, bottom left quadrant) and CD45-, 
Ter119-, PDGFR-α+, Sca-1- (purple, bottom right quadrant) cells expressed no CD34 
on the cell surface. However CD45-, Ter119, PDGFR-α-, Sca-1+ cells (green, top left 
quadrant) showed high levels of CD34 on the cell surface. In order to compare PαS 
cells with the P5 bone marrow mMSC population isolated and characterised in 
Chapter 3, various markers on the cell surface of PαS cells were analysed including 
murine MSC markers, VEGFRs (Fig. 5.4) and chemokine receptors (Fig. 5.5). PαS cells 
were negative for CD45, CD11b, CD34, AC133 and VEGFR-3 on the cell surface. PαS 
cells expressed high levels of CD105, Sca-1, VEGFR-1, and an intermediate 
percentage of the population expressed VEGFR-2. It appears that there was a sub-
population expressing VEGFR-1 and VEGFR-2. Uncultured PαS cells expressed high 
levels of CXCR3 (88.20 ± 1.98%), CXCR4 (87.72 ± 3.58%), and CCR10 (54.55 ± 7.14%).   
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Fig. 5.4. Expression of murine MSC markers on P5 PαS cells. 
Fig. 5.4.a. Quantification of MSC markers on P5 PαS cells. n=1-2. Fig. 5.4.b. Representative 
histogram plots of MSC markers on P5 PαS cells. 
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Fig. 5.5. External chemokine receptor expression on P5 PαS cells. 
Fig. 5.5.a. Flushed bone marrow cells were stained for CD45, Ter119, PDGFRα, Sca-1 and 
either CXCR3, CXCR4 or CCR10. Expression levels of CXCR3, CXCR4 and CCR10 were recorded 
on cells that were CD45- Ter119- PDGFRα+ Sca-1+. n = 3. Fig. 5.5.b. Sorted PαS cell 
populations were cultured in Mesencult (StemCell technologies) at 37oC. 5% CO2 to passage 
5. Cells were trypsinised, recovered and analysed for external chemokine receptor 
expression. 1 x 105 cells were used to stain for each receptor. Representative external 
chemokine receptor expression levels of P5 PαS cells were measured using a FACSCalibur 
flow cytometer (BD Biosciences) and analysed using CellQuest software. n = 1. Fig. 5.5.c. 
FACS histogram plots of external chemokine receptor expression on PαS cells at passage 5. 
Data shown is representative. Fig. 5.6.d. A comparison of CXCR3, CXCR4 and CCR10 
expression on uncultured PαS cells, PαS cells cultured to P5 and murine bone marrow MSCs 
isolated by plastic adherence alone. n=1-3. 
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Fig. 5.6. Quantitative PCR of PαS cells, mES cells and mMSCs. 
Quantitative PCR of P5 PαS cells, P5 mES cells and P5 mMSCs. RNA isolation and DNAse 
treatment was performed using a liquid handling system (BiomekFxp, Beckman Coulter) to 
automate and integrate protocols from Agencourt RNAdvance Cell v2 (Beckman Coulter) 
and TURBO DNA-free (Applied Biosystems). Reverse transcription was performed using the 
High-capacity cDNA Reverse Transcription kit (Applied Biosystems) using Veriti thermal 
cycler (Applied Biosystems). Quantitative PCR was performed on a 7900HT (Applied 
Biosystems) using Taqman gene expressions assays including FAM™ dye-labelled TaqMan® 
MGB probe and primers set spanning 2 exons each specific for the target genes (Fgfr1, Fgfr2, 
Fgfr3 and Fgfr4) and the loading controls (Hmbs and Gapdh). 
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Upon culture to passage 5 in the same culture conditions in which P5 bone 
marrow mMSCs were cultured in Chapter 3, PαS cells expressed high levels of 
CXCR3, CXCR4, CCR3 and CCR7. They expressed lower levels of CXCR2, CXCR6, CCR4, 
CCR6 and CCR10. When the external CXCR3, CXCR4 and CCR10 levels are compared 
in Fig. 5.5.d. between P5 bone marrow mMSCs, uncultured PαS cells and P5 PαS 
cells, there were notable differences. P5 bone marrow mMSCs and P5 PαS cells 
showed comparable expression of CXCR4 and CCR10. Uncultured PαS cells 
expressed higher levels of CXCR4 on the cell surface than P5 PαS cells and P5 bone 
marrow mMSCs. There was no difference in CXCR3 expression between uncultured 
and P5 PαS cells. However CXCR3 was expressed on a much lower percent of P5 
bone marrow mMSCs. Due to the rarity of PαS cells in the bone marrow, less than 1 
x 105 cells can be sorted at any one time, at great cost. For this reason, only 
preliminary experiments investigating the culture of PαS cells have been carried out 
to date. 
PαS cells can differentiate into cells of the neural lineage and express 
markers which are used to identify ES cells such as AbcG2 and Tbx2. It has been 
hypothesised that PαS cells may be phenotypically closer to mES cells than mMSCs 
[124]. To compare PαS, mMSCs and mES cells in more detail, QRT-PCR was carried 
out on the three cell populations to compare the expression of 45 relevant genes. In 
Fig. 5.6. it can be seen that PαS cells were phenotypically closer to mMSCs and that 
there are notable differences in the gene expression profile between PαS cells an 
mES cells, including Nanog, a transcription factor critically involved with self renewal 
of undifferentiated ES cells [24]. 
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The isolation of a homogeneous population of mMSCs is very appealing with 
respect to their characterisation in vivo. However, investigation into their 
therapeutic potential may require larger numbers than those which can be 
efficiently sorted. To achieve this, the cells must be cultured ex vivo. Bone marrow 
derived MSCs isolated by plastic adherence alone have been shown to be a 
heterogeneous population that undergo phenotypic and functional changes with 
continued culture in vitro [129]. To ascertain whether this is also true for PαS cells, 
PαS cells were cultured to passage 5 and compared with P5 and P25 murine bone 
marrow mMSCs for expression of CD45, Ter119, PDGFR-α and Sca-1 (Fig. 5.7). At 
passage 5, only 41.8% of cultured PαS cells stain as CD45-, Ter119-, PDGFR-α+, Sca-
1+, meaning that only 41.8% of this population is a homogeneous population of 
MSCs and the remaining 58.2% have undergone phenotypic changes due to in vitro 
culture conditions. In Fig. 5.7.e. the levels of PαS cells within uncultured bone 
marrow, P5 bone marrow mMSCs, P5 PαS cells and P25 bone marrow mMSCs are 
compared. There is no significant difference in the percentage of the cells that are 
PαS cells in the P5 PαS, P5 bone marrow mMSC, P25 bone marrow mMSC cultures. 
There is no difference in the levels of CD45-, Ter119-, PDGFR-α+, Sca-1- cells and 
CD45-, Ter119-, PDGFR-α-, Sca-1+ cells in the P5 and P25 bone marrow mMSC 
populations. P5 PαS cells have within their number higher levels of CD45-, Ter119-, 
PDGFR-α+, Sca-1- and lower levels of CD45-, Ter119-, PDGFR-α-, Sca-1+ cells when 
compared to P5 and P25 bone marrow mMSCs. Interestingly, the dot plots in Figs. 
5.7.a-d highlight differences in the profiles of the PαS cells within the cultured 
populations (e.g. PαS cells in the P5 bone marrow mMSC population are Sca-1lo 
whereas PαS cells in the P25 bone marrow mMSC  
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Fig. 5.7. Percentage of PαS cells in different cell populations. 
Cells from different sources were stained for CD45, Ter119, PDGFRα and Sca-1. Fig. 5.7.a. 
Quantification of PαS levels in bone marrow cell populations isolated by flushing of murine 
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femurs and tibias measured by FACS (Fig. 5.7.a.i). Representative dot plot of PαS levels in 
bone marrow cell populations isolated by flushing of murine femurs and tibias measured by 
FACS (Fig. 5.7.a.ii). Fig. 5.7.b. Quantification of PαS levels in P5 mMSCs isolated by plastic 
adherence alone, measured by FACS (Fig. 5.7.b.i). Representative dot plot of PαS levels in P5 
mMSCs isolated by plastic adherence alone, measured by FACS (Fig. 5.7.b.ii). Fig. 5.7.c. 
Quantification of PαS levels in FACS sorted PαS cultured to P5 in Mesencult, measured by 
FACS (Fig. 5.7.c.i). Representative dot plot of PαS levels in FACS sorted PαS cultured to P5 in 
Mesencult, measured by FACS (Fig. 5.7.c.ii). Fig 5.7.d. Quantification of PαS levels in P25 
mMSCs isolated by plastic adherence alone, measured by FACS (Fig. 5.7.d.i). Representative 
dot plot of PαS levels in P5 mMSCs isolated by plastic adherence alone, measured by FACS 
(Fig. 5.7.d.ii). Fig. 5.7.e. Comparison of sub-populations between sources of PαS cells as a 
percentage of the source population. n = 1-3. 
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population are Sca-1hi), demonstrating the impact of continued culture on the PαS 
cells. 
It has been reported that cultured MSCs when administered to mouse 
models i.v. can result in death, as well as causing pulmonary and hemodynamic 
alterations, thus preventing the intended access to other organs. [193]. We propose 
that the increase in the size of the MSCs upon culture leads to entrapment of the 
cells within the lungs. Upon their characterisation, the small size of VSELs was seen 
as an advantageous quality as these cells can circumvent any entrapment problems 
when administered [331]. In Fig. 5.8.a. the size of cultured PαS cells is compared to 
VSELs. Both sets of cells are of similar size and are very small in relation to other cells 
residing in the bone marrow. To confirm whether or not cells grow in size upon 
continued culture on plastic surfaces, the size of uncultured PαS cells has been 
compared to PαS cells within the P25 bone marrow mMSC population. (Fig. 5.8.b) 
Whilst there is some overlap between the two sets of cells, there is a lot more 
variation in the size of the PαS cells cultured to P25. The vast majority of PαS cells in 
the P25 bone marrow mMSC population are much larger than the uncultured PαS 
cells.  
As PαS cells are a newly characterised population of cells, there are still 
several variables which are yet to be investigated. In humans, adults have lower 
levels of MSCs in the bone marrow than infants [71]. This has implications when 
deciding what age mice to use for future research on PαS cells. To see if this 
difference is maintained for PαS cells, levels were compared between young (2.5 
160 
 
weeks) and old (30 weeks) mice. There are more PαS cells in the bone marrow of 
young mice (1086 ± 80.16) than old mice (568.3 ± 179.6) (Fig. 5.9). 
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Fig. 5.8. Comparison of PαS cells with VSELs. 
Fig. 5.8.a. PαS cells were identified using FACS analysis (blue). Fig. 5.8.b. The PαS cells were 
back-gated in order to visualise their size in comparison with the rest of the cells of the bone 
marrow. Fig. 5.8.c. Data from Kucia et al, 2006 [321] illustrating the size of very small 
embryonic like (VSEL) cells in comparison to the rest of the bone marrow. Fig. 5.8.d. Density 
plot to compare the size of uncultured PαS cells (blue) to PαS cells in the population of late 
passage (P25) cultured bone marrow derived mMSCs (red). 
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Fig. 5.9. Comparison of PαS cells in the bone marrow of young (2.5 weeks old) and old (30 
weeks old) mice. 
Bone marrow was flushed from murine femurs and tibias. Fig. 5.9.a. Quantification of the 
levels of PαS cells in the bone marrow of young (2.5 weeks old) and old (30 weeks old) mice 
per million bone marrow cells. Fig. 5.9.b. Representative dot plot of PαS cells (blue) in young 
(2.5 weeks old) mice (Fig 5.9.b.i). Representative dot plot of PαS cells (blue) in old (30 weeks 
old) mice (Fig. 5.9.b.i). 
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5.4 Discussion. 
 
In identifying PαS cells as bone marrow derived mMSCs, the properties of 
MSCs in their natural state in vivo can be investigated. As PαS cells are a newly 
characterised population, isolation of the cells using reported methodology needed 
to be shown to be reproducible [124]. PαS cells cannot be identified in humans due 
to the lack of a Sca-1 homolog. The homogeneity of the population combined with 
the availability of mouse models of disease and inflammation makes PαS cells a 
good candidate for the interrogation of MSC biology in vivo. PαS cells are very small 
in relation to the rest of the cells in the bone marrow. This may be a functional 
requirement of MSCs in order to traffic efficiently around the body. It is known that 
cultured PαS cells when injected into mice i.v., become entrapped in the lungs 
whereas uncultured cells migrate to the bone marrow and adipose tissue therefore 
being able to circulate unhindered [124]. The rarity of the PαS cells is not surprising, 
at 0.01% of the bone marrow. This is consistent with previous reports of MSC cell 
numbers [278,332]. Previous reports interrogating the functionality of the 4 subsets 
of CD45- Ter119- bone marrow cells, as defined by their PDGFRα and Sca-1 
expression, showed that both CD45-, Ter119-, PDGFRα+, Sca-1- cells and CD45-, 
Ter119-, PDGFRα-, Sca-1+ cells can be classified as heterogeneous populations of 
MSCs. This is because they fulfil all of the criteria to be classified as MSCs [278]. They 
adhere and proliferate on plastic surfaces and a percentage of the population can be 
differentiated along osteogenic, adipogenic and chondrogenic lineages. It was 
hypothesised that these subsets may be mesenchymal progenitor cells as opposed 
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to the homogeneous population of PαS cells which have greater levels of plasticity 
and proliferation [144]. Two methods of isolating PαS from the femurs of mice have 
been reported, with differing levels of efficiency. By treating flushed and crushed 
femurs with collagenase, a higher percentage of PαS cells were isolated [124]. 
Flushed and crushed femurs were treated with different forms of 
collagenase. These results show that PαS cells harvested from crushed femurs is 
dependent on collagenase-1 and that treatment with collagenase 2 and 4 does not 
result in the isolation of these cells. Fig. 5.2.a. shows that when using collagenase-1 
treatment on crushed femurs, 0.3% of the cells isolated were PαS cells. Although this 
is significantly higher than the percentage obtained from untreated flushed bone 
marrow, the levels were not consistent with previous reports, which showed higher 
levels of PαS cells isolated [124]. Significantly, absolute numbers of PαS cells were 
higher in the bone marrow of naïve mice when compared to collagenase-1 treated 
crushed bones. This is due to differences in the total number of cells from which PαS 
cells can be sorted e.g. 15.9 x 106 cells from the bone marrow of one femur versus 
3.9 x 106 cells from a collagenase-1 treated crushed femur. In attempting to further 
characterise the subsets of CD45- Ter 119-, as defined by PDGFRα and Sca-1 
expression, CD34 expression levels on the sub-populations were investigated. CD34 
is generally used as a marker for haematopoietic and endothelial progenitor cells, 
however subsets of MSCs which are CD34+ have been reported [85]. Analysis of the 
4 subsets shows that the CD45-, Ter119-, PDGFRα-, Sca-1+ cells express high levels 
of CD34, whereas the other 3 subsets including PαS cells do not. This CD34+ subset 
is one of the two that Morikawa et al referred to as a progenitor subset. Morikawa 
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et al hypothesised that these cells have slightly less plasticity than the PαS cells, and 
are more likely to be progenitors for osteoblasts [124]. 
Identification of these cells within the bone marrow allowed the opportunity 
to check whether the P5 bone marrow mMSCs characterised in Chapter 3, were a 
true population of MSCs in comparison to their in vivo state. Having illustrated the 
detrimental effect continued passage has on chemokine receptor expression on 
these cells, the effects of culture on the phenotype of MSCs was investigated. When 
looking at stem cell markers, the PαS cells displayed a similar phenotype to the P5 
bone marrow mMSCs isolated and characterised in Chapter 3. Interestingly, PαS cells 
also express high levels of VEGFR-1, an intermediate population express VEGFR-2 
and there is no surface expression of VEGFR-3. This data is consistent with previous 
reports which state that VEGFR-2 is expressed at an intermediate level on the cell 
surface and found no expression of VEGFR-3 [124]. The VEGFR-2 expression on a 
sub-population of PαS cells demonstrates that there are differences in the 
phenotype at the individual cell level. In order to look further at any differences 
there may be, Quantitative PCR of P5 PαS cells, P5 mES cells and P5 mMSCs was 
carried out, looking at 45 genes of interest. The pattern of the gene profiles of P5 
bone marrow mMSCs and PαS cells is highly conserved. Comparison of PαS cells and 
P5 bone marrow mMSCs to mES cells shows there are many genes expressed on 
mES cells that are not expressed on PαS or P5 bone marrow mMSCs. Taking all of 
this information together we can conclude that although PαS cells may be a useful 
set of stem cells to be used therapeutically due to their homogeneity, they are much 
closer phenotypically to classically defined MSCs than ES cells. One of the features 
that make MSCs attractive as a candidate for cell therapy is their ability to home to 
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sites of injury and inflammation. As chemokine receptors on the cell surface of MSCs 
play a critical role in this pathway and chemokine receptor levels decreased with 
repeated passage, chemokine receptor levels on the PαS cells were analysed before 
the cells were cultured. By sorting the PαS cells, chemokine receptor profile on the 
PαS cells following culture in vitro could also be assessed. On uncultured PαS cells, 
CXCR3, CXCR4 and CCR10 are all highly expressed. Upon culture in vitro, due to the 
highly proliferative nature of the cells and a resultant larger population at passage 5, 
a wider range of chemokine receptors could be investigated. When comparing the 2 
sets of data, it is clear that culture of the cells has led to a dramatic decrease in 
CXCR4 and CCR10 on the cell surface. When both sets were compared to the P5 
bone marrow mMSC external receptor profile analysed in Chapter 3, the levels of 
CXCR4 and CCR10 were similarly expressed by both sets of cultured cells at a much 
lower level than the uncultured cells. This provides data to support the hypothesis 
that MSCs, when extracted from the bone marrow and cultured, lose chemokine 
receptors on the cell surface which may impact on the efficiency with which they 
home to sites. The recent characterisation work carried out on PαS cells by 
Morikawa et al [144] suggests that these are a true MSC population. The chemokine 
receptor expression levels reported here, may explain the low levels of engraftment 
at sites of damage in human clinical trials. Interestingly, CXCR3 levels remain high 
when compared to P5 bone marrow mMSCs. This difference is another example of 
how differences in culture techniques can lead to variation in MSC populations 
between labs. This may be due to the paracrine effects of other bone marrow cells 
on the MSCs upon initial culture. 
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Having observed that cultured PαS cells were phenotypically different to 
their uncultured counterparts, maintenance of the CD45-, Ter119-, PDGFRα+, Sca-1+ 
phenotype in cultured PαS cells was investigated. The result of this can be seen in 
Fig. 5.7.a. and 5.7.b. When cultured to passage 5, although 100% of the cells are 
CD45- and Ter119-, only 40% of cells retain both PDGFRα and Sca-1 expression. 10% 
of cells are negative for both of these markers, meaning nearly 50% of the cells are 
now falling into the gates which represent the MPCs. This means that either, the 
adherence of the cells to plastic, the proliferation of cell population, or factors in the 
media are causing the cells to differentiate down specific lineages. The majority of 
the cells in the cultured PαS cell population are CD45-, Ter119-, PDGFRα+, Sca-1- 
MPCs as analysed by FACS. If time permitted, analysis of whether the cells express 
any specific differentiation markers over time may provide information about how 
these culture conditions influence differentiation potential on cultured PαS cells. 
Interestingly, this set of experiments illustrated differences between PαS 
cells and MSCs isolated by plastic adherence alone. Both P5 and P25 bone marrow 
mMSCs have a subset of PαS cells which represent 30-35% of the total population. 
The main difference in the distribution of the PDGFRα±, Sca-1± subsets between 
cultured PαS cells and the MSCs isolated by plastic adherence is that cultured PαS 
have nearly 40% PDGFRα+, Sca-1- and <10% PDGFRα-, Sca-1- cells, whereas P5 and 
P25 bone marrow mMSCs have <10% PDGFRα+, Sca-1- and nearly 40% PDGFRα-, 
Sca-1- cells. This difference in the number of the two progenitor subsets, between 
cultured PαS and bone marrow mMSCs illustrates that the other cells within the 
bone marrow that are initially cultured with the bone marrow mMSCs drive 
differentiation of a population of these stem cells down a specific lineage to become 
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PDGFRα-, Sca-1+ mesenchymal progenitor cells. MSCs isolated by plastic adherence 
alone do indeed represent a heterogeneous population of progenitor cells with a 
sub-population of MSCs, while PαS cells may start off as stem cells but will inevitably 
divide and differentiate upon culture. 
It has been suggested that culture of MSCs changes their size [129]. To 
investigate this further, the size of the PαS cell population in uncultured bone 
marrow and P25 bone marrow mMSCs isolated by plastic adherence alone was 
compared. Fig. 5.8.b. is a density plot which compares the size of these two subsets 
directly. Uncultured PαS cells are very small whilst the vast majority of the P25 PαS 
cells are significantly larger in size. Whether this would affect their functional ability 
to migrate around the body, is yet to be verified. However, considering the mortality 
reports due to airway blockages caused by the i.v. administration of cultured MSCs, 
it can be hypothesised that uncultured PαS cells may traffic more efficiently. 
Development of culture conditions to maintain ‘stemness’ whilst driving 
proliferation is thus desirable for use of MSCs as therapeutic tools. 
The relevance of the size of bone marrow stem cells has been previously 
referred to by Zuba Surma et al in their paper which classifies another subset of 
bone marrow derived mMSCs, VSELs [142]. These cells are CD45-, Lin-, Sca-1+, as are 
PαS cells. VSELs were shown to be mobilised following myocardial infarction [143]. 
They demonstrate a marked increase in the trafficking of VSELs in the peripheral 
blood early after myocardial infarction, which raises the possibility that these 
pluripotent cells may contribute to myocardial repair in this setting. Knowing that 
the PαS cells share the markers which define the VSELs and are originally located in 
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the murine bone marrow, PαS cells were compared with VSELs in terms of size 
relative to the rest of the bone marrow. Fig. 5.8.a. illustrates the FACS plots of this 
analysis. This reveals that the two cells types are indeed similar in terms of size, in 
relation to the rest of the bone marrow. This also suggests that the two populations 
may have a large amount of overlap in their characterisation. Future experiments 
could investigate the similarities of these cells further to clarify whether they are 
indeed the same cells or if PαS cells are a subset of VSELs as the data to date 
suggests. 
Stem cells do not appear to function as well in the elderly as they do in 
children in terms of tissue repair [71]. This may be due to alterations to stem cells 
caused by an aged micro-environment [333], or a reported decrease in adult stem 
cell numbers. Following the identification of PαS cells, we can now see if this is true 
for this subset of MSCs. Upon comparing numbers in young mice aged 2.5 weeks to 
older mice aged 30 weeks and over it was found that younger mice did have a 
greater percentage of PαS cells in the bone marrow. However, due to their smaller 
size, young mice have lower absolute numbers of PαS cells in the bone marrow. This 
has implications for the isolation of PαS cells and the importance of using age 
matched mice in comparative studies. 
The work described in this chapter is ongoing. Although PαS cells offer an 
easy way to characterise MSCs in their natural state, advances in technology are 
constantly refining the best practice for MSC analysis. By further characterising PαS 
cells, it has been shown that only a sub-population of PαS cells express VEGFR-2. 
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Future characterisation will focus on comparing subsets of PαS cells and their 
potential for use in cell therapies. 
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6. 
 
Mobilisation of endogenous mMSCs from the 
bone marrow into the peripheral blood.  
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6. Mobilisation of endogenous mMSCs from the bone marrow into the peripheral 
blood. 
 
6.1 Introduction. 
 
In previous chapters, MSC populations isolated from different sources using 
different isolation techniques have been characterised in vitro. However, there are 
both practical and technical complications associated with the harvesting, isolation, 
ex vivo expansion, and delivery of these cells [334,335]. Upon culture, all MSC 
populations examined here were shown to be heterogeneous. Continued culture 
and passage of bone marrow mMSCs in vitro has resulted in a reduction in external 
chemokine receptor levels. Upon i.v. administration of in vitro cultured PαS cells, 
large numbers becoming entrapped in the lungs. Conversely, uncultured PαS cells 
traffic efficiently and integrate into the bone marrow and adipose tissue [124]. For 
this reason, it has been postulated that a more efficient form of regenerative 
medicine may involve the mobilisation of endogenous MSCs [129]. However, MSCs 
have been reported to home to tumours and contribute to tumourigenesis [336], a 
factor that needs to be taken into consideration when increasing circulating 
numbers of MSCs. The bone marrow contains many progenitor cell populations, 
including MSCs, HPCs, fibrocytes, and EPCs. In response to disease or tissue injury, 
these cells are mobilised from the bone marrow and recruited into tissues where 
they can contribute to disease progression or tissue repair [244,245]. Infusion of 
HSCs and cultured EPCs has been shown to augment neovascularisation of tissue 
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following ischemia and contribute to re-endothelialisation after injury [337]. Due to 
the known immuno-modulatory effects and multipotent differentiation potential of 
MSCs, mobilisation of these cells into the peripheral blood could aid repair of tissue 
in response to injury and inflammation. HPC mobilising agents have had a profound 
impact in the field of haematological transplantation [338]. If MSCs can be efficiently 
mobilised into the blood in a similar manner, there is great potential for directing 
these cells for therapeutic benefit. This may also be useful as a method for 
harvesting MSCs in a non-invasive manner. 
The critical aspect when mobilising cells from the bone marrow is to ensure 
specific mobilisation so that only cells which will enhance regenerative capacity are 
mobilised. Knowledge of inducible, selective mobilisation of sets of stem and 
progenitor cells from the bone marrow was expanded upon by Pitchford et al in 
2009 [120]. This research documented the specific mobilisation of HPCs, EPCs and 
MSCs. The study described a mechanism for the mobilisation of EPCs and HPCs, but 
no explanation for the mechanism by which MSCs are mobilised. Further, there was 
no experimental evidence that MSCs that are mobilised are functional and effective 
in enhancing the body’s ability to repair. The protocol for this mobilisation can be 
seen in Fig. 6.i. 
VEGF exists in several isoforms, the most commonly researched of which 
being VEGF-A165, which is often referred to as VEGF. VEGF-A165 plays a critical role in 
blood vessel formation and the migration of endothelial cells. VEGF-A165 was used as 
a test agent in Pitchford et al’s experiments due to its role in stimulating EPC 
mobilisation [257]. The mobilisation of stem and progenitor cells out of the bone 
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marrow is thought to be a multi-step process [339]. The cells are released from their 
respective niches within the bone marrow, followed by migration across the bone 
marrow to the sinusoidal endothelium [261]. With regards to MSC mobilisation, 
Kolonin and Simmons state that it is likely VEGF plays a role in mobilising MSCs from 
the bone marrow in an indirect manner as MSCs do not express VEGFRs [255]. 
However, in Chapter 5 cultured PαS cells were shown to express VEGFR-1 and a sub-
population expressed VEGFR-2. 
Fig 6.i. Protocol for mobilising MSCs from the blood into the bone marrow. 
 
 
The CXCL12/CXCR4 axis is critical for the retention of HPCs in the bone 
marrow [340]. Inhibition of this axis by CXCR4 antagonism using AMD3100 rapidly 
releases HPCs into the circulation in naïve mice. In contrast, while MSCs express 
CXCR4, administration of the antagonist alone does not stimulate mobilisation of 
MSCs. However, disrupting this axis using AMD3100 following VEGF-A165 treatment, 
resulted in the mobilisation of MSCs into the blood. VEGF-A165 treatment alone 
results in no mobilisation [120]. Administration of VEGF-A165 was shown to stimulate 
the entry of HPCs into the S/G2/M phase of the cell cycle in vivo, severely impairing 
the migratory capacity. As such AMD3100 did not mobilise HPCs in mice pre-treated 
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with VEGF-A165. The mechanisms by which MSCs are mobilised using this treatment 
regimen remain unclear. There are thought to be several stem cell niches other than 
the bone marrow from which stem cells can be mobilised. Notable example include: 
myocardial tissue, adipose tissue, spleen, liver and lungs [341]. However, by 
perfusing the murine femoral bone marrow in isolation, MSCs were shown to be 
mobilised via VEGF-A165 and AMD3100 in a manner consistent with mobilisation and 
enumeration by cardiac bleed. Whilst the MSCs could be being mobilised from the 
tissue surrounding the femoral bone marrow, the higher numbers of MSCs in the 
bone marrow compared to muscle suggests that the bone marrow is the major 
source of mobilised MSCs [341]. 
By mobilising MSCs into the blood using pharmacological agents, it is 
hypothesised that the healing process could be ramped up, resulting in a quicker 
recovery time and/or a greater level of repair. This hypothesis infers that the speed 
and level of recovery is dependent upon the number of MSCs mobilised into the 
circulating blood. VEGF-A165 and AMD3100 have been identified as potential 
pharmacological agents for the mobilisation of MSCs. It is therefore hypothesised 
that optimisation of the dosage and duration of treatment with each of these agents 
could result in a greater level of MSC mobilisation into the blood. Previous work 
demonstrated that pre-treatment with VEGF-A165 was critical for MSC mobilisation, 
in that acute administration of VEGF-A165 alone or in combination with AMD3100 did 
not elicit MSC mobilisation. 
As well as optimisation of the mobilisation regimen, it is also important to 
investigate if this mobilisation can be achieved using other factors. Chemokines have 
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been shown to act as a chemoattractant guiding migration of cells throughout the 
body [342,343]. CXCR4 is one of the highest expressed external chemokine receptors 
on all sets of MSCs investigated and its ligand CXCL12 is a potent chemoattractant 
for MSCs [230]. Other highly expressed receptors include CXCR3 and CCR10. CXCR3 
and its ligand CXCL11, modulate leukocyte trafficking and CCR10 with its ligand 
CCL27 direct homing of T cells to the skin in immuno-modulatory pathways 
[344,345]. Both VEGF-A165 and PDGF have been shown to stimulate cells to migrate 
[346,347]. PDGF has been shown to be involved in ligand-dependent chemotactic 
signalling [346]. It was hypothesised that each of these factors may play a role in the 
mobilisation of mMSCs by inducing mobilisation following VEGF-A165 pre-treatment. 
Interruption of the CXCR4/CXCL12 axis following VEGF-A165 treatment results in 
mMSC mobilisation. This may be due in part to the subsequent CXCL12 gradient 
causing cells to migrate from low CXCL12 concentrations in the bone marrow to 
elevated levels in the peripheral blood [294]. Further interrogation of this pathway 
via the direct administration of CXCL12 to the bloodstream may also result in MSC 
mobilisation.  
Once the cells have been mobilised, it is important to investigate the 
functionality of the MSCs. That is, whether the mobilised bone marrow mMSCs can 
efficiently home to sites of injury and inflammation. Experiments have been 
performed to set up a model to investigate trafficking of endogenous MSCs to 
establish whether MSCs mobilised pharmacologically from the bone marrow can 
traffic to sites of tissue injury and inflammation. 
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6.2 Aims. 
 
 Optimisation of mMSC mobilisation from the bone marrow into the 
peripheral blood using VEGF-A165 and AMD3100. 
 To investigate the pharmacokinetics of the MSC mobilisation with respect to: 
 Duration of enhanced mobilisation. 
 Ability to induce multiple mobilisation time points. 
 To investigate other factors that may be able to mobilise endogenous MSCs in 
vivo. 
 To determine the functionality of mobilised MSCs in terms of homing ability. 
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6.3 Results. 
 
First experiments were performed to optimise the mobilisation of MSCs 
using the VEGF-A165/AMD3100 combined therapy. Specifically, to optimise the dose 
of VEGF-A165 or number of pre-treatments. Mice were therefore pre-treated with 
VEGF-A165 for 2 or 4 days with 10, 50 or 100μg/kg VEGF-A165followed by a single 
dose of AMD3100 on day 5. After 4 days treatment using differing VEGF-A165 daily 
doses (10, 50 or 100μg/kg i.p.) followed by a single dose of AMD3100 (5mg/kg), 
MSCs were mobilised from the bone marrow into the blood in a dose dependent 
manner (Fig. 6.1. 0µg/kg 0, 10µg/kg 5.30 ± 5.30, 50µg/kg 18.36 ± 11.66, 100µg/kg 
32.25 ± 8.76 MSCs/ml). The greatest numbers are mobilised after 4 daily doses of 
100µg/kg VEGF-A165 followed by a single dose of AMD3100 (5µg/kg). After 2 days 
VEGF-A165 pre-treatment at various doses (10, 50 or 100μg/kg i.p.), followed by a 
single dose of AMD3100 on day 3, MSCs were not mobilised in significant numbers 
(Fig. 6.1).  
Since AMD3100 is fast acting with a half life of 3-5 hours, it is not known how 
long the MSC mobilisation persists for [348]. To investigate the kinetics of 
mobilisation, MSC numbers in the blood were determined at 0, 1, 6 and 24 hours 
post AMD3100 administration in VEGF-A165 treated mice. As shown in Fig. 6.2. MSC 
numbers in the blood are highest 1 hour post AMD3100 injection (32.25 ± 12.37 
MSCs/ml) with MSC numbers returning to basal levels 6 hours post AMD3100 
administration (3.07 ± 3.07 MSCs/ml). 
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Fig. 6.1. Optimisation of dose and duration of VEGF-A165 pre-treatment for MSC 
mobilisation by AMD3100. 
Mice were pre-treated with VEGF-A165 (10, 50 or 100μg/kg i.p.), or vehicle (PBS) once daily 
for 2 or 4 days. Twenty-four hours after the last injection, mice were administered a CXCR4 
antagonist (AMD3100 5mg/kg i.p,) or vehicle (PBS). Sixty minutes later, blood was taken for 
analysis of circulating MSCs. MSC numbers are shown as number of colonies per ml blood. n 
= 5–14 mice per group. Data are means ± SEM. **p < 0.01, between selected groups. 
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Fig. 6. 2. Kinetics of MSC mobilisation by AMD3100 in VEGF-A165 pre-treated mice. 
Mice were pre-treated with VEGF-A165 or vehicle (PBS) once daily for 4 days (100μg/kg i.p.). 
Twenty-four hours after the last injection, mice were administered a CXCR4 antagonist 
(AMD3100 5mg/kg i.p,) or vehicle (PBS). Blood was taken for analysis of circulating MSCs at 
0, 1, 6, or 24hours post AMD3100 administration. MSC numbers are shown as number of 
colonies per ml blood. n = 6–14 mice per group. Data are means ± SEM. 
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Fig. 6.3. Effect of repeated AMD3100 administration on MSC mobilisation in VEGF-A165 
pre-treated mice. 
Mice were pre-treated with VEGF-A165 or vehicle (PBS) once daily for 4 days (100μg/kg i.p.). 
Twenty-four hours after the last injection, mice were administered a CXCR4 antagonist 
(AMD3100 5mg/kg i.p,) or vehicle (PBS). 6 hours post initial AMD3100 administration, 2 of 
the groups were administered AMD3100 (5mg/kg i.p.) 24 hours post initial AMD3100 
administration, 1 of the groups was administered AMD3100 (5mg/kg i.p.). Blood was taken 
for analysis of circulating MSCs 60 minutes post final AMD3100 administration. MSC 
numbers are shown as number of colonies per ml blood. n = 6 mice per group. Data are 
means ± SEM. 
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It is currently not known whether a single peak of MSCs would be sufficient 
to induce a therapeutic effect (e.g. following tissue ischemia) or whether a more 
sustained increase in MSC numbers would be desirable. Experiments were designed 
to ascertain whether MSCs could be mobilised repeatedly by multiple dosing with 
AMD3100 following single pre-treatment with VEGF-A165. MSCs are most effectively 
mobilised after a single AMD3100 dose, following 4 daily doses of VEGF-A165 (39.02 ± 
20.01 MSCs/ml). MSCs were also present in the blood following a 2nd AMD3100 
injection, 6 hours after the 1st AMD3100 dose, although to a lesser extent (20.08 ± 
14.07 MSCs/ml). There was no significant mobilisation of MSCs when mice were 
given 3 AMD3100 doses at 1, 6 and 24 hours following VEGF-A165 administration and 
culled 1 hour post the final AMD3100 injection (3.72 ± 2.43 MSCs/ml), as 
determined by one way-ANOVA and bonferroni post test. Attempts were also made 
to alter the timing and chronicity of VEGF-A165 administration. In Fig. 6.4. it can be 
seen that neither administration of a single dose of AMD3100 5 days post initial 
dosing regimen, or a subsequent administration of 4 days VEGF-A165 and a single 
dose of AMD3100 at day 10, could mobilise MSCS to a comparable level to that of 4 
days VEGF-A165 treatment and a single dose of AMD3100 on day 5. There does 
appear to be some mobilisation having re-administered VEGF-A165 + AMD3100, but 
this mobilisation was not significant. 
Chemokines are involved in the directed migration of cells [349]. CXCR3 and 
its ligand CXCL11, modulate leukocyte trafficking and CCR10 with its ligand CCL27 
direct homing of T cells to the skin in immuno-modulatory pathways. PDGF has been 
shown to be involved in ligand-dependent chemotactic signalling [346]. Receptors 
for these chemokines were demonstrated to be expressed on MSCs, therefore Fig.  
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Fig. 6.4. Effect of repeated VEGF-A165 + AMD3100 administration on MSC mobilisation. 
Mice in group A were pre-treated with vehicle (PBS) once daily for 9 days (100μg/kg i.p.). 
Twenty-four hours after the last injection, mice were administered a CXCR4 antagonist 
(AMD3100 5mg/kg i.p,). Mice in group B were pre-treated with VEGF-A165 once daily for 4 
days (100μg/kg i.p.). On day 5 they received a CXCR4 antagonist (AMD3100 5mg/kg i.p,). On 
days 6-9 they were treated with vehicle (PBS) once daily. Twenty-four hours after the last 
injection, mice were administered a CXCR4 antagonist (AMD3100 5mg/kg i.p,). Mice in 
group C were pre-treated with VEGF-A165 once daily for 4 days (100μg/kg i.p.). On day 5 they 
received a CXCR4 antagonist (AMD3100 5mg/kg i.p,). On days 6-9 they received further 
treatment with VEGF-A165 once daily (100μg/kg i.p.) Twenty-four hours after the last 
injection, mice were administered a CXCR4 antagonist (AMD3100 5mg/kg i.p,). Blood was 
taken for analysis of circulating MSCs 60 minutes post final AMD3100 administration. MSC 
numbers are shown as number of colonies per ml blood. n = 6 mice per group. Data are 
means ± SEM. 
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Fig. 6.5. MSC mobilisation following VEGF-A165 pre-treatment and chemokine or growth 
factor challenge i.p. or i.v. 
Mice were pre-treated with VEGF-A165 or vehicle (PBS) once daily for 4 days (100μg/kg i.p.). 
Twenty-four hours after the last injection, mice were administered a vehicle (PBS), CCL27, 
CXCL11 or PDGF (250μl 50nM i.v.) or a CXCR4 antagonist (AMD3100 5mg/kg i.p.). Sixty 
minutes later, blood was taken for analysis of circulating MSCs. Data are means ± SEM. n=3. 
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6.5 shows the effects and efficiency of CCL27, CXCL11 and PDGF in mobilising MSCs, 
either alone or in combination with 4 days VEGF-A165 pre-treatment. CCL27 and 
CXCL11, ligands for CXCR3 and CCR10 respectively did not cause mobilisation of 
MSCs into the blood either when administered alone or injected iv 24 hours after 4 
daily doses of VEGF-A165 (i.p. 100 mg/kg). PDGF, when administered i.p (100µg/kg) 
24 hours after 4 days of daily intra-peritoneal injections of PBS did not result in any 
MSC mobilisation. Combining a single dose of PDGF (i.p. day 5) with 4 day VEGF-A165 
pre-treatment resulted in MSC mobilisation (19.20 ± 19.20 MSCs/ml), although there 
is a high level of variability between mice and the numbers mobilised are not 
significant over controls.  
The CXCR4/CXCL12 axis is important in the retention of stem cells in the 
bone marrow [294]. (Fig. 6.6). It has previously been shown that delivery of CXCL12 
via an adenovirus stimulated HPC mobilisation into the blood [348]. To investigate 
whether CXCL12 could similarly mobilise MSCs, mice pre-treated with VEGF-A165 
over 4 days were administered a single i.v. dose of CXCL12 or AMD3100. While 
disrupting the CXCR4/CXCL12 axis using a CXCR4 antagonist (AMD3100, i.p. 5mg/kg) 
resulted in mobilisation into the blood, CXCL12 did not mobilise MSCs (Fig. 6.6). To 
determine whether AMD3100 displaced CXCL12 into the plasma, CXCL12 levels were 
measured following treatment with VEGF-A165 (100μg/kg i.p.) or PBS once daily for 4 
days and a single administration of AMD3100 on day 5. There was no significance 
between the levels of CXCL12 in the blood plasma when comparing each of these 
groups. 
Injection of matrigel sub-cutaneously causes an inflammatory response in  
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Fig. 6.6. The role of CXCL12 in the mobilisation from the bone marrow following VEGF-A165 
and AMD3100 treatment. 
(Fig. 6.6.a) Mice were pre-treated with VEGF-A165 or vehicle (PBS) once daily for 4 days 
(100μg/kg i.p.). Twenty-four hours after the last injection, mice were administered a CXCR4 
antagonist (AMD3100 5mg/kg i.p,), CXCL12 (50nM, 200µl, i.v.), or vehicle (PBS, 200µl, i.v.). 
Sixty minutes later, blood was taken for analysis of circulating MSCs by colony assays. Data 
are means ± SEM. **p < 0.01, between selected groups. n = 6-18. (Fig. 6.6.b) CXCL12 levels 
in blood plasma following treatment with VEGF-A165 or vehicle (PBS) once daily for 4 days 
(100μg/kg i.p.). Twenty-four hours after the last injection, mice were administered a CXCR4 
antagonist (AMD3100 5mg/kg i.p,), CXCL12, or vehicle (PBS). Sixty minutes later, blood was 
taken from which plasma was obtained for analysis of CXCL12 levels via ELISA. 
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Fig. 6.7. MSC recruitment in vivo to matrigel injected subcutaneously, following pre-
treatment with VEGF-A165 and AMD3100. 
Fig. 6.7.a. Matrigel was injected subcutaneously under the dorsal skin. Mice were pre-
treated with VEGF-A165 or vehicle (PBS) once daily for 4 days (100 mg/kg i.p.). Twenty-four 
hours after the last injection, mice were administered a CXCR4 antagonist (AMD3100 5 
mg/kg i.p.). Mice were culled and the matrigel harvested 5 days post the final injection. Data 
are means ± SEM. n = 2-4. Fig. 6.7.b. Upon culture the MSCs obtained from the matrigel 
were tested for their collagen 1 expression Fig. 6.7.b.ii. using immunohistochemistry and 
compared with P5 bone marrow mMSCs (Fig. 6.7.b.i) and murine tracheal fibroblasts (Fig. 
6.7.b.iii). (Fig. 6.7.c) FACS analysis of P5matrigel derived MSCs for a selection of mMSC 
markers (CD45, CD11b, CD29, CD105, Sca-1) n=1. 
  
188 
 
mice [350]. MSCs injected into animals or patients have been shown to home to 
sites of injury in vivo [134,351]. A model was set up to investigate whether 
endogenous MSCs mobilised into the blood could traffic to sites of tissue injury. 
Thus Matrigel was injected sub-cutaneously and then mice were treated with VEGF-
A165 (100μg/kg i.p.) or PBS for 4 days followed by a single injection of AMD3100 on 
day 5. Matrigel plugs were harvested on day 10. The recruitment of MSCs into 
matrigel plugs at the site of inflammation in vivo is shown in Fig. 6.7.a. Matrigel 
plugs were dissolved in dispase and subsequent MSC numbers in the matrigel were 
quantified using CFU-F assays in vitro. MSCs were quantified per g/matrigel plug 
excised from the mouse. Mice who were treated with PBS for 4 days (250µl i.p.) 
followed by a single dose of AMD3100 on day 5 (5 mg/kg i.p.) had low levels of MSCs 
present in the matrigel plugs on day 5 (105.3 ± 105.3 MSCs/g matrigel). Matrigel 
plugs in mice treated with the MSC mobilising regimen (4 daily VEGF-A165 injections 
i.p., 100 mg/kg, single AMD3100 injection on day 5, i.p., 5 mg/kg) had higher levels 
of MSCs present (847.5 ± 213.0 MSCs/g matrigel). The significance of this finding 
cannot be calculated due to low n numbers. To further characterise CFU-Fs obtained 
from matrigel plugs, immunohistochemistry for collagen-1 was performed. As shown 
in Fig. 6.7.b, cells cultured from the Matrigel plugs did not express collagen-1 while 
murine tracheal fibroblasts did express collagen-1. Further characterisation of the 
matrigel derived MSCs can be seen in Fig. 6.7.c, which shows that the cells did not 
express the haematopoietic markers CD45 and CD11b, but did express the MSC 
surface markers CD29, CD105 and Sca-1. 
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6.4 Discussion. 
 
Identifying molecular mechanisms by which MSCs egress from the bone 
marrow and the physiological role of these distinct stem and progenitor cell subsets 
remain to be major hurdles for regenerative medicine. Clinically, G-CSF has been 
used to mobilise HPCs for more than 30 years for bone marrow transplants 
[352,353]. G-CSF induces HPC mobilisation by decreasing bone marrow CXCL12 
levels and increasing CXCR4 levels in the bone marrow [354]. AMD3100 is a bicyclam 
molecule that selectively and reversibly antagonises the binding of CXCL12 to its 
receptor CXCR4 causing subsequent egress of HPCs from the bone marrow to the 
peripheral blood [355]. However, this has been shown to be ineffective as a 
mobilising agent in 20% of patients. When patients are treated with a combination 
of G-CSF and AMD3100, the number of responsive patients is increased further, 
compared to G-CSF alone [356]. 
The detection of circulating MSCs in response to tissue injury suggests that 
MSCs can be mobilised from their niches upon appropriate signals in order to recruit 
to damaged tissue [250]. Treatment with VEGF-A165 for 4 days followed by a single 
dose of AMD3100 is a reproducible strategy for mobilising MSCs from the bone 
marrow into the blood [120]. In Pitchford et al’s study, distinct pathways were 
identified regulating the differential mobilisation of progenitor cells. Furthermore, 
significant numbers of MSCs were detected in peripheral blood when the CXCR4 
antagonist, AMD3100, was administered to mice pre-treated with VEGF-A165 but not 
G-CSF [120]. In this chapter I first sought to establish the kinetics of this response 
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and develop strategies to enhance MSC numbers in the blood over a more sustained 
period, as might be required for effective treatment of a chronic disease or serious 
acute injury (e.g. myocardial infarction). Attempts to mobilise MSCs from the bone 
marrow with G-CSF treatment have been largely disappointing [357]. 
There are several VEGF isoforms, of which the most heavily researched is 
VEGF-A [358]. VEGF-A165 has been shown to play a role in angiogenesis, 
vasodilatation (indirectly by NO release), is chemotactic for macrophages and 
granulocytes, and notably, stimulates EPC migration [257,359]. Upon pre-treatment 
with VEGF-A165 and the acute administration of AMD3100, MSCs and EPCs are 
mobilised, whereas HPC and neutrophil mobilisation is suppressed. 
To date, the pharmacokinetics of the dosing regimen and its clinical 
relevance have not previously been investigated. It was first important to establish 
the lowest dose of VEGF-A165 required to mobilise MSCs, to reduce cost and the 
potential for side-effects when research is translated into man. Investigation into 
lower dosing regimens of VEGF-A165 looking at whether MSC mobilisation levels 
equal to or greater than those previously described (4 days VEGF-A165 100µg/kg i.p., 
day 5: AMD3100 5mg/kg i.p.) could be achieved can be seen in Fig. 6.1. Differing 
daily doses and time courses of 2 or 4 days were investigated. When VEGF-A165 was 
administered for 2 days at 10, 50 or 100µg/kg followed by a single dose of AMD3100 
(5mg/kg) on day 3, there was no significant mobilisation of MSCs into the blood. This 
suggests that the bone marrow needs to be exposed to a prolonged administration 
of VEGF-A165 in order for the mMSCs to be released following CXCR4 antagonism. 
Lowering the dose of VEGF-A165 from 100 to 50 or 10µg/kg substantially reduced the 
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mobilisation of MSCs. Indeed at the lower concentrations of VEGF-A165, MSC levels 
were not significantly elevated. From this, it can be seen that the described VEGF-
A165 treatment protocol is the optimum dose of the 4 investigated. Interestingly, the 
apparent dose dependent response in the 4 day VEGF-A165 treated mice suggests 
that a greater level of mobilisation could be achieved if the dose was increase above 
100µg/kg. Similarly, the fact that there is no mobilisation in the 2 day experiments 
but there is significant mobilisation in the 4 day treatments, suggests that even 
longer dosing regimens e.g. 6, 8 days may result in an enhanced mobilisation over 
that caused by 4 day treatment with VEGF-A165. Experiments using longer 
treatments or higher concentrations of VEGF-A165 were not performed due to the 
cost implications. 
Analysing MSC numbers in this way gives representative circulating levels at 
a single time point. AMD3100 has been shown to have rapid effects and a short half 
life in experiments investigating HPC mobilisation from the bone marrow [356]. The 
optimum time point for HPC mobilisation has been shown to be 60 minutes post 
intra-peritoneal AMD3100. In order to understand the kinetics of this mobilisation 
and to see if the analysis was taking place at the appropriate time point, circulating 
MSC numbers were quantified at various time points post AMD3100 administration. 
Within 6 hours of administration, MSC numbers in the peripheral blood have 
returned to basal levels. This is likely to be due to MSCs homing back to the bone 
marrow or redistributed to other tissues with local stem cell niches such as the liver, 
spleen and lungs [330]. Having returned to basal levels, MSC numbers in the 
circulating blood remain at basal levels 24 hours after AMD3100 administration. Fig. 
6.2. provides significant evidence that the time point of 1 hour proves optimum as a 
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model to be used to characterise the mechanism of mobilisation further. Having 
previously noted that using a combination of VEGF-A165 and AMD3100 mobilises 
MSCs but not HPCs, it is known that the AMD3100 is causing mobilisation of MSCs 
via a different pathway to that of HPC mobilisation [120]. Having optimised the 
conditions by which MSCs are mobilised, future studies could investigate the 
potential of different CXCR4 antagonists in this mobilisation regimen. 
With regards to the clinical applications of mobilising MSCs from the bone 
marrow into the blood, many candidate diseases for treatment would require 
multiple applications as opposed to a single curative treatment. In particular, 
degenerative diseases such as multiple sclerosis [360] in which the MSCs will act 
only in a temporary manner as opposed to having a curative effect. For this reason, 
repeated mobilisation of MSCs into the circulating blood via CXCR4 antagonism was 
investigated. The effect of repeated AMD3100 administration in VEGF-A165 pre-
treated mice can be seen in Fig. 6.3. Dosing regimen A is a control and B shows the 
optimum dosing regimen identified to date. Additional doses of AMD3100 (5mg/kg) 
in the hours that follow, as can be seen in C, do not provide a second peak of 
mobilisation. From this, it can be assumed that the number of MSCs primed for 
mobilisation by AMD3100 has been exhausted. 24 hours may not be sufficient for 
the niche from which the MSCs are mobilised to re-populate. Alternatively, the bone 
marrow may be generating new MSCs which have not received the prior VEGF-A165 
treatment. This latter point was investigated via re-treating with VEGF-A165. 
Alternatively, the bone marrow could benefit from a longer recovery period before 
repeated AMD3100 dosing. MSC levels in the blood of mice treated with the 
optimum mobilisation regimen followed by a second AMD3100 application on day 
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10 is shown in Fig. 6.4.b. A lack of a second peak indicates that allowing time for the 
bone marrow to re-populate is not sufficient for repeated MSC mobilisation by 
AMD3100 after 5 days. In Fig. 6.4.c. mice were given the optimum dosing regimen 
twice in succession. The numbers mobilised suggest that a second mobilisation may 
be possible, however any increase over control is not significant. Due to the nature 
of MSCs, it is also possible that there is only a small subset of MSCs that can be 
mobilised from the bone marrow which, following initial release have homed back 
to the bone marrow where they have been primed for a second release. In order to 
investigate this further using existing technology, mice would need to receive blood 
transfusions following initial MSC mobilisation to remove the mobilised MSCs and 
prevent them homing back to the bone marrow. For the purposes of this 
investigation this is not feasible in terms of time or cost. 
A CXCR4 antagonist is used as a short acting pharmacological agent in this 
series of experiments due to the known action of the CXCR4/CXCL12 in the retention 
of stem and progenitor cells in the bone marrow. However, a lot of research has 
been published on the role that other chemokines and their receptors play in the 
trafficking of leukocytes throughout the body [361,362]. Having elucidated in 
Chapter 3 that CXCR4 is one of several highly expressed chemokine receptors on the 
surface of P5 bone marrow mMSCS, an obvious route to investigate other pathways 
which can cause MSC mobilisation is to target these other receptors and analyse 
their ability to cause MSC egress. Administration of AMD3100 has been shown to 
increase levels of CXCL12 in the blood [363] such that a chemokine gradient is 
created along which cells can migrate into the blood. CXCR3 and CCR10 are both 
highly expressed on the surface of MSCs. However, when their ligands CXCL11 
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(CXCR3) and CCL27 (CCR10), were administered to mice systemically, either alone or 
following 4 day VEGF-A165 treatment of cells, there was no significant mobilisation of 
MSCs above basal levels. This suggests that VEGF-A165 treatment and a chemokine 
gradient down which MSCs can chemotax in vitro, are not sufficient for mobilisation. 
This finding is confirmed in Fig. 6.6. which shows that administration of CXCL12 to 
the blood directly following VEGF-A165 pre-treatment, does not result in MSC 
mobilisation. VEGF-A165 was initially investigated due to its role in angiogenesis. 
PDGF supports vascular development and angiogenesis in a number of organs [364] 
and has been shown to be a potent chemoattractant for bone marrow derived 
hMSCs in vitro [365,366]. As shown in Fig. 6.5. there was some indication that PDGF 
could mobilise MSCs, but the data was not significant. This will be worth further 
investigation in the future. 
In Chapters 3 & 4, it was confirmed that both human and murine MSCs can 
migrate towards chemokines using in vitro chemotaxis assays. It is well documented 
that chemokines are produced at sites of injury and inflammation [228,367]. 
However, following systemic administration of bone marrow mMSCs in Fig 3.13. to 
an LPS model of inflammation in the lungs in mice, there was no recruitment of 
MSCs to the lungs in the time period analysed. Having successfully mobilised the 
MSCs into the circulating blood, it was critical to test whether these cells could be 
recruited to sites of inflammation. To do this, a model of injury was used, whereby 
matrigel plugs were injected subcutaneously in mice which were subsequently 
treated with the VEGF-A165 and AMD3100 mobilisation regimen, or PBS and 
AMD3100. Matrigel is a gelatinous protein mixture that resembles the complex 
extracellular environment found in many tissues. 5 days post AMD3100 
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administration, matrigel plugs were removed and the MSC numbers (per g of 
Matrigel), were quantified using colony assays. Mice treated with the MSC 
mobilising regimen had greater numbers of MSCs at the site of injury in the matrigel, 
than mice treated with PBS and AMD3100. This provides evidence to support that 
these MSCs can migrate to sites of tissue injury, having been mobilised from the 
bone marrow. This has far reaching implications in terms of clinical applications. We 
know now that MSCs mobilised using this pharmacological approach will both 
migrate to, and be retained at sites of injury without the need for further direction 
via physical or pharmacological interventions. The MSCs harvested from the matrigel 
plugs formed CFU's in vitro and stained negatively for collagenase-1, confirming that 
they are not fibroblasts. This model system may be used to further investigate MSC 
trafficking from bone marrow to sites of inflammation in vivo.  
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7. 
 
Interrogating the molecular mechanisms of MSC 
mobilisation from the bone marrow.  
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7. Interrogating the molecular mechanisms of MSC mobilisation from the bone 
marrow. 
 
7.1 Introduction. 
 
Having ascertained that VEGF-A165 plays a critical role in priming bone 
marrow for the mobilisation of MSCs, it was important to investigate the molecular 
mechanisms underlying this response. There are 3 known subtypes of VEGFRs, 
VEGFR-1 (Flt-1), VEGFR-2 (KDR, Flk-1) and VEGFR-3 (Flt-4) [368]. VEGFR-1 promotes 
the migration and proliferation of haematopoietic cells whilst VEGFR-2 promotes the 
proliferation of endothelial cells [265] and VEGFR-3 is involved in lymphangiogenesis 
[266]. It has been reported that hMSCs express mRNA for VEGFR-1, VEGFR-2 and 
VEGFR-3 [347] and preliminary data in Chapter 5 suggested that PαS cells express 
VEGFR-1 and a sub-population express VEGFR-2. It was therefore important to 
characterise P5 bone marrow MSCs in terms of their external VEGFR expression 
levels. VEGF-A165 only binds to VEGFR-1 and VEGFR-2, with a higher affinity for 
VEGFR-1 [271]. The high affinity of VEGFR-1 for VEGF-A165 is critical in angiogenesis, 
where VEGFR-1 acts as a decoy receptor for VEGF-A165, thereby preventing it from 
binding to and activating VEGFR-2 [369]. Pitchford et al [120] investigated selective 
binding to VEGFRs when looking at the mechanism of HPC release from the bone 
marrow following 4 day VEGF-A165 treatment. It was found that selective blockade of 
VEGFR-1 abolishes the ability of exogenous VEGF-A165 to stimulate HPC entry into 
the cell cycle in vivo, thus, restoring the ability of CXCR4 antagonists to mobilise 
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HPCs from the bone marrow [120]. Previous mouse studies which have blocked 
VEGFR-1 have also reported a strong inhibition of inflammation and atherosclerotic 
plaque formation [370]. Given that VEGF-A165 is acting on these cells via VEGFR-1 
and/or VEGFR-2 binding, VEGFR-1 and VEGFR-2 blocking experiments and their 
subsequent effect on MSC mobilisation will be investigated in this chapter. Various 
VEGF isoforms exist including VEGF-A165, PlGF, VEGF-B, VEGF-C and VEGF-D [269]. 
VEGF related proteins have also been discovered named VEGF-E and VEGF-F 
[262,271]. PlGF has been shown to act specifically on VEGFR-1 [271] and VEGF-E is 
known to activate VEGFR-2 [262]. Experiments in this chapter will focus on the 
isoforms of VEGF that bind specifically to VEGFR-1 and VEGFR-2 in order to 
determine their ability to mobilise MSCs from the bone marrow into the peripheral 
blood. These experiments will provide novel mechanistic data as to the roles of 
VEGFRs in MSC mobilisation. Future studies could involve the optimisation of 
specific VEGFR binding in the mobilising pathway in order to enhance MSC numbers 
in the blood, as has been investigated in Chapter 6 with VEGF-A165. 
As detailed in Chapter 5, the characterisation of PαS cells and specifically 
their surface marker profile (CD45- Ter119- PDGFRα+ Sca-1+) means that the 
identification of MSCs in vivo is now possible [124]. This chapter aims to identify PαS 
cells in the blood and confirm whether this highly homogeneous population of MSCs 
can be mobilised via VEGF-A165 and AMD3100 treatment. Confirmation of this result 
means that analysing the effects of VEGF-A165, VEGFR blocking and VEGF isoform 
treatment on the phenotype of the MSCs is possible. In terms of identifying a 
mechanism by which the cells are primed for mobilisation, there are several 
pathways which could be playing a critical role. If VEGFRs are present on the cell 
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surface as is the case for PαS cells, the action of VEGF-A165 may result in changes to 
VEGFR surface expression levels. This is the case with hMSCs, which when treated 
with VEGF-C demonstrate an upregulation of VEGFR-2 on the cell surface [371]. 
HPCs are mobilised from the bone marrow in G0 [120]. Mobilisation of MSCs may be 
dependent on their cell cycle status. Chapter 6 illustrated that no MSCs are 
mobilised via VEGF-A165 treatment alone, confirming that CXCR4 antagonism drives 
the mobilisation of primed cells. It could be hypothesised that VEGF is affecting 
CXCR4 expression levels on the surface of the MSCs, making them more susceptible 
to mobilisation. Each of these parameters will be investigated by analysing the bone 
marrow PαS cells of mice treated with different VEGF regimens over 4 days, prior to 
AMD3100 treatment. As with the effects of MSCs at sites of injury and inflammation, 
VEGF-A165 may be acting on MSCs by affecting their paracrine function. Migration of 
leukocytes through extra-cellular matrix is facilitated by ECM-degrading enzymes 
such as matrix metalloproteases (MMPs) [214]. In cancer stem cells, which share 
many of the defining characteristics of MSCs, an autocrine positive loop exists where 
VEGF-A165 binds to VEGFR-1 and VEGFR-2 resulting in the release of MMP-2 and 
MMP-9 [372]. If VEGF-A165 is acting in a similar way on MSCs, this may explain how 
the cells are being primed in such a manner that MSCs can move along a CXCL12 
gradient into the blood upon AMD3100 treatment. 
If a therapeutic benefit is to be achieved using endogenous MSCs mobilised 
into the blood using pharmacological agents, a key factor may be the numbers of 
cells that are mobilised. It is not yet known what level of MSC numbers is sufficient 
to provide an enhanced repair. It is not yet known if any of the therapeutic effects of 
MSCs are acting in a dose dependent manner in vivo. Cellular treatments thus far 
200 
 
have shown low engraftment levels, yet still had a therapeutic benefit [373]. This 
suggests that this enhancement may be achieved by relatively low numbers. 
However, in order to ensure this mobilisation of endogenous MSCs is sufficient to 
pass this threshold, further optimisation of this mobilisation regimen must be 
investigated. 
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7.2 Aims. 
 
 To characterise P5 bone marrow mMSCs in terms of VEGFR surface 
expression. 
 Interrogate VEGF biology with respect to mobilisation. 
 To investigate whether PαS cells can be mobilised from the bone marrow to 
blood in a quantifiable manner. 
 To elucidate a mechanism by which MSCs are mobilised from the bone 
marrow following VEGF and AMD3100 treatment. 
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7.3 Results. 
 
It has been reported that mMSCs do not express VEGFRs on the cell surface 
[255]. However, this proved not to be the case for P5 bone marrow mMSCs. Fig. 7.1. 
shows the varying levels of external VEGFR expression on P5 bone marrow derived 
mMSCs. In particular, high numbers of mMSCs express VEGFR-1 (69.26 ± 7.86%), an 
intermediate number of cells (23.95 ± 8.17%) express VEGFR-2 and none of the cells 
express VEGFR-3. Figs. 7.1.b,c,d. show representative histogram FACS plots for each 
of the receptors analysed. From this it can be seen that VEGFR-1 is expressed on a 
defined sub-population of P5 bone marrow mMSCs. Fig. 7.1.d. is a FACS dot plot 
showing both VEGFR-1 and VEGFR-2 expression on the same set of P5 bone marrow 
mMSCs. This illustrates that of the cells which are VEGFR-2 positive, nearly all (98%) 
are VEGFR-1 positive. 
VEGF-A165 is acting on these cells via VEGFR-1 and/or VEGFR-2 binding. 
VEGFR-1 and VEGFR-2 blocking experiments were conducted to investigate the 
subsequent effect on MSC mobilisation. Enhanced mobilisation of MSCs into the 
peripheral blood using VEGFR-1 blocking antibodies (mAbs) was observed (Fig. 7.2). 
The numbers of MSC CFU-Fs/ml of blood, formed after 21 days culture for blood 
taken from mice treated with different pharmacological agents can be seen in Fig. 
7.2.a. Mice treated with PBS for 5 days had little or no circulating MSCs in the 
circulating blood 60 minutes after the final PBS injection (7.64 ± 4.28 MSCs/ml 
blood). Mice treated for 4 days with IgG and VEGF-A165, in combination with a single  
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Fig. 7.1. External VEGFR1, VEGFR2 and VEGFR3 expression on passage 5 bone marrow 
derived murine MSCs. 
Fig 7.1.a. Quantification of VEGFR expression on P5 bone marrow derived mMSCs. n = 3. 
FACS histogram plots of VEGFR1 (Fig 7.1.b) and VEGFR2 (Fig 7.1.c) and VEGFR3 (Fig 7.1.d) on 
bone marrow MSCs at passage 5 isolated by plastic adherence. (Fig 7.1.e). FACS dot plot 
analysis of passage 5 bone marrow MSCs co-stained for VEGFR1 in APC (FL4-H) and VEGFR2 
in PE (FL2-H). 
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Fig. 7.2. Enhanced mobilisation of MSCs using VEGFR blocking antibodies. 
Mice were pretreated with VEGF-A165 (100μg/kg i.p.), or vehicle (PBS) once daily for 4 days. 
At day 0 and 2, groups were treated with IgG, anti VEGFR1 +/or anti VEGFR 2 blocking 
antibodies. Twenty-four hours after the last injection, mice were administered a CXCR4 
antagonist (AMD3100 5mg/kg i.p,) or vehicle (PBS). Sixty minutes later, blood was taken for 
analysis of circulating MSCs and hind leg femurs were flushed with 1ml DMEM + 10% FCS for 
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analysis of bone marrow MSCs. MSC numbers are shown as number of colonies per ml 
blood (Fig 7.2.a) and MSCs in the bone marrow /1 x 105 bone marrow cells (Fig 7.2.b). n = 5 
mice per group. Data are means ± SEM. ***p < 0.001 between selected groups. 
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AMD3100 dose on day 5, had an increased number of MSCs in the circulating blood 
than the PBS controls (30.78 ± 12.75 MSCs/ml blood). Mice treated with VEGF-A165 
for 4 days, anti-VEGFR-1 mAbs on days 1 and 3 and a single dose of AMD3100 on day 
5 showed very high levels of MSC mobilisation into the blood 60 minutes post 
AMD3100 injection (326.5 ± 76.17 MSCs/ml blood). Mice treated with either anti-
VEGFR-2 mAbs, or both anti-VEGFR-1 and anti-VEGFR-2 mAbs in combination with 
VEGF-A165 over 4 days and a single dose of AMD3100 dose on day 5, resulted in 
significantly increased mobilisation of MSCS, above that of control levels, but an 
order of magnitude below that of mice treated with VEGF-A165, anti-VEGFR-1 mAbs 
and AMD3100 (anti-VEGFR-1 68.25 ± 29.07 MSCs/ml blood, anti-VEGFR-1 + anti-
VEGFR-2 65.57 ± 17.18 MSCs/ml blood). Mice in the group treated with VEGF-A165, a 
VEGFR-1 mAbs and AMD3100 had significantly more MSCs in the blood than mice in 
all 4 of the other treatment groups. Fig. 7.2.b. shows the MSC number in the bone 
marrow of mice for each of the treatment groups explained above (PBS 763.7 ± 
288.2, IgG 529 ± 200.8, anti-VEGFR-1 686.1 ± 409.7, anti-VEGFR-2 470.4 ± 118, anti-
VEGFR-1 + anti-VEGFR-2 384 ± 98.06 MSCs/1 x 105 bone marrow cells). There were 
no significant differences in MSC numbers in the bone marrow, as quantified by 
colony assay, between each of the 5 groups. 
PlGF has been shown to act specifically on VEGFR-1 [271] and VEGF-E is 
known to specifically activate VEGFR-2 [262]. In order to compare activation of 
either VEGFR-1 or VEGFR-2 individually, PlGF and VEGF-E were administered over 4 
days and the resulting MSC mobilisation was compared to VEGF-A165. MSC numbers 
in peripheral blood for groups of mice treated with PBS or growth factors for 4 days  
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Fig. 7.3. MSC mobilisation into blood following growth factor pre-treatment and challenge 
with AMD3100.  
Mice were pretreated with VEGF-A165 (100μg/kg i.p.), PlGF (100μg/kg i.p.), VEGF-E (100μg/kg 
i.p.), or vehicle (PBS) once daily for 4 days. Twenty-four hours after the last injection, mice 
were administered a CXCR4 antagonist (AMD3100 5mg/kg i.p,) or PBS. Sixty minutes later, 
blood was taken for analysis of circulating MSCs. MSC numbers are shown as number of 
colonies per ml blood. n = 5-12 mice per group. Data are means ± SEM. ***p < 0.001 
between selected groups. 
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followed by a single dose of either PBS or AMD3100 on day 5 can be seen in Fig. 7.3. 
For mice treated with PBS, VEGF-A165, PlGF or VEGF-E for 4 days followed by a single 
dose of PBS on day 5, there were no significant numbers of MSCs mobilised into the 
blood (2.50 ± 1.71, 2.33 ± 1.42, 11.96 ± 5.16, 7.50 ± 4.67 MSCs/ml blood, 
respectively). Mice treated for 4 days with PBS followed by a single dose of 
AMD3100 on day 5 did not display an elevated number of MSCs in the peripheral 
blood above that of control (5.39 ± 4.10 MSCs/ml blood). Mice treated with VEGF-
A165 for 4 days followed by a single dose of AMD3100 showed significant 
mobilisation of MSCs into the peripheral blood when compared to control (32.56 
±11.24 MSCs/ml blood). Mice treated with PlGF for 4 days followed by a single dose 
of AMD3100 showed no significant mobilisation of MSCs into the peripheral blood 
when compared to control (9.94 ± 8.13 MSCs/ml blood). Mice treated with VEGF-E 
for 4 days followed by a single dose of AMD3100 showed significant mobilisation of 
MSCs into the peripheral blood when compared to control (141.9 ± 33.35 MSCs/ml 
blood). Mice treated with VEGF-E and AMD3100 showed significant enhanced 
mobilisation of MSCs into the peripheral blood than mice treated with VEGF-A165 
and AMD3100 (141.9 ± 33.35 vs. 32.56 ± 11.24 MSCs/ml blood).  
Fig. 7.4. compares MSC numbers in the blood of mice treated with single 
growth factors and AMD3100 in comparison to mice treated with both VEGF-E and 
PlGF plus AMD3100. Mice treated for 4 days with PBS followed by a single dose of 
AMD3100 on day 5 did not result in an elevated number of MSCs in the blood above 
that of control (1.25 ± 0.91 MSCs/ml blood). Mice treated with VEGF-A165 for 4 days 
followed by a single dose of AMD3100 showed significant mobilisation of MSCs into  
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Fig. 7.4. MSC mobilisation into blood following growth factor pre-treatment and challenge 
with AMD3100.  
Mice were pretreated with VEGF-A165 (100μg/kg i.p.), PlGF (100μg/kg i.p.), VEGF-E (100μg/kg 
i.p.), PlGF (100μg/kg i.p.) + VEGF-E (100μg/kg i.p.), or vehicle (PBS) once daily for 4 days. 
Twenty-four hours after the last injection, mice were administered a CXCR4 antagonist 
(AMD3100 5mg/kg i.p,) or PBS. Sixty minutes later, blood was taken for analysis of 
circulating MSCs. n = 5-12. Data are means ± SEM. **p < 0.01, and ***p < 0.001 between 
selected groups. 
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the peripheral blood when compared to control (17.37 ± 4.43 MSCs/ml blood). Mice 
treated with PlGF for 4 days followed by a single dose of AMD3100 showed no 
significant mobilisation of MSCs into the peripheral blood when compared to control 
(8.964 ± 4.26 MSCs/ml blood). Mice treated with VEGF-E for 4 days followed by a 
single dose of AMD3100 showed significant mobilisation of MSCs into the peripheral 
blood when compared to control (127.1 ± 28.61 MSCs/ml blood). Mice treated with 
VEGF-E and PlGF for 4 days followed by a single dose of AMD3100 on day 5 again 
showed significant enhanced mobilisation of MSCs into the peripheral blood, 
consistent with mice treated with VEGF-E + AMD3100 (108.9 ± 33.78 vs. 127.1 ± 
28.61 MSCs/ml blood). (Fig. 7.3) 
The characterisation of PαS cells and specifically their surface marker profile 
(CD45- Ter119- PDGFRα+ Sca-1+) means that murine MSCs can be identified in vivo. 
When comparing Figs. 7.5.a. and 7.5.b., it is evident that the PαS cells and MPCs 
identified in murine bone marrow (shown in red) are found in very low numbers in 
the blood of PBS treated mice. In contrast, the blood of mice treated with VEGF-A165, 
anti-VEGFR-1 and AMD3100, as illustrated in Fig 7.5.c. contains significant numbers 
of PαS cells and both sets of MPCs (CD45- Ter119- PDGFRα+ Sca-1-, CD45- Ter 119- 
PDGFRα- Sca-1+). The differences in the numbers of CD45- Ter119- PDGFRα/Sca-1± 
cells in the blood of PBS treated mice when compared to VEGF-A165, anti-VEGFR-1 
mAb, AMD3100 treated mice, are quantified in Figs. 7.5.d,e,f and g. The enhanced 
numbers of PαS cells in the blood of VEGF-A165, anti-VEGFR-1 mAbs, AMD3100 
treated mice when compared to PBS treated mice (51.57 ± 12.77 vs. 8.02 ± 1.18 PαS 
cells/ml blood) can be seen in Fig. 7.5.d. Fig 7.5.e. The enhanced numbers of CD45-  
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Fig. 7.5. PαS cell mobilisation into blood following growth factor and blocking antibodies 
pre-treatment and challenge with AMD3100. 
 Mice were pretreated with VEGF-A165 (100μg/kg i.p.), or vehicle (PBS) once daily for 4 days. 
At day 0 and 2, mice treated with VEGF-A165 were treated with anti VEGFR1 blocking 
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antibodies. Twenty-four hours after the last injection, mice were administered a CXCR4 
antagonist (AMD3100 5mg/kg i.p,) or vehicle (PBS). Sixty minutes later, blood was taken for 
analysis of circulating PαS cells. FACS analysis shows levels of PαS cells mobilised into the 
blood per ml blood, as determined by staining for CD45, Ter119, PDGFRα and Sca-1. Fig. 
7.5.a. Dot plot showing PαS cells, CD45 - Ter119 - PDGFRα + Sca-1 - cells, and CD45 - Ter119 
- PDGFRα - Sca-1 + cells (red) in murine bone marrow from naïve mice. Fig. 7.5.b. Dot plot 
showing PαS cells, CD45 - Ter119 - PDGFRα + Sca-1 - cells, and CD45 - Ter119 - PDGFRα - 
Sca-1 + cells (red) in blood of mice treated for 4 days with PBS and a single dose of 
AMD3100. Fig. 7.5.c. Dot plot showing PαS cells, CD45 - Ter119 - PDGFRα + Sca-1 - cells, and 
CD45 - Ter119 - PDGFRα - Sca-1 + cells (red) in blood of mice treated for 4 days with VEGF-
A165 combined with anti VEGFR1 blocking antibodies on day 2 and 4 and AMD3100 on day 5. 
Fig. 7.5.d. Quantification of PαS cells in blood in mice treated for 4 days with VEGF-A165 
combined with anti VEGFR1 blocking antibodies on day 2 and 4 and AMD3100 on day 5. Fig. 
7.5.e. Quantification of CD45 - Ter119 - PDGFRα + Sca-1 - cells in blood in mice treated for 4 
days with VEGF-A165 combined with anti VEGFR1 blocking antibodies on day 2 and 4 and 
AMD3100 on day 5. Fig. 7.5.f. Quantification of CD45 - Ter119 - PDGFRα - Sca-1 + cells in 
blood in mice treated for 4 days with VEGF-A165 combined with anti VEGFR1 blocking 
antibodies on day 2 and 4 and AMD3100 on day 5. Fig. 7.5.g. Quantification of CD45 - 
Ter119 - PDGFRα - Sca-1 - cells in blood in mice treated for 4 days with VEGF-A165 combined 
with anti VEGFR1 blocking antibodies on day 2 and 4 and AMD3100 on day 5. n = 3. Data are 
means ± SEM. 
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Ter119- PDGFRα+ Sca-1- cells in the blood of VEGF-A165, anti-VEGFR-1 mAbs, 
AMD3100 treated mice when compared to PBS treated mice (969 ± 462.9 vs. 104.0 ± 
13.61 cells/ml blood) can be seen in Fig. 7.5.e. Fig. 7.5.f. illustrates the enhanced 
numbers of CD45- Ter119- PDGFRα- Sca-1+ cells in the blood of VEGF-A165, anti-
VEGFR-1 mAbs, AMD3100 treated mice when compared to PBS treated mice (146.6 
± 49.02 vs. 71.82 ± 40.73 cells/ml blood). There are no differences between the two 
groups in terms of CD45- Ter119- PDGFRα- Sca-1- cell numbers in the blood (17848 ± 
2392 vs. 16719 ± 2301 cells/ml blood) (Fig. 7.5.g). Quantification of PαS cell numbers 
in the blood of mice treated with various combinations of VEGF isoforms, anti-
VEGFR-1 mAbs, AMD3100 and PBS can be seen in Fig. 7.6.a. Mice treated with VEGF-
A165 or VEGF-E for 4 days and a single dose of PBS on day 5 do not show a significant 
increase in the numbers of the PαS cells in the peripheral blood. Mice treated with 
VEGFA165 for 4 days ± anti-VEGFR-1 mAbs on days 1 and 3 and AMD3100 on day 5, 
show a trend towards enhanced levels of PαS cells, however this is not significant. 
Mice treated with VEGF-E for 4 days and a single dose of AMD3100 on day 5 showed 
significantly enhanced numbers of PαS cells in the blood over PBS treated mice, mice 
treated with VEGF-A165 and AMD3100 and mice treated with VEGF-E and AMD3100. 
Numbers of PαS cells in the bone marrow of mice treated with PBS, VEGF-A165 or 
VEGF-E for 4 days and a single dose of PBS or AMD3100 are quantified in Fig 7.6.b. 
There are no significant differences between PαS cell numbers in the bone marrow 
of any of the groups. 
If a therapeutic benefit is to be achieved using endogenous MSCs mobilised 
into the blood using pharmacological agents, a key factor may be the numbers of 
cells that are mobilised. In order to enhance this mobilisation, it is critical to  
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Fig. 7.6. PαS Cells mobilised into the blood following VEGF isoform pre-treatment and 
challenge with AMD3100. 
 Mice were pretreated with VEGF-A165, VEGF-E (100μg/kg i.p.), or vehicle (PBS) once daily for 
4 days. At day 0 and 2, groups were treated with IgG, anti VEGFR1 blocking antibody. 
Twenty-four hours after the last injection, mice were administered a CXCR4 antagonist 
(AMD3100 5mg/kg i.p,) or vehicle (PBS). Sixty minutes later, blood and bone marrow were 
taken for analysis of circulating PαS cells. FACS analysis shows levels of PαS cells mobilised 
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into the blood per ml blood (Fig. 7.6.a) and PαS numbers in the bone marrow/million bone 
marrow cells (Fig. 7.6.b), as determined by staining for CD45, Ter119, PDGFRα and Sca-1. n = 
3-12. Data are means ± SEM. ***p < 0.001 between selected groups. 
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Fig 7.7. CXCL12 levels in blood and bone marrow following growth factor pre-treatment 
and challenge with AMD3100.  
Mice were pretreated with VEGF-A165 (100μg/kg i.p.), PlGF (100μg/kg i.p.), VEGF-E (100μg/kg 
i.p.), or vehicle (PBS) once daily for 4 days. Twenty-four hours after the last injection, mice 
were administered a CXCR4 antagonist (AMD3100 5mg/kg i.p,), or vehicle (PBS). Fig. 7.7.a. 
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Sixty minutes after the final injection, femurs were flushed with 0.5ml PBS. These cell 
suspensions were spun down and the supernatant analysed for CXCL12 levels via ELISAs. n = 
3-10 mice per group. Data are means ± SEM. Fig. 7.7.b. Sixty minutes after the final 
injection, blood was taken via cardiac bleed. The blood was spun down and the blood 
plasma analysed for CXCL12 levels via ELISAs. n = 5-6 mice per group. Data are means ± SEM. 
*p < 0.05 between selected groups. 
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understand the mechanism by which the MSCs egress the bone marrow. Therefore, 
comparison of the levels of the CXCR4 ligand CXCL12 in the bone marrow and blood 
of mice treated for 4 days with growth factors ± AMD3100 on day 5 were compared. 
CXCL12 in the bone marrow of mice in these groups are compared in Fig. 7.7.a. Mice 
treated for 4 days with VEGF-A165, PlGF or VEGF-E for 4 days followed by a single 
dose of PBS on day 5 showed no difference in CXCL12 levels when compared to mice 
treated with PBS alone. However, groups that received AMD3100 on day 5 (PlGF + 
AMD3100 91.49 ± 14.75pg, VEGF-A165 + AMD3100 120.8 ± 22.72pg, VEGF-E + 
AMD3100 112.1 ± 18.65pg) all displayed ~50% reduction in CXCL12 levels in the 
bone marrow in comparison to PBS treated mice (PBS 213 ± 143.4pg, IgG 196.8 ± 
55.18pg, VEGF-A165 176 ± 6.5pg, VEGF-E 208.1 ± 60.08pg). In Fig. 7.7.b., CXCL12 
levels in the blood plasma of mice treated with growth factors + AMD3100 were 
compared to PBS treated mice. In each of the different treatment groups, (VEGF-A165 
+ AMD3100, PlGF + AMD3100, VEGF-E + AMD3100), there appeared to be an 
increase in the amount of CXCL12 present in the blood plasma, which amounted to 
about a doubling (PBS 106.7 ± 68.8pg, VEGF-A165 216.6 ± 115.4pg, PlGF 240.2 ± 
62.58pg, VEGF-E 186.5 ± 9.21pg). However, this increase was only significant in the 
group of mice treated for 4 days with PlGF followed by a single dose of AMD3100. 
VEGFR expression on bone marrow PαS cells in mice treated for 4 days with PBS or 
VEGF-E was compared in Fig 7.8. There was no significance in the difference in the 
percentage of PαS cells expressing VEGFR-1 (PBS 68.97 ± 7.36%, VEGF-E 82.5 ± 
4.57%) or VEGFR-2 (PBS 40.9 ± 16.66%, VEGF-E 55.4 ± 19.12%) on the surface 
between the two groups (Fig. 7.8.a). Representative histogram FACS plots of both 
VEGFR-1 and VEGFR-2 in mice treated with PBS or VEGF-E can be seen in Fig. 7.8.b.  
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Fig. 7.8. VEGFR expression on PαS cells in the bone marrow following chronic VEGF-E 
treatment. 
Fig 7.8.a. Mice were pretreated with VEGF-E (100μg/kg i.p.), or vehicle (PBS) once daily for 4 
days. 24 hours after the 4th injection, bone marrow was analysed via FACS to quantify the 
expression of VEGFR-1 and VEGFR-2 on PαS cells. n = 3. Data are means ± SEM. Fig. 7.8.b 
FACS histogram of VEGFR-1 and VEGFR-2 expression on bone marrow PαS cells in mice 
treated with PBS or VEGF-E (100μg/kg i.p.), for 4 days. 
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Fig. 7.9. CXCR4 expression on PαS cells after chronic VEGF isoform treatment.  
Mice were pretreated with VEGF-A165, VEGF-E (100μg/kg i.p.), or vehicle (PBS) once daily for 
4 days. 24 hours after the 4th injection, bone marrow was analysed via FACS to quantify the 
expression CXCR4 on PαS cells. (Fig. 7.9.a) n = 3. Data are means ± SEM. (Fig. 7.9.b) FACS 
histogram of CXCR4 expression on bone marrow PαS cells in mice treated with PBS for 4 
days. (Fig. 7.9.c) FACS histogram of CXCR4 expression on bone marrow PαS cells in mice 
treated with VEGF-A165 (100μg/kg i.p.), for 4 days. (Fig. 7.9.d) FACS histogram of CXCR4 
expression on bone marrow PαS cells in mice treated with VEGF-E (100μg/kg i.p.), for 4 
days. 
 
221 
 
 
Fig. 7.10. Cell cycling of PαS cells in bone marrow following chronic VEGF treatment.  
Fig. 7.10.a Mice were pre-treated with VEGF-A165, VEGF-E (100μg/kg i.p.), or vehicle (PBS) 
once daily for 4 days. Twenty-four hours after the last injection, bone marrow was analysed 
to see what population of PαS cells were in the S/G2/M phase of the cell cycle. n = 6. Data 
are means ± SEM. Fig. 7.10.b Dot plots of TO-PRO staining of bone marrow PαS cells in mice 
treated with VEGF-A165, VEGF-E (100μg/kg i.p.), or PBS for 4 days. Fig. 7.10.c FACS 
histograms of TO-PRO expression on bone marrow PαS cells in mice treated with VEGF-A165, 
VEGF-E (100μg/kg i.p.), or PBS for 4 days. 
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There were no differences in MFI levels (as illustrated by the shift in peak) in VEGFR-
1 expression or VEGFR-2 expression between mice treated with PBS or VEGF-E. 
CXCR4 expression on bone marrow PαS cells in mice treated with PBS, VEGF-
A165, or VEGF-E is compared in Fig. 7.9. High percentages (PBS 87.72 ± 3.54%, VEGF-
A165 83.48 ± 6.6%, VEGF-E 59.50 ± 5.88%) of the PαS cells from each group express 
CXCR4. There is no difference in terms of percentage of cells expressing CXCR4 (Fig. 
7.9.a.) and the amount of receptors each cell is expressing (MFI, Fig. 7.9.b.) between 
mice treated with PBS, VEGF-A165, or VEGF-E. 
The cell cycle status of the PαS cells, and more specifically the number of PαS 
cells actively dividing in the bone marrow of mice treated with either PBS, VEGF-A165 
or VEGF-E for 4 days is compared in Fig. 7.10. There is no significant difference in the 
number of PαS cells in the S/G2/M phase of the cell cycle between mice treated with 
PBS, VEGF-A165 or VEGF-E (PBS 40.73 ± 10.35%, VEGF-A165 32.37 ±10.09%, VEGF-E 
28.03 ± 10.69%). This is further confirmed in Fig. 7.10.c. which shows representative 
histogram plots of the cell cycle status for each bone marrow PαS cell population. 
The fact that the histogram plots are very similar in terms of the shift and height of 
each peak suggests that the cell cycle status of PαS cells is not affected by treatment 
with VEGF-A165 or VEGF-E over 4 days. 
MMPs have been cited as a factor involved in the mobilisation of other 
undifferentiated cells through the ECM [214]. MSC markers in circulating blood after 
VEGF isoform treatment combined with a single dose of AMD3100, with or without 
the application of the broad-spectrum MMP inhibitor, marimastat were compared  
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Fig 7.11. Inhibition of MSC mobilisation using a broad-spectrum matrix metalloproteinase 
inhibitor. 
Mice were treated with PBS, vehicle (0.01% tween) or a broad-spectrum matrix 
metalloproteinase inhibitor (Marimastat 30mg/kg) once daily for 4 days. Mice were treated 
with VEGF-A165 (100μg/kg i.p.), VEGF-E (100μg/kg i.p.), or vehicle (PBS) 1 hour after first 
injection, once daily for 4 days. Twenty-four hours after the last injection, mice were 
administered a CXCR4 antagonist (AMD3100 5mg/kg i.p,), or PBS. Sixty minutes later, blood 
was taken for analysis of circulating MSCs. n = 7-9. Data are means ± SEM. ***p < 0.001 
between selected groups. 
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(Fig. 5.11). Mice treated with VEGF-A165 (10.69 ± 14.88 cells/ml blood) or VEGF-E 
(10.64 ± 16.55 cells/ml blood) and marimastat for 4 days followed by a single 
injection of AMD3100 on day 5 did not show any enhanced mobilisation of MSCs 
into the blood over levels in PBS treated mice (5.85 ± 4.53 cells/ml blood), as 
quantified by colony assay. Mice treated with VEGF-A165 and the marimastat vehicle 
(0.01% tween) mobilised a number of MSCs into the blood (45.55 ± 15.43 cells/ml 
blood) that was not significantly lower than numbers found in the blood of mice 
treated with VEGF-A165 plus AMD3100 alone (55.64 ± 14.48 cells/ml blood). Mice 
treated with VEGF-E and AMD3100 showed mobilisation levels that were 
significantly higher than PαS cell levels in the blood of mice treated with VEGF-E + 
AMD3100 in combination with marimastat (220 ± 29.99 vs. 10.64 ± 7.40 cells/ml 
blood). 
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7.4 Discussion. 
 
Previous work by Pitchford et al and the results presented in Chapter 6 
indicate that VEGF pre-treatment of mice is necessary for AMD3100 induced 
mobilisation of MSCs. In this chapter the molecular mechanisms whereby VEGF 
promotes mobilisation were further investigated. Firstly, it was important to 
establish which VEGFRs are expressed by MSCs. While some studies have reported 
that MSCs express mRNA for VEGFR-1, 2 and 3, others suggest that MSCs do not 
express VEGFRs [255,374]. FACS analysis of P5 bone marrow mMSCs showed a high 
level of VEGFR-1 expressed by 69.29% of the mMSC population, while only 23.95% 
expressed VEGFR-2 at low levels. Of relevance, 98% of mMSCs expressing VEGFR-2 
expressed VEGFR-1. There was no expression of VEGFR-3 on the surface of the 
mMSCS. This evidence, combined with previous reports that VEGF-A165 can only bind 
VEGFR-1 or VEGFR-2 [262] meant that the focus of the investigation could be 
narrowed to these 2 receptors. To further analyse the role of these 2 receptors in 
MSC mobilisation via VEGF-A165 and AMD3100 treatment, mice were treated with 
this MSC mobilisation regimen whilst also blocking either VEGFR-1, VEGFR-2 or both 
VEGFR-1 and VEGFR-2 using anti-VEGFR mAbs [120]. As Fig. 7.2.a shows, using the 
existing mobilisation regimen whilst blocking VEGFR-1 results in a 10 fold (30.78 ± 
12.75 vs. 325.54 ± 76.17 CFU-Fs/ml blood) amplification of MSC numbers in the 
circulating blood over the previously established optimum mobilising regimen. This 
enhancement is negated when VEGFR-2 is blocked, or both VEGFR-1 and VEGFR-2 
are blocked in combination with the mobilising regimen. This suggests a model that 
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when VEGF-A165 is administered in the absence of blocking antibodies, the majority 
binds to VEGFR-1 which is expressed at high levels and has a high affinity for VEGFR-
1, but does not elicit the signal for mobilisation. The remaining VEGF-A165 binds to 
VEGFR-2 which is required for mobilisation. Blocking VEGFR-1 permits VEGF-A165 to 
bind to VEGFR-2, thereby increasing the signal for mobilisation. This is highly 
indicative that the priming of MSCs in the bone marrow for release via AMD3100 
administration is due to VEGF-A165 acting solely through VEGFR-2. It is also evident 
that VEGF-A165 acting through VEGFR-1 is not responsible for this mobilisation. The 
fact that the mobilised MSC numbers are not reduced to basal levels in the 
treatment groups which were given anti-VEGFR-2 mAbs or both anti-VEGFR-1 and 
anti-VEGFR-2 mAbs, may be due to sub-optimal blocking conditions. As the blocking 
mAbs were only administered on days 1 and 3, there may not have been a complete 
saturation of the receptors with the blocking mAbs. This means that VEGF-A165 may 
still be acting through VEGFR-2, although at much lower levels. This may also explain 
why there is mobilisation when mice are treated with VEGF-A165 and AMD3100 
alone, as VEGFR-1 has a much higher affinity for affinity for VEGF-A165 than VEGFR-2.  
The remaining numbers of MSCs present in the bone marrow following the 
MSC mobilisation treatment do not differ between any of the aforementioned 
groups. The bone marrow origin of these cells has been previously confirmed using 
perfusion assays by Pitchford et al [341]. This indicates that the treatment is not 
exhausting MSC numbers in the bone marrow. This also supports the theory that 
multiple mobilisations are possible without any long term affects on the health of 
the bone marrow. This could suggest that the MSCs are being mobilised from a 
specific bone marrow niche and as yet, the mobilisation regimen is not accessing the 
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remaining niches. Alternatively, further optimisation of the regimen and more 
specific binding may enable further boosting of MSC mobilisation into the blood. 
PlGF is a ligand which binds specifically to VEGFR-1 [271]. Importantly, while 
PlGF is a natural ligand which has been shown to stimulate chemotactic migration of 
human MPCs [347], VEGF-E does not occur in man [375] but acts as a specific ligand 
for VEGFR-2 [262]. As previously noted, the mobilisation regimen may be further 
optimised by using specific VEGFR ligands. The aim of using specific ligands was to 
enable mobilisation of MSCs in a more efficient manner in terms of pharmacological 
dosing, level of mobilisation, or both. Following 4 day treatment with VEGF-E and 
AMD3100 challenge on day 5, there is enhanced mobilisation of MSCs as compared 
to VEGF-A165 (112.3 ± 50.62 vs. 15.07 ± 4.58 CFU-Fs/ml blood). This mobilisation is 7 
fold higher than that seen with VEGF-A165 and AMD3100. 4 days treatment with PlGF 
followed by AMD3100 challenge on day 5 does not result in any mobilisation of 
MSCs above that of basal levels. This is further confirmation that priming of MSCs 
for mobilisation by AMD3100 is a VEGFR-2 dependent event. The doses of PlGF and 
VEGF-E used in these experiments are the optimal doses for VEGF-A165 dependent 
mobilisation. In future experiments, optimisation of VEGF-E dosing could result in 
further enhancement of MSC levels in the blood and/or a reduction in the amount of 
ligand needed to elicit the same effect. Following the analysis of this experiment, it 
was still not clear whether VEGFR-1 serves simply as a scavenger for VEGF-A165 on 
MSCs or actually delivers a negative signal inhibiting the MSC mobilisation. To test 
this, the experiment was repeated with an extra treatment group in which mice 
were pre-treated with PlGF and VEGF-E in combination (Fig. 7.4). Importantly, when 
mice were treated with both PlGF and VEGF-E in combination, mobilised MSC levels 
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were not significantly different to those in mice treated with VEGF-E alone, in 
combination with AMD3100. This demonstrates that VEGFR-1 interaction is not 
playing an inhibitory role in the mobilisation of endogenous MSCs and therefore, 
mobilisation is solely dependent on activation of MSCs through VEGFR-2. We can 
speculate that the high level of VEGFR-1 may operate as an effective homeostatic 
mechanism to prevent MSC mobilisation when presented with small fluctuations of 
VEGF-A165 levels in the bone marrow. As noted above, there are no selective VEGFR-
2 agonists in man. Having optimised the mobilisation protocol, it was critical to 
investigate the mechanisms by which these cells are released. In knowing the 
mechanism by which VEGF isoforms acting on VEGFR-2 primes the cells, more 
targets may become apparent which could help improve this technique in terms of 
efficient dosing and increased mobilisation of MSCs into the blood.  
The publication of a set of markers (CD45- Ter119- PDGFRα+ Sca-1+, PαS 
cells) which identify a homogeneous population of mMSCs, makes investigating 
whether true stem cells are mobilised during this treatment regimen possible [144]. 
Having ascertained in previous chapters that P5 bone marrow mMSCs are a 
heterogeneous population made up of 34.96 ± 10.66% PαS cells, confirmation was 
needed that these cells are amongst the MSCs which are being mobilised via VEGF 
and AMD3100 administration. To do this, PαS cell numbers were quantified in the 
blood of mice treated with the different variations of treatment regimens in 
comparison to PBS treated control mice. In Figs. 7.5 and 7.6, it can be seen that PαS 
cells are mobilised using these treatment regimens, and that the PαS cells are 
mobilised in a quantitative manner similar to that observed using colony assay 
analysis. Furthermore, cell populations defined by Morikawa et al to be 
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mesenchymal progenitor cells (CD45- Ter119- PDGFRα+ Sca-1-, CD45- Ter119- 
PDGFRα- Sca-1+) were also mobilised into the blood following VEGF-A165, anti-
VEGFR-1 mAbs and AMD3100 treatment. It has been reported that the successful 
treatment of degenerative diseases such as retinal degeneration [376] are 
dependent upon the differentiation state of the cells administered to the site of 
injury or inflammation. By increasing circulating numbers of stem and progenitor 
cells, the chances of a suitable cell type homing to the site of injury or inflammation 
is increased. Of note, the small size of the cells in relation to the rest of the bone 
marrow (and cultured MSCs Fig. 5.8) is maintained after mobilisation, as can be seen 
in Fig. 7.5.c. in which the PαS and MPCs are highlighted in red. This increases the 
likelihood that these cells will not become trapped in the pulmonary circulation, and 
they therefore may have an enhanced rate of successful recruitment to sites of 
injury or inflammation when compared to cultured MSCs or indeed culture 
expanded PαS cells. There is no significant depletion of PαS cells in the bone marrow 
suggesting that there is therefore the potential for increased levels of mobilisation 
from the bone marrow. There may also be other MSC and PαS cell niches that are 
not accessed using this mobilisation regimen e.g. the perivascular niche of MSCs 
thought to be present in almost all adult tissues [84,377]. 
By analysing the PαS cells in the bone marrow and blood, it is possible to 
analyse the effects of these treatment regimens on the cells in vivo. Having 
identified that MSC mobilisation is VEGFR-2 dependent, and that VEGFR-2 is only 
expressed on a small population of MSCs, it was hypothesised that treatment with 
VEGF isoforms may be upregulating VEGFR-2 expression, or down-regulating VEGFR-
1 expression on the surface of these cells. However, as Fig. 7.8. illustrates, there was 
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no change in the expression levels of VEGFR-1 or VEGFR-2 on PαS cells in the bone 
marrow following treatment with the VEGFR-2 specific ligand VEGF-E when 
compared to PBS treated mice. Strikingly, VEGFR-2 was only expressed by a sub-
population of the PαS cells in the bone marrow in both treatment groups (PBS 40.9 ± 
16.66, VEGF-E 55.4 ± 19.12). Knowing that the CXCL12/CXCR4 axis is critical in the 
retention of several types of stem cell in the bone marrow [120,221,294,378], it was 
hypothesised that changes to CXCR4 expression levels on the PαS cells, or CXCL12 
levels in the blood or bone marrow may play a role in the release of PαS cells and 
MSCs. However, there was no change in the CXCR4 expression on PαS cells in the 
bone marrow between mice treated with PBS, VEGF-A165 or VEGF-E (Fig 7.9.a). There 
is also no shift in MFI of CXCR4 expression of PαS cells between these groups (Fig. 
7.9.b). The CXCL12 levels in the bone marrow following treatment with PlGF, VEGF-
A165 or VEGF-E alone were not significantly different from that of PBS. Interestingly, 
treatment with AMD3100 reduced levels of CXCL12 in the bone marrow and 
increased levels in the blood irrespective of the VEGF isoforms pre-treatment, 
although changes in bone marrow did not reach significance. These data suggest 
AMD3100 displaces CXCL12 from bone marrow into blood thereby reversing the 
chemokine gradient. 
Given that the levels were altered in both blood and bone marrow for all 
groups following AMD3100 treatment, it can be assumed that the priming effect of 
VEGFR-2 binding isoforms does not impact on, and is therefore not regulated by 
CXCR4 expression or CXCL12 levels in the bone marrow and the blood. This is further 
confirmed when comparing the results of PlGF pretreatment and subsequent 
AMD3100 challenge in Fig. 7.7. to VEGF-A165 or VEGF-E plus AMD3100 treatment. 
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The CXCL12 gradient going from a reduction in the bone marrow to the significant 
increase in the blood is a feature of this treatment regimen, and yet we observe no 
mobilisation of MSCs into the blood. Cell cycle has been reported to regulate HPC 
mobilisation [120], in that HPCs mobilised into the blood are in G0 and HPC 
proliferation reduces the extent of their mobilisation. It was therefore hypothesised 
that the mobilisation of MSCs and PαS cells from the bone marrow could be a result 
of VEGFR-2 induced quiescence. Fig. 7.10. suggests this is not the case. When the 
cell cycle status is compared between PαS cells in the bone marrow of mice treated 
with PBS, VEGF-A165 or VEGF-E, there are no significant differences. Between 60% 
and 70% of PαS cells in the bone marrow are in G0. Potentially, a separate 
pharmacological agent could be added to the treatment regimen in order to 
promote MSC quiescence. 
This enhanced mobilisation may also be due to VEGF-A165 or VEGF-E binding 
the heparin sulphate binding glycosaminoglycans (GAG) chains of the extracellular 
matrix and the cellular basement membranes upon VEGFR-1 blocking. VEGF-A165 
also binds to neuropilin-1 (NRP-1), however this is a non-signalling receptor. MMPs 
have been implicated in the mobilisation of HPCs from the bone marrow 
[379,380,381]. It was therefore of interest to investigate whether MMPs regulated 
MSC mobilisation. Marimastat is a broad-spectrum MMP inhibitor that has 
previously been used in vivo in attempts to inhibit tumour metastasis [382]. Mice 
were treated with VEGF-A165 or VEGF-E with or without accompanying marimastat 
application and AMD3100 challenge. Strikingly, marimastat inhibited MSC 
mobilisation driven by both VEGF-A165 and VEGF-E. These data suggest that MMPs 
may act downstream of VEGFR-2 eliciting MSC mobilisation. It can be hypothesised 
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that treatment over 4 days with VEGF isoforms, increases MMP activity via VEGFR-2 
binding. These MMPs then prime the MSCs and PαS cells for release by breaking 
down the surrounding extracellular matrix. AMD3100 treatment creates a CXCL12 
gradient, down which MSCs and PαS cells can migrate out of the bone marrow into 
the blood. CXCR4 expression levels on PαS cells were shown to be unchanged 
following VEGF isoform treatment. This suggests that PαS cells mobilised via these 
treatment regimens retain the capacity to efficiently migrate to sites of injury and 
inflammation. 
Current therapies rely upon the application of MSCs which have been 
cultured ex vivo. These culture techniques have had significant effects on the 
functional capacity of these cells, in particular their chemokine receptor expression 
levels, size and capacity to differentiate [383,384]. Using VEGFR-2 specific ligand 
treatment over 4 days in combination with a single AMD3100 challenge, significant 
numbers of MSCs and PαS cells were mobilised into the circulating blood. Having 
demonstrated that this mobilisation does not exhaust MSC numbers within the bone 
marrow and identified the key mechanisms by which the cells are mobilised, further 
research and optimisation of this treatment regimen should boost mobilised MSC 
levels further still. In terms of clinical applications, this is a non-invasive treatment 
which has huge significance in terms of tissue repair following disease or injury. 
Following optimisation of the protocol, the next step would be to investigate the 
effectiveness of this treatment protocol in models of disease and injury to identify 
potential targets for clinical trials. 
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8. General Discussion. 
 
8.1. Ten-fold enhancement of endogenous MSC mobilisation. 
 An alternative way of harnessing MSCs for cellular therapy rather than 
extracting, culturing and re-injecting them either locally or systemically, is to 
selectively mobilise MSCs from the bone marrow into the blood directly using a 
pharmacological approach. To date, selective mobilisation of endogenous MSCs 
from the bone marrow to the blood using pharmacological agents has only been 
reported using VEGF-A165 in combination with the CXCR4 antagonist, AMD3100, or 
G-CSF alone [120,254]. However, there have been several papers reporting that MSC 
mobilisation is not detected in the peripheral blood when mice are treated with G-
CSF [120,253]. Studies in mice treated with VEGF-A165 and AMD3100 in combination 
showed low but significant numbers of MSCs in the peripheral blood one hour post 
AMD3100 administration, when compared to PBS treated mice [120]. Further 
interrogation of this selective mechanism of mobilisation investigated here has 
enhanced this mobilisation ten-fold to levels significantly higher than previously 
reported using any MSC mobilisation regimen. It is hypothesised that a greater 
number of MSCs in the circulating blood as a result of this treatment regimen will 
result in greater levels of MSC engraftment at sites of injury or inflammation, and a 
subsequent enhanced resolution of the damaged tissue. This enhanced selective 
mobilisation of mMSCs requires VEGFR-2 stimulation and CXCR4 antagonism. The 
dependence on VEGFR-2 is illustrated in Fig. 8.1., which shows the resultant 
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mobilisation of MSCs following specific VEGFR blocking and treatment with VEGF-
A165 and the CXCR4 antagonist, AMD3100. 
Fig. 8.1. Enhanced mobilisation of MSCs via blockade of specific VEGFRs. 
 
8.2. Enhanced mobilisation of MSCs using specific VEGF isoforms. 
By targeting VEGFR-1 and VEGFR-2 using the specific ligands PlGF and VEGF-E 
respectively, the enhanced mobilisation of MSCs occurred through VEGFR-2 
interaction directly and the redundancy of VEGFR-1 in the mobilisation was 
confirmed (Fig. 8.2). Importantly, when mice were treated with both PlGF and VEGF-
E in combination, mobilised MSC levels were not significantly different to those in 
mice treated with VEGF-E alone, in combination with AMD3100. This demonstrates 
that VEGFR-1 interaction is not playing an inhibitory role in the mobilisation of 
endogenous MSCs and therefore, mobilisation is solely dependent on activation of 
MSCs through VEGFR-2. Optimisation of the protocols using VEGFR-2 specific ligands 
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in combination with a CXCR4 antagonist means that 2 receptors, VEGFR-2 and 
CXCR4 must play a role at some level. 
Fig. 8.2. Enhanced mobilisation of MSCs using VEGFR-2 specific ligands. 
 
8.3. Mechanism of MSC mobilisation from the bone marrow to the peripheral 
blood. 
Interestingly, VEGFR-1 and VEGFR-2 are both expressed on a percentage of 
P5 bone marrow mMSCs and PαS cells. Treatment with any of the VEGF isoforms did 
not affect the levels of VEGFR-1 or VEGFR-2 expression by PαS cells in the bone 
marrow, indicating that this mechanism was not involved in mobilisation. The 
CXCR4/CXCL12 chemokine axis is critical for the retention of HPCs in the bone 
marrow and it has been shown that G-CSF stimulates HPC mobilisation through a 
down-regulation of CXCL12 levels in the bone marrow [218]. In contrast, treatment 
of mice with the different isoforms of VEGF did not change levels of CXCL12 in the 
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bone marrow. Further, expression of CXCR4 was not altered by VEGF pre-treatment, 
suggesting that changes in this chemokine axis are not involved in MSC mobilisation 
by VEGF. It is not yet known whether VEGF isoforms acting through VEGFR-2 are 
acting directly on the MSCs themselves in the bone marrow or through VEGFR-2 on 
other resident cells in the bone marrow that might affect cell egress. If VEGF is 
activating other cell populations in the bone marrow, these cells may then be 
producing factors which result in MSC mobilisation. VEGF-E interacts specifically 
with VEGFR-2, whereas VEGF-A165 binds to both VEGFR-1 and VEGFR-2, with a higher 
affinity for VEGFR-1. The fact that MSCs do express VEGFR-2 means that VEGF-E and 
VEGF-A165 may be having a direct effect on MSCs, making them more accessible in 
the bone marrow for mobilisation down a CXCL12 gradient. There was no difference 
in CXCL12 levels in the bone marrow following 4 day treatment with PBS, VEGF-A165 
or VEGF-E. Levels are only altered for all groups following AMD3100 treatment. This 
suggests that the priming effect of VEGFR-2 binding isoforms is not through an effect 
on the CXCR4/CXCL12 chemokine axis. 
It has been reported that upon 4 day treatment with VEGF, HPCs within the 
bone marrow enter the cell cycle. It is thought that these actively dividing cells 
cannot migrate and hence HPC mobilisation by subsequent CXCR4 antagonism is 
negated [120]. This is not the case for MSCs. The percentage of PαS cells actively 
dividing in the bone marrow is comparable for mice treated with PBS, VEGF-A165 or 
VEGF-E for 4 days suggesting that changes in MSC proliferation are not key to MSC 
mobilisation by VEGF. While the bone marrow origin of these cells has been 
previously confirmed using in situ perfusion of the bone marrow [341], there is no 
significant depletion of PαS cells in the bone marrow following VEGF/AMD3100 
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treatment. This suggests that a very small proportion of the total MSC population 
has been mobilised and indicates that there is potential for increased levels of 
mobilisation. This also supports the theory that multiple mobilisations are possible 
without any long term affects on the health of the bone marrow. Recently, 
prolonged treatment of mice with G-CSF has been shown to increase MSC numbers 
in the bone marrow [385]. It is possible therefore that by increasing MSC numbers in 
the bone marrow, with such a G-CSF treatment prior to administration of VEGF-E 
and AMD3100, the numbers of MSCs which are mobilised to the peripheral blood 
may be increased yet further.  
Analysis of CXCR4 and cell cycle status of MSCs and PαS cells following VEGF 
isoform treatment suggests that these cells retain their migratory capacity and 
should in theory migrate to sites of injury and inflammation. Current therapies rely 
upon the application of MSCs which have been cultured ex vivo [386]. These culture 
techniques have had significant effects on the functional capacity of these cells, in 
particular their chemokine receptor expression levels, size and capacity to 
differentiate.  
 
8.3.1. The role of MMPs in the mobilisation of MSCs using VEGF isoforms in 
combination with AMD3100. 
MMPs have been implicated in playing a role in angiogenesis, tissue repair 
and even metastasis [379,387]. MMP-2, -3, -10, -11, -13, and -14, as well as TIMP-2, 
have been detected in MSCs at the mRNA and protein level [388]. Indeed hMSCs 
have been shown to secrete MMP-2 in response to co-culture with damaged corneal 
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epithelial cells [389]. hMSCs have been shown to degrade and penetrate type I 
collagen networks in tandem with the expression MMPs. Specifically, MT1-MMP is 
required for hMSC-mediated collagenolysis, involved in invasion [381]. Taken 
together, this suggests that MMPs may play a role in making MSCs in the bone 
marrow mobilisable. Marimastat is a broad spectrum MMP inhibitor. Administering 
marimastat during treatment with the mobilising regimen results in no MSCs found 
in the circulating blood 1 hour post AMD3100 administration, suggesting that MMPs 
are playing a critical role in this mobilisation. Without formerly treating with VEGF, 
MSCs are not mobilised following AMD3100 administration. VEGF must be acting in 
a way which alters the state of the MSCs in the bone marrow. It is likely that MMPs 
play a role in this mechanism. Taking this data together, it is hypothesised that 
treatment over 4 days with VEGF isoforms increases MMP activity via VEGFR-2 
interaction. These MMPs then prime the MSCs and PαS cells for their release by 
breaking down the surrounding extracellular matrix prior to AMD3100 treatment, 
and the subsequent formation of a CXCL12 gradient out of the bone marrow into the 
blood. However it is not yet known whether the VEGF acts directly through VEGFR-2 
on the MSCs themselves, which then secrete MMPs as a result, or whether there are 
other cell populations in the bone marrow involved which may be secreting MMPs 
or activated in some other way via their VEGFR-2 expression. 
 
8.4. PαS cells as a source for cell therapy. 
PαS cells have been characterised as a highly homogeneous population of 
bone marrow mMSCs [124]. By demonstrating their induced mobilisation using a 
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pharmacological method it becomes easier to investigate mobilised MSC 
populations, how they traffic to, and act at sites of injury and inflammation in a 
regenerative manner. PαS cells have been further characterised in Chapter 5. PαS 
cells are very small and have high levels of external chemokine receptors. This 
makes them an ideal candidate for use as a cell therapy. Their small size relative to 
cultured MSCs reduces their chance of being entrapped in the respiratory 
vasculature or other highly branching capillary networks. High chemokine receptor 
expression on the cell surface of MSCs directly correlates with their ability to 
migrate to ligands of said receptors. Chemokines such as IL-8 and CXCL12 are 
produced at high levels in sites of injury or inflammation [390,391]. In a normal 
repair model, the number of cells local to the injury or inflammation is increased 
over time via recruitment of cells through the blood stream. By mobilising the PαS 
cells into the blood, it is hoped the amount of stem cells local to injured tissue over 
time will be increased further. It can be hypothesised that the high levels of 
chemokine receptors on these PαS cells will result in efficient homing and greater 
numbers of PαS cells recruited to the site of injury or inflammation. The benefits of 
uncultured PαS cells over cultured PαS cells have been investigated previously. 
Uncultured PαS cells homed efficiently to the bone marrow and adipose tissue, both 
of which express high levels of CXCL12, whereas cultured PαS cells become 
entrapped in the respiratory system [144]. 
 
8.5. Pharmacokinetics of MSC mobilisation. 
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Dose and timing of VEGF-A165 were originally determined to compare directly 
with G-CSF, as this dosing regimen had been successfully used to show EPC 
mobilisation [257]. Experiments performed to determine whether the dose or pre-
treatment could be reduced showed that bone marrow needs to be exposed to a 
prolonged administration of VEGF-A165 in order for the mMSCs to be released 
following CXCR4 antagonism. 
The adult body contains many stem cell niches other than the bone marrow 
from which stem cells can be mobilised. Notable examples include: myocardial 
tissue, adipose tissue, spleen, liver, and lungs [392,393,394,395]. Previously in situ 
perfusion of the femoral vasculature in mice treated with VEGF-A165 and AMD3100 
has shown that MSCs are mobilised directly from the bone marrow using the 
regimen [341]. Once mobilised, stem cells can be rapidly recruited to the site of 
injury, home back to the bone marrow (within minutes) or redistribute to other 
tissues with local stem cell niches such as the liver, spleen, and lungs 
[391,392,396,397]. By investigating the pharmacokinetics of mobilisation using VEGF 
and AMD3100 in Chapter 6, it is now evident that MSC mobilisation is rapid with 
optimum mobilisation occurring 1 hour post AMD3100 administration. However, 
due to the rapid homing of MSCs to stem cell niches around the body, further 
studies are required to determine strategies to provide a more sustained 
mobilisation of MSCs. 
 
8.6. Pharmacologically mobilised MSCs vs. ex vivo cultured MSCs. 
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The favourable characteristics of MSCs for cellular therapy documented in 
vitro have not yet been translated into man [98]. Although this area has been heavily 
researched of late, a lack of understanding of the basic biology through which these 
cells exert their beneficial properties may explain the underwhelming results in 
clinical trials [386]. This project has attempted to increase the understanding by 
investigating isolation methodology, the effects of in vitro culture on MSCs, and 
alternative strategies for administering MSCs as a cellular therapy.  
 
8.6.1. Phenotypic switching of cultured MSCs. 
There are reports suggesting that MSCs should only be used clinically at early 
passage numbers due to phenotypic and functional changes that occur as the result 
of repeated passaging [59,168]. There have been previous reports of both human 
and murine MSCs losing migratory capacity and ability to migrate to sites of injury or 
inflammation in vivo, following culture in vitro [168,335]. However, the phenotypic 
changes which result in this reduction have not previously been characterised. It has 
been hypothesised that an increase in proliferation rate leads to a decrease in 
migratory capacity, with the suggestion that the actively dividing cells will not 
migrate efficiently due to their increased size and a phenotypic switching from 
migratory action to a proliferative action [398]. In Chapter 3, mMSCs were shown to 
display reduced external chemokine receptor profiles following 25 passages, when 
compared to mMSCs which had been passaged 5 times. However, both sets of cells 
appeared morphologically similar and displayed the same antigen phenotype. Loss 
of chemokine receptor expression on the surface of P25 bone marrow mMSCs 
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resulted in a loss of chemokine dependent motility. From this it is apparent that cells 
which have undergone excessive passaging are not suitable for systemic 
administration in clinical therapies because they may lose their ability to migrate 
into specific areas of injury within tissue. This corresponds with previous studies 
where MSCs could home to bone marrow with high efficiency but lost homing ability 
following culture [129]. MSCs may function if administered locally, but it has not yet 
been assessed whether this in vitro culture methodology results in the loss of further 
surface molecules, including adhesion molecules such as VCAM-1, which may be 
critical for engraftment at sites of administration [295]. This loss of chemokine 
receptor expression upon culture may explain why the in vitro promise of MSCs has 
not been realised in vivo. For example, the beneficial properties for MSCs in treating 
graft versus host disease in vitro [399,400] have not been mirrored in the recent 
Osiris phase III clinical trials evaluating Prochymal (in vitro cultured hMSCs), for the 
treatment of GvHD, where Prochymal recipients showed no statistical benefit at 
primary endpoints [386]. In contrast, recent studies showed a positive effect using 
early passage MSCs to treat GvHD [401]. The difference may be a mass produced, 
possibly extensively expanded MSC product versus individual MSC preparations. 
Alternatively, endogenously mobilised MSCs provide a more efficacious approach to 
cell therapy. 
Once the cells are recruited to the site of injury or inflammation, it is not yet 
known how the MSCs are exerting their beneficial effects. Various reports have 
stated that this is due to the immuno-modulatory capacity of MSCs 
[165,166,191,194]. In culture, hMSCs were shown to produce high levels of CXCL12. 
It is not known whether CXCL12 is being produced in order to maintain the MSCs in 
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a proliferative state or whether MSCs constitutively produce CXCL12 and this aids 
the repair and regeneration of tissues. CXCL12 is a well recognised chemoattractant 
for stem cells [7,351,402]. By producing large amounts of CXCL12 at the site of 
injury, MSCs may be attracting other leukocytes and stem cells that express CXCR4, 
including CD34+ haematopoietic progenitors [391], T lymphocytes, monocytes, pro 
and pre-B cells [79] or greater numbers of MSCs to aid regeneration via alternative 
pathways. Chemokines acting upon MSCs may determine functionality through 
various pathways. Angiogenesis during wound healing is regulated by numerous 
biological mediators, including chemokines [403]. It is also known that the 
immunosuppressive function of MSCs relies on chemokines [404]. MSCs in the 
presence of IFN-γ plus TNF-α, IL-1α, or IL-1β promotes the expression of high levels 
of chemokines and NO. Chemokines drive T cell migration into proximity with MSCs, 
where T cell responsiveness is suppressed by NO [405]. 
 
8.6.2. Heterogeneity of cultured MSCs. 
P25 mMSCs were found to have a higher proliferation rate than P5 mMSCS. 
The increased proliferative capacity may be a result of culture conditions. MSCs are 
cultured in vitro to increase cell numbers. The optimum culture conditions are 
therefore set for proliferative action as opposed to maintenance of cellular 
phenotype. This apparent phenotypic switching upon culture is also apparent when 
culturing a homogeneous population of MSCs, PαS cells. Assuming PαS cells are 
stem cells, with culture a mix of stem cells and progenitors are produced.  
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The percentage of PαS cells in all cultured mMSC populations investigated 
(P5 PαS, P5 bone marrow mMSCs, P25 bone marrow mMSCs) showed no significant 
difference between populations. Even within their niche in the bone marrow, 
mMSCs are surrounded by many other cell types, all of which are maintained in a 
steady state by their interaction with other cells and the factors that these cells 
produce. The heterogeneous population may come about as a result of mMSCs 
producing factors to revert to the steady state conditions of the bone marrow. 
Herein lies a major obstacle for the use of MSCs as a cellular therapy. By treating 
patients with heterogeneous cell populations, it is difficult to assess which cell types 
are responsible for the resulting outcome. Designing experimental conditions to 
allow MSCs to proliferate in an undifferentiated state is one of the current 
challenges for the scientific community. 
In order to increase the likelihood of MSCs reaching and acting at the site of 
interest, the MSCs need to be administered as a homogeneous population in which 
the migratory capacity is maintained. It is not yet known whether the loss of 
chemokine receptor on MSCs cultured in vitro is due to differentiation of MSCs into 
cell types which subsequently do not express chemokine receptors on the cell 
surface, or a loss of chemokine receptors of the cell surface of MSCs directly. The 
percentage of PαS cells in the P5 bone marrow mMSCs and P25 bone marrow 
mMSCs is not significantly different, suggesting that mMSCs are losing chemokine 
receptors on the cell surface. The migratory potential may also be limited by an 
increase in cell size upon culture, reported here. Previous reports of cultured MSCs 
becoming entrapped in the lungs [130,193,406] are consistent with the results 
reported here, in which P5 bone marrow mMSCs when administered intravenously 
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were also found in large numbers in 
the lungs 4 hours post administration. 
These findings suggest that MSCs 
should not be cultured at all, or a 
method of culture should be found in 
which the size of MSCs is maintained 
if the cells are to be used safely in 
clinical applications. Comparison of 
mMSC distribution when administered i.v. or i.p. in mice demonstrated how the 
route of application of MSCs plays a critical role in MSCs reaching clinical targets. 
Analysis of the clinical trials reported on clinicaltrials.gov reveals that in the majority 
of studies MSCs are administered i.v. (Fig. 8.3). For these cells to successfully treat 
the damaged tissue, they must first migrate to sites of injury or inflammation.  
As there are differences in the manner in which mMSCs and hMSC are 
obtained, there may be some differences in the initial heterogeneity of the cell 
populations which may be amplified upon prolonged culture in vitro. In his thesis, I 
have shown that chemokine receptor expression is consistent across species and 
between tissue sources, suggesting that with respect to trafficking properties 
mMSCs may represent a good model of their human counterparts. But importantly, 
chemokine receptor profiles reveals distinct sub-populations of MSCs and future 
work will explore the functional attributes of these sub-populations, with respect to 
trafficking but also their differentiation and immuno-modulatory properties. 
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8.7. Murine MSCs as a model for human MSCs. 
It has previously been reported that mMSCs act as a good representative 
population for hMSCs [134]. The chemokine receptor profile has been characterised 
for all 5 sets of hMSCs investigated here. Strikingly, when comparing the chemokine 
receptor profiles of P5 MSCs derived from human fetal blood, fetal bone marrow, 
1st trimester amniotic fluid, 2nd trimester amniotic fluid and placenta, it was found 
that the overall internal and external chemokine receptor profile was conserved 
across all sources. There were however differences in expression levels of certain 
chemokine receptors between sources e.g. Fetal bone marrow derived MSCs 
expressed higher levels of CXCR3, CXCR4, CXCR6 and CCR10 on the cell surface than 
fetal blood derived MSCs. Initial results investigating the functional relevance of 
these differences showed that fetal bone marrow did not show a significantly 
greater chemotactic response to CXCL12, CXCL16, CCL27 and CXCL11 than fetal 
blood. This may have clinical relevance when selecting MSCs for future clinical trials. 
Following culture, MSCs which retain the greatest chemotactic ability should be used 
if the MSCs are to be administered systemically. This should allow a greater number 
of MSCs to migrate to sites of injury where their therapeutic benefit is increased. 
The hMSC populations used in this study were all investigated at passage 5 so that 
their phenotype could be compared directly to the P5 bone marrow mMSCs isolated 
in Chapter 3. However, the findings in Chapter 5 regarding repeated passage and 
culture of a homogeneous population of MSCs (PαS cells) shows that any in vitro 
culture results in a reduction in the surface chemokine receptor levels on MSCs. 
Although this has only been shown thus far for mMSCs, it can be assumed that the 
same is true for hMSCs due to the conserved chemokine receptor profiles across 
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species. In order to be confirmed as MSCs, the cells must possess the ability to 
proliferate on plastic surfaces. Whilst this may help to confirm the cells populations 
as MSCs, it may in turn be having immediate detrimental effects on the MSCs should 
they ever be used for systemic administration clinically.   
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8.8. Summary. 
 This project determines chemokine receptor profile on murine bone marrow 
MSCs at early and late passage numbers and human MSCs derived from a range of 
fetal tissues including fetal blood, bone marrow, amniotic fluid and placenta. The 
overwhelming result from this analysis is the consistency across species and tissue 
source with respect to chemokine receptor profiles. In addition it is clear that 
expression of specific chemokine receptors defines sub-populations of MSCs. It has 
previously been shown that pre-treatment of mice with VEGF-A165 supports the 
subsequent mobilisation of MSCs by the CXCR4 antagonist AMD3100. In this thesis 
the VEGF biology with respect to this response has been investigated and it was 
shown that mMSCs express high levels of VEGFR-1 and a sub-population express 
VEGFR-2, but signalling via VEGFR-2 is required for mobilisation. Indeed VEGF-A165 in 
combination with aVEGFR-1 mAbs enhanced mobilisation 10 fold, suggesting that 
under normal homeostatic conditions VEGFR-1 acts as a sink for VEGF-A165. To 
exploit this phenomenon we used VEGF-E, a selective VEGFR-2 agonist, and were 
able to show 7 fold enhanced mobilisation of mMSCs over VEGF-A165. Further 
characterisation of mobilised mMSCs by flow cytometry on PαS cells, as elaborated 
upon in Chapter 5 now provides a way to investigate the biology of MSCs, both in 
their steady state in vivo and in models of injury and inflammation. Molecular 
mechanisms lying downstream of VEGFR-2 have been explored and it has been 
shown that MMPs play a critical role in mobilisation. Pharmacological mobilisation 
of MSCs may provide an alternative strategy to stem cell therapy to promote tissue 
regeneration or immune suppression. Such a strategy may be more commercially 
viable for financial and technical reasons. Culture of MSCs generates a 
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heterogeneous population of stem and progenitor cells with poor trafficking 
abilities, it will therefore be of interest in the future to compare pharmacological 
mobilisation, versus stem cell therapy with respect to tissue regeneration. 
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8.9. Future Work. 
 
 Develop methodology for sustained MSC mobilisation via the optimisation of 
the current protocol along with other approaches, such as administration of 
adenoviruses expressing VEGF-isoforms. 
 
 Investigate which MMPs are activated in response to treatment with different 
VEGF isoforms. 
 
 Further investigate the role of the CXCR4/CXCL12 axis in mobilisation, 
specifically whether blocking CXCL12 inhibits mobilisation. 
 
 
 Assess resolution of tissue damage in mouse models of injury and 
inflammation when endogenous MSCs are mobilised pharmacologically. 
 
 
 Characterise and compare sub-populations of MSCs as defined by the 
expression of extracellular chemokine receptors, in terms of: 
 Differentiation potential. 
 Chemotactic ability in vitro and in vivo. 
 Immuno-modulatory capacity. 
 
 Compare the chemotactic ability in vitro and pattern of distribution of MSCs 
isolated from different tissues, when administered in vivo. 
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